Copper complexes for the treatment of neurodegenerative disorders

JP2023544965A5Active Publication Date: 2024-11-06ALS THERAPY DEV INST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023513488
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-08-26
Filing Date
2021-08-26
Publication Date
2024-11-06
Estimated Expiration
2041-08-26

AI Technical Summary

Technical Problem

Current treatments for neurodegenerative diseases such as ALS are limited, with only two FDA-approved drugs that offer modest extensions of lifespan and no cure, and there is a need for improved therapeutic agents that can address neurological diseases and copper deficiency-related disorders.

Method used

Development of copper complexes, represented by compounds of formulas (I) to (V), which are administered to subjects to treat or prevent neurodegenerative diseases like ALS, frontotemporal dementia, Parkinson's disease, and Alzheimer's disease, by targeting copper-zinc superoxide dismutase (SOD1) mutations.

Benefits of technology

The copper complexes demonstrate therapeutic benefits in animal models of ALS, including slowing disease progression, extending survival time, and maintaining muscle function, as shown by improved muscle action potential and survival rates in SOD1G93A mice.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure relates to copper complexes, pharmaceutical compositions containing these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS).
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] Cross-reference of related applications This application claims the benefit of U.S. No. 63 / 070,792, filed August 26, 2020, the disclosure of which is incorporated herein by reference in its entirety. [Background technology]

[0002] Neurodegenerative diseases are age-dependent disorders that are becoming increasingly prevalent, due in part to the growing elderly population (Heemels, Nature (2016) 539:179).

[0003] For example, amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, Lou Gehrig's disease, or Charcot disease, affects 30,000 Americans and more than 400,000 people worldwide at any given time. It is estimated that the Approximately 5,000 Americans are diagnosed with ALS each year. The disease causes constant death of motor neurons, leading to progressive paralysis that kills its victims within one to five years on average. Most people diagnosed with ALS survive three to five years after the first signs of the disease. Approximately 10% of people with ALS survive for at least 10 years. The variable rate of disease progression makes prognosis difficult to predict and therapy development difficult.

[0004] Only two drugs (riluzole and edaravone) have been approved by the FDA for the treatment of ALS, and both can slow disease progression and extend lifespan by up to several months in a subset of patients, but neither can slow disease progression or extend lifespan by up to several months. It cannot be treated or cured.

[0005] Some inherited forms of ALS are caused by genetic mutations. The genetic change alters an enzyme in the cell called copper-zinc superoxide dismutase (Cu-Zn superoxide dismutase, now commonly referred to as SOD1). This enzyme functions to keep cells safe from metabolic waste products that can cause damage if not cleared.

[0006] The compound CuATSM has shown protective effects in a transgenic mouse model of ALS in which transgenic mice were engineered to express human SOD1 with mutations found in SOD1 familial ALS using rigorous methods established in the art. It has been shown that there is.

[0007] However, there is a need in the art for improved therapeutic agents that can treat neurological diseases and / or copper deficiency related disorders. [Summary of the invention]

[0008] Provided herein are compounds useful in methods of treating or preventing neurodegenerative diseases in a subject in need thereof.

[0009] In one aspect, the present disclosure provides compounds of formula (I): [ka] or a pharmaceutically acceptable salt thereof, where L, R 1 ,R 2 ,R 3 , and R 4 is as defined herein.

[0010] In certain embodiments, the compound of formula (I) is selected from the group consisting of compounds 1-22, or a pharmaceutically acceptable salt thereof.

[0011] In another aspect, the disclosure provides compounds of formula (II): [ka] or a pharmaceutically acceptable salt thereof, wherein R 1 ,R 2 ,R 3 , and R 4 is as defined herein.

[0012] In certain embodiments, the compound of formula (II) is selected from the group consisting of compounds 23-46.

[0013] In another aspect, the disclosure provides compounds of formula (III): [ka] or a pharmaceutically acceptable salt thereof, where L, R 1 ,R 2 , and R 3 is as defined herein.

[0014] In certain embodiments, the compound of formula (III) is selected from the group consisting of compounds 47-53.

[0015] In another aspect, the disclosure provides compounds of formula (IV): [ka] or a pharmaceutically acceptable salt thereof, where L, R 1 ,R 2 ,R 3 , and R 4 is as defined herein.

[0016] In certain embodiments, the compound of formula (IV) is selected from the group consisting of compounds 1-22, 57, 59-61, and 66-78.

[0017] In another aspect, the disclosure provides compounds of formula (V): [ka] or a pharmaceutically acceptable salt thereof, wherein R 1 ,R 2 ,R 3 , and R 4 is as defined herein.

[0018] In certain embodiments, the compound of formula (V) is selected from the group consisting of compounds 23-46 and 79-127.

[0019] In another aspect, the disclosure provides a compound selected from the group consisting of compounds 56-65.

[0020] In another aspect, the disclosure provides a pharmaceutical composition comprising a compound of the disclosure, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, diluent, or carrier. do.

[0021] In another aspect, the disclosure provides a method of treating or preventing a neurodegenerative disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of the disclosure.

[0022] In certain embodiments, the neurodegenerative disease is amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson's disease, Huntington's disease, and Alzheimer's disease. In another embodiment, the neurodegenerative disease is ALS. In further embodiments, ALS is familial or sporadic.

[0023] In another aspect, the disclosure provides methods of making the compounds of the disclosure. [Brief explanation of drawings]

[0024]

Figure 1

Figure 2

[0025] As used herein, compounds of formula (I): [ka] and its pharmaceutically acceptable salts, compounds of formula (II): [ka] and its pharmaceutically acceptable salts, compounds of formula (III): [ka] and its pharmaceutically acceptable salts, compounds of formula (IV): [ka] and pharmaceutically acceptable salts thereof, as well as compounds of formula (V): [ka] and pharmaceutically acceptable salts thereof, all of which are useful in the treatment of neurological diseases and / or copper deficiency related disorders.

[0026] definition Listed below are definitions of various terms used herein. These definitions apply to the terms used throughout this specification and claims, unless otherwise limited individually or as part of a larger group in a particular case.

[0027] Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the nomenclature and test procedures in cell culture, molecular genetics, organic chemistry, and peptide chemistry used herein are those well known and commonly used in the art.

[0028] As used herein, the articles "a" and "an" refer to one or more than one (ie, at least one) of the grammatical object of the article. By way of example, "element" means one element or more than one element. Further, the use of the term "including" and other forms such as "include," "includes," and "includes" is limiting. isn't it.

[0029] As used herein, the term "about" is understood by those skilled in the art and will vary to some extent depending on the context in which it is used. As used herein when referring to a measurable value, such as an amount, length of time, etc., the term "about" means ±20% or ±10% (±5%) from the stated value. , ±1%, and ±0.1%) are intended to be included as such variations are appropriate in practicing the disclosed methods.

[0030] As used herein and in the claims, the term "comprising" may include embodiments "consisting of" and "consisting essentially of." As used herein, "comprise(s)," "include(s)," "having," "has," "not" The terms "may", "contain", and variations thereof are open-ended transitional phrases that require the presence of the mentioned component / step and permit the presence of other components / steps; intended to be a term or word. However, such statements ``consist of'' and ``consist of'' the listed compounds, permitting the presence of only the mentioned compounds, and excluding other compounds, together with any pharmaceutically acceptable carrier. Compositions or processes consisting essentially of the same should also be construed as descriptive.

[0031] As used herein, the term "alkyl" by itself or as part of another substituent means a straight or branched carbonized chain having the specified number of carbon atoms, unless otherwise specified. means hydrogen (i.e. C 1 ~C 6Alkyl means alkyl having 1 to 6 carbon atoms), including straight and branched chains. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, and 1-hexyl.

[0032] As used herein, the term "haloalkyl" refers to an alkyl group as defined above substituted with one or more halo substituents, where alkyl and halo are As defined in the book. Haloalkyl includes, by way of example, chloromethyl, trifluoromethyl, bromoethyl, chlorofluoroethyl, and the like.

[0033] As used herein, the term "alkoxy" refers to the group -O-alkyl, where alkyl is as defined herein. Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, t-butoxy, and the like.

[0034] As used herein, the term "halo" or "halogen", alone or as part of another substituent, means a fluorine, chlorine, bromine, or iodine atom, unless otherwise specified. , As used herein, the term "cycloalkyl" means a partially or fully saturated non-aromatic carbocyclic ring system having the specified number of carbon atoms. A cycloalkyl group can be a monocyclic, fused polycyclic, bridged polycyclic, or spiro polycyclic carbocyclic compound. The term "cycloalkyl" includes, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[3.1.0]hexyl, spiro[3.3]heptanyl, and bicyclo[1.1.1]pentyl.

[0035] As used herein, the term "heterocyclyl" or "heterocycloalkyl" contains the specified number of ring atoms and the ring atoms are independently selected from carbon atoms and N, O, and S. a non-aromatic saturated or partially saturated monocyclic, fused polycyclic, bridged polycyclic, or spiro polycyclic ring system of 1, 2, 3, or 4 heteroatoms means. The term "heterocyclyl" includes cyclic esters (i.e., lactones) and cyclic amides (i.e., lactams), and also includes epoxidyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl (i.e., oxanyl), pyranyl , dioxanyl, aziridinyl, azetidinyl, pyrrolidinyl, 2,5-dihydro-1H-pyrrolyl, oxazolidinyl, thiazolidinyl, piperidinyl, morpholinyl, piperazinyl, thiomorpholinyl, 1,3-oxazinanyl, 1,3-thiazinanyl, 2-azabicyclo[2.1.1 ]hexanyl, 5-azabicyclo[2.1.1]hexanyl, 6-azabicyclo[3.1.1]heptanyl, 2-azabicyclo[2.2.1]heptanyl, 3-azabicyclo[3.1.1]heptanyl, 2-azabicyclo[3.1.1] ]heptanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.2.1]octanyl, 8-azabicyclo[3.2.1]octanyl, 3-oxa-7-azabicyclo [3.3.1]nonanyl, 3-oxa-9-azabicyclo[3.3.1]nonanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 6-oxa-3-azabicyclo[3.1.1]heptanyl, 2 -Azaspiro[3.3]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 2-oxaspiro[3.3]heptanyl, 2-oxaspiro[3.5]nonanyl, 3-oxaspiro[5.3]nonanyl, and 8-oxabicyclo[3.2 .1] Octanyl. Unless otherwise noted, a heterocycle or heterocycloalkyl is attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.

[0036] As used herein, the term "aromatic" includes one or more polyunsaturated rings and has aromatic properties, i.e., (4n+2) delocalized Refers to a carbocyclic compound or heterocycle having π (pi) electrons, where n is an integer.

[0037] As used herein, the term "aryl" means an aromatic carbocyclic ring system containing the specified number of ring atoms. An aryl group can be a single ring or multiple rings (up to three rings) that are fused or covalently bonded together. If the rings are fused, one of the rings must be fully unsaturated; the fused ring(s) may be fully saturated, partially unsaturated, or fully unsaturated. The term "aryl" includes, but is not limited to, phenyl, naphthyl, indanyl, and 1,2,3,4-tetrahydronaphthalenyl.

[0038] As used herein, the term "heteroaryl" refers to an aromatic carbocyclic system containing 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S. means. A heteroaryl group can be a single ring or multiple rings (up to three rings) that are fused or covalently bonded together. If the rings are fused, one of the rings must be fully unsaturated; the fused ring(s) may be fully saturated, partially unsaturated, or fully unsaturated. The term "heteroaryl" includes: furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazo[1,2-a]pyridinyl , pyrazolo[1,5-a]pyridinyl, benzo[d][1,3]dioxolyl, 5,6,7,8-tetrahydroisoquinolinyl, 5,6,7,8-tetrahydroquinolinyl, 6 ,7-dihydro-5H-cyclopenta[b]pyridinyl, 6,7-dihydro-5H-cyclopenta[c]pyridinyl, 1,4,5,6-tetrahydrocyclopenta[c]pyrazolyl, 2,4,5,6 -Tetrahydrocyclopenta[c]pyrazolyl, 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolyl, 6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4] Triazolyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl, 4 , 5,6,7-tetrahydro-1H-indazolyl, and 4,5,6,7-tetrahydro-2H-indazolyl. Unless otherwise noted, a heterocycle or heterocycloalkyl is attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.

[0039] As used herein, the term "substituted" means that an atom or group of atoms replaces a hydrogen as a substituent attached to another group.

[0040] "Pharmaceutically acceptable salt" means a free acid or base salt of a compound of the present disclosure that is non-toxic and biologically acceptable or otherwise biologically suitable for administration to a subject. is intended to mean. It should have the desired pharmacological activity of the parent compound. In general, G. S. Paulekuhn, et al., “Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database”, J. Med. Chem., 2007, 50:6665-72, S. M. Berge, et al. ., “Pharmaceutical Salts”, J Pharm Sci., 1977, 66:1-19, and Handbook of Pharmaceutical Salts, Properties, Selection, and Use, Stahl and Wermuth, Eds., Wiley-VCH and VHCA, Zurich, 2002. Please refer.

[0041] The term "therapy" refers to the application of one or more specific procedures used for the amelioration of a disease. In certain embodiments, the particular procedure is the administration of one or more pharmaceutical agents. "Treatment" of an individual (eg, a mammal, such as a human) or a cell is any type of intervention used in an attempt to alter the natural course of the individual or cell. Treatment includes, but is not limited to, the administration of pharmaceutical compositions, and may be carried out either prophylactically or following the initiation of a pathological event or contact with a pathogen. Treatment includes any desired effect on the symptoms or pathology of the disease or condition, including, for example, minimal change or amelioration of one or more measurable markers of the disease or condition being treated. Good too.

[0042] As used herein, the term "prevent" or "prevention" refers to the absence of a disorder or disease if no disorder or disease had occurred, or the occurrence of a disorder or disease. If already present, this means that no further disorder or disease will develop. Also considered is the ability to prevent some or all of the symptoms associated with the disorder or disease.

[0043] As used herein, the term "use" includes any one or more of the following embodiments of the invention, respectively: Unless otherwise specified, as appropriate and convenient, use in the treatment of these diseases, use for the manufacture of pharmaceutical compositions for use in the treatment of these diseases, e.g. use in the manufacture of medicaments; methods of using the compounds of the invention in the treatment of these diseases; pharmaceutical preparations comprising compounds of the invention for the treatment of diseases; and compounds of the invention for use in the treatment of these diseases.

[0044] As used herein, the terms "patient," "individual," or "subject" are those suffering from or capable of suffering from a disease, disorder, or condition associated with protein kinase activity. It is intended to include organisms such as prokaryotes and eukaryotes. Examples of subjects include mammals, such as humans, dogs, cows, horses, pigs, sheep, goats, cats, mice, rabbits, rats, and transgenic non-human animals. In certain embodiments, the subject is a human, eg, suffering from, at risk of suffering from, or potentially capable of suffering from ALS. In another embodiment, the subject is a cell. The terms "patient," "individual," or "subject" do not refer to a particular age or gender.

[0045] As used in connection with the therapeutic / preventive methods and uses of the compounds and pharmaceutical compositions thereof described herein, an individual "in need" is one who has been diagnosed with or has previously had the condition being treated. The individual may have been previously treated. With respect to prevention, individuals in need may also be those at risk for the condition (eg, family history of the condition, lifestyle factors indicative of risk for the condition, etc.). Typically, when the step of administering a compound of the invention is disclosed herein, the invention will be directed to an individual in need of the particular treatment being administered or having a particular medical condition being treated. A further step of identifying the target is contemplated.

[0046] As used herein, the terms "effective amount," "pharmaceutically effective amount," and "therapeutically effective amount" refer to an amount that is nontoxic but sufficient to provide the desired biological result. Refers to the drug. The result may be a reduction or alleviation of the signs, symptoms, or causes of a disease, or any other desired change in a biological system. The appropriate therapeutic amount in any individual case may be determined by one of skill in the art using routine experimentation.

[0047] As used herein, the term "composition" or "pharmaceutical composition" refers to a combination of at least one compound useful within the invention and a pharmaceutically acceptable diluent, excipient, or carrier. refers to a mixture of Pharmaceutical compositions facilitate administration of the compound to a patient or subject. Multiple techniques exist in the art for administering compounds including, but not limited to, intravenous, oral, aerosol, parenteral, intraocular, pulmonary, and topical administration.

[0048] As used herein, the term "combination," "therapeutic combination," or "pharmaceutical combination" refers to a fixed combination, or a non-fixed combination, in one unit dosage form, or two or more combinations, in which the therapeutic agents may be administered independently, simultaneously or separately within time intervals, especially if these time intervals allow their combination partners to exhibit a cooperative (e.g., synergistic) effect. Refers to one of the kits of parts for administration.

[0049] The term "sporadic" refers to neurodegenerative diseases that are not inherited (eg, ALS). Sporadic ALS accounts for approximately 90% of cases, where the affected individual is the only member of the family with the disease. The causes of sporadic ALS are not fully understood but may be due to a combination of environmental and genetic risk factors.

[0050] The term "familial" refers to neurodegenerative diseases (eg ALS) that are hereditary. Familial ALS accounts for about 10% of cases, where two or more members of the family have ALS, and family members may also have frontotemporal dementia. People with familial ALS often start showing symptoms at an earlier age than those with sporadic ALS. Familial ALS is most often autosomal dominant.

[0051] Compounds of the present disclosure In one aspect, herein a compound of formula (I): [ka] or a pharmaceutically acceptable salt thereof, wherein: L is C 3 ~C 7 cycloalkyl, C 1 ~C 6 is alkyl or absent; R 1 is a 5- to 10-membered heteroaryl, NH 2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 is alkyl, R 2 is a 5- to 10-membered heteroaryl, NH 2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 is alkyl, R 3 However, C 6 ~C 10 Aryl, 5- to 10-membered heteroaryl, C(O)NH-(C 1 ~C 6 alkyl)-PPh 3 , hydroxy, C 1 ~C 6 Alkoxy, or O-(C 1 ~C 6 alkyl)-O-(C 1 ~C 6 alkyl), where C 6 ~C 10 Aryl is a group R 3a 5- to 10-membered heteroaryl substituted once, twice, or three times with R 3b is replaced once, twice, or three times with R 3a , but independently for each occurrence, C 3 ~C 7 cycloalkyl or 4- to 8-membered heterocycle, where the 4- to 8-membered heterocycle is optionally C 1 ~C 3 further substituted once, twice, or three times with alkyl, R 3b , but independently for each occurrence, C 1 ~C 3 Alkoxy, C 3 ~C 7 cycloalkyl, or a 4- to 8-membered heterocycle, where the heterocycle is optionally C 1 ~C 3 further substituted once, twice, or three times with alkyl, R 4 is hydrogen, C 1 ~C 3 alkyl, or C 6 ~C 10 Although it is an aryl, However, if L is absent, R 3 is the group R 3a C replaced once, twice, or three times with 6 ~C 10 If aryl or L is absent, then R 3 is the group R 3b The condition is that it is a 6- to 10-membered heteroaryl substituted with once, twice, or three times.

[0052] In some embodiments, L is C 3 ~C 7 cycloalkyl or C 1 ~C 6 It is an alkyl. In some embodiments, L is C 3 ~C 7 It is cycloalkyl. In some embodiments, L is C 1 ~C 6 It is an alkyl. In some embodiments, L is C 3 ~C 5 cycloalkyl or C 1 ~C 3 It is an alkyl. In some embodiments, L is C 3 ~C 5 It is cycloalkyl. In some embodiments, L is C 1 ~C 3 It is an alkyl.

[0053] In certain embodiments, L is -CH 2 -is. In certain embodiments, L is -CH 2 CH 2 -is. In certain embodiments, L is -CH 2 CH 2 CH 2 -is. In certain embodiments, L is -CH 2 CH 2 CH 2 CH 2 -is. In certain embodiments, L is -CH(CH 3 )-is. In certain embodiments, L is -CH(CH 2 CH 3 )-is. In certain embodiments, L is -C(CH 3 ) 2 -is.

[0054] In some embodiments, L is C 3 ~C 7 cycloalkyl or C 3 ~C 5 cycloalkyl, where the cycloalkyl group is a group R 3 and a quaternary carbon that forms the point of attachment to the rest of the scaffold. Thus, in certain embodiments, L is represented by one of the following groups: [ka]

[0055] In some embodiments, R 1 is C 1-6 It is an alkyl. In some embodiments, R 1 is C 1-3 It is an alkyl. In some embodiments, R 1 is methyl or ethyl. In some embodiments, R 1 is methyl. In some embodiments, R 1 is ethyl.

[0056] In some embodiments, R 2 is C 1-6 It is an alkyl. In some embodiments, R 2 is C 1-3 It is an alkyl. In some embodiments, R 2 is methyl or ethyl. In some embodiments, R 2 is methyl. In some embodiments, R 2 is ethyl.

[0057] In some embodiments, R 1 and R 2 are the same.

[0058] In some embodiments, R 3 is C 6 ~C 10 Aryl, 6- to 10-membered heteroaryl, C(O)NH-(C 1 ~C 6 alkyl)-PPh 3 , hydroxy, C 1 ~C 6 Alkoxy, or O-(C 1 ~C 6 alkyl)-O-(C 1 ~C 6 alkyl), where C 6 ~C 10 Aryl is the group R 3a 5- to 10-membered heteroaryl substituted once, twice, or three times with R 3b is substituted once, twice, or three times.

[0059] In some embodiments, R 3 is phenyl, pyridinyl, C(O)NH-(C 1 ~C 6 alkyl)-PPh 3 , hydroxy, C 1 ~C 6 Alkoxy, or O-(C 1 ~C 6 alkyl)-O-(C 1 ~C 6 alkyl), where phenyl is a group R 3a , the pyridinyl is optionally substituted once, twice, or three times with 3b is substituted once, twice, or three times.

[0060] In some embodiments, R 3 is phenyl, pyridinyl, C(O)NH-(C 1 ~C 6 alkyl)-PPh 3 , hydroxy, C 1 ~C 6 Alkoxy, or O-(C 1 ~C 6 alkyl)-O-(C 1 ~C 6 alkyl), where phenyl is a group R 3a , the pyridinyl is optionally substituted once with the group R 3b is replaced once.

[0061] In some embodiments, R 3a is independently for each occurrence, C 1 ~C 3 A 4- to 8-membered heterocycle optionally further substituted once, twice, or three times with alkyl. In some embodiments, R 3a is a 4- to 8-membered heterocycle optionally further substituted once with methyl, independently at each occurrence.

[0062] In some embodiments, R 3a is, independently at each occurrence, pyrrolidinyl, pyrrolidinonyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, or piperazinyl, each of which is optionally C 1 ~C 3 Further substituted once, twice, or three times with alkyl. In some embodiments, R 3a is, independently at each occurrence, pyrrolidinyl, pyrrolidinonyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, or piperazinyl, each of which is optionally further substituted once with methyl. In some embodiments, R 3a is, independently at each occurrence, pyrrolidinyl, pyrrolidinonyl, or morpholinyl. In some embodiments, R 3a is represented, at each occurrence independently, by a group selected from: [ka]

[0063] In some embodiments, R 3b is independently for each occurrence, C 1 ~C 3 alkoxy or a 4- to 8-membered heterocycle, where the heterocycle is optionally a C 1 ~C 3 Further substituted once, twice, or three times with alkyl. In some embodiments, R 3b is independently for each occurrence, C 1 ~C 3 Alkoxy or a 4- to 8-membered heterocycle, where the heterocycle is optionally further substituted once with methyl.

[0064] In some embodiments, R 3b is independently for each occurrence, C 1 ~C 3 alkoxy or a heterocycle selected from the group consisting of pyrrolidinyl, pyrrolidinonyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, and piperazinyl, wherein the heterocycle 1 ~C 3 Further substituted once, twice, or three times with alkyl. In some embodiments, R 3b is independently for each occurrence, C 1 ~C 3 alkoxy or a heterocycle selected from the group consisting of pyrrolidinyl, pyrrolidinonyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, and piperazinyl, where the heterocycle is optionally further substituted once with methyl. be done. In some embodiments, R 3b is, independently at each occurrence, methoxy or a heterocycle selected from the group consisting of pyrrolidinyl and morpholinyl. In some embodiments, R 3b is represented, at each occurrence independently, by a group selected from: [ka]

[0065] In some embodiments, R 4 is hydrogen, C 1 ~C 3 Alkyl or phenyl. In some embodiments, R 4 is hydrogen, methyl, or phenyl. In some embodiments, R 4 is hydrogen or C 1 ~C 3 It is an alkyl. In some embodiments, R 4 is hydrogen or methyl. In some embodiments, R 4 is hydrogen. In some embodiments, R 4 is methyl. In some embodiments, R 4 is phenyl.

[0066] In some embodiments, R 3 The group represented by -L has one of the following structures: [ka]

[0067] In some embodiments, R 3 is C 1 ~C 3 is pyridinyl, optionally substituted once, twice, or three times with alkoxy or a 4- to 8-membered heterocycle, where the 4- to 8-membered heterocycle is optionally substituted with C 1 ~C 3 Substituted once with alkyl.

[0068] In some embodiments, L is absent and R 3 is C 1 ~C 3 Pyridinyl substituted once, twice, or three times with alkoxy.

[0069] In some embodiments, L is absent and R 3 is phenyl substituted with a 4- to 8-membered heterocycle.

[0070] In some embodiments, L is C 3 ~C 5 cycloalkyl or C 1 ~C 3 is alkyl and R 3 is pyridinyl optionally substituted once, twice, or three times with a 4- to 8-membered heterocycle, and R 4 is methyl.

[0071] In certain embodiments, the compound of formula (I) has the structure of compound 9: [ka]

[0072] Exemplary compounds of formula (I) include the compounds described below, or a pharmaceutically acceptable salt thereof: [ka] [ka]

[0073] In another aspect, herein a compound of formula (II): [ka] or a pharmaceutically acceptable salt thereof, wherein: R 1 is a 5- to 10-membered heteroaryl, NH 2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 is alkyl, R 2 is a 5- to 10-membered heteroaryl, NH 2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 is alkyl, R 3 is a 4- to 8-membered heterocycle or a 5-membered heteroaryl, where the 4- to 8-membered heterocycle is optionally a group R 3a , the 5-membered heteroaryl is optionally substituted once, twice, or three times with R 3b is replaced once, twice, or three times with R 3a , but independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkyl-(C 6 ~C 10 aryl), S(O) 2 H, S(O) 2 -(C 1 ~C 6 alkyl), S(O) 2 -(C 3 ~C 7 cycloalkyl), or S(O) 2 -(C 6 ~C 10 aryl), R 3b , but independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkyl, halo, nitro, cyano, C(O)-(4- to 8-membered heterocycle), or C 1 ~C 6 alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle is optionally C 1 ~C 3 further substituted once, twice, or three times with alkyl, R 4 is hydrogen or C 1-3 It is an alkyl.

[0074] In some embodiments, R 1 is C 1-6 It is an alkyl. In some embodiments, R 1 is C 1-3 It is an alkyl. In some embodiments, R 1 is methyl or ethyl. In some embodiments, R 1 is methyl. In some embodiments, R 1 is ethyl.

[0075] In some embodiments, R 2 is C 1-6 It is an alkyl. In some embodiments, R 2 is C 1-3 It is an alkyl. In some embodiments, R 2 is methyl or ethyl. In some embodiments, R 2 is methyl. In some embodiments, R 2 is ethyl.

[0076] In some embodiments, R 1 and R 2 are the same.

[0077] In some embodiments, R 3 is a 6-membered heterocycle or a 5-membered heteroaryl, where the 6-membered heterocycle is optionally a group R 3a , the 5-membered heteroaryl is optionally substituted once, twice, or three times with R 3b is substituted once, twice, or three times.

[0078] In some embodiments, R 3 is morpholinyl, piperidinyl, furyl, thiophenyl, or pyrazolyl, where morpholinyl and piperidinyl optionally represent the group R 3a Furyl, thiophenyl, and pyrazolyl are optionally substituted once, twice, or three times with R 3b is substituted once, twice, or three times.

[0079] In some embodiments, R 3 is the group R 3b is furyl, thiophenyl, or pyrazolyl, optionally substituted once, twice, or three times with . In some embodiments, R 3 is the group R 3b is furyl, thiophenyl, or pyrazolyl, substituted once, twice, or three times with .

[0080] In some embodiments, R 3 is the group R 3b is a frill that is optionally replaced once, twice, or three times with . In some embodiments, R 3 is the group R 3b is a frill that is replaced once, twice, or three times.

[0081] In some embodiments, R 3 is the group R 3a is morpholinyl or piperidinyl, optionally substituted once, twice, or three times with .

[0082] In some embodiments, R 3a is independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkyl-(C 6 ~C 10 aryl), S(O) 2 -(C 1 ~C 6 alkyl), or S(O) 2 -(C 6 ~C 10 aryl).

[0083] In some embodiments, R 3a is independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkyl-(phenyl), S(O) 2 -(C 1 ~C 6 alkyl), or S(O) 2 -(phenyl).

[0084] In some embodiments, R 3a is represented, at each occurrence independently, by a group selected from: [ka]

[0085] In some embodiments, R 3b is independently for each occurrence, C 1 ~C 6 Alkyl, halo, nitro, C(O)-(4- to 8-membered heterocycle), or C 1 ~C 6 alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle is optionally C 1 ~C 3 Further substituted once, twice, or three times with alkyl.

[0086] In some embodiments, R 3b is independently for each occurrence, C 1 ~C 6Alkyl, halo, nitro, C(O)-(4- to 8-membered heterocycle), or C 1 ~C 6 Alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle is independently from the group consisting of pyrrolidinyl, pyrrolidinonyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, and piperazinyl. and each 4- to 8-membered heterocycle is optionally C 1 ~C 3 Further substituted once, twice, or three times with alkyl.

[0087] In some embodiments, R 3b is independently for each occurrence, C 1 ~C 6 Alkyl, halo, nitro, C(O)-(4- to 8-membered heterocycle), or C 1 ~C 6 alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle is independently selected from the group consisting of morpholinyl, piperidinyl, and piperazinyl; The 8-membered heterocycle is optionally further substituted with methyl once, twice, or three times.

[0088] In some embodiments, R 3b is represented, at each occurrence independently, by a group selected from: [ka] In some embodiments, R 4 is hydrogen or methyl. In some embodiments, R 4 is hydrogen. In some embodiments, R 4 is methyl.

[0089] In some embodiments, R 3 is C(O)-(4- to 8-membered heterocycle) or C 1 ~C 6 Furyl substituted once, twice, or three times with alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle is optionally C 1 ~C 3 Further substituted once, twice, or three times with alkyl.

[0090] In some embodiments, R 3 is C(O)-(4- to 8-membered heterocycle) or C 1 ~C 6 Furyl substituted once, twice, or three times with alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle is independently pyrrolidinyl, pyrrolidinonyl, tetrahydrofuran. selected from the group consisting of Cyl, morpholinyl, thiomorpholinyl, piperidinyl, and piperazinyl, and each 4- to 8-membered heterocycle 1 ~C 3 Further substituted once, twice, or three times with alkyl.

[0091] In some embodiments, R 3 is C(O)-(4- to 8-membered heterocycle) or C 1 ~C 6 Furyl substituted once, twice, or three times with alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle is independently morpholinyl, piperidinyl, and each 4- to 8-membered heterocycle is selected from the group consisting of piperazinyl, and each 4- to 8-membered heterocycle is optionally C 1 ~C 3 Further substituted once, twice, or three times with alkyl.

[0092] In some embodiments, R 3 is C(O)-(morpholinyl) or C 1 ~C 6 Furyl is substituted once, twice, or three times with alkyl-(morpholinyl).

[0093] In some embodiments, R 3 is represented by a group selected from: [ka]

[0094] In certain embodiments, the compound of formula (II) has the structure of compound 24: [ka]

[0095] In certain embodiments, the compound of formula (II) has the structure of compound 25: [ka]

[0096] In certain embodiments, the compound of formula (II) has the structure of compound 37: [ka]

[0097] Exemplary compounds of formula (II) include the compounds described below, or a pharmaceutically acceptable salt thereof: [ka] [ka] [ka]

[0098] In yet another aspect, herein a compound of formula (III): [ka] or a pharmaceutically acceptable salt thereof, wherein: L is C 1 ~C 6 is alkyl or absent; R 1 is a 5- to 10-membered heteroaryl, NH 2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 is alkyl, R 2 is a 5- to 10-membered heteroaryl, NH 2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 is alkyl, R 3 However, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkyl, halo, hydroxy, C(O)NH 2 ,C(O)NH(C 1 ~C 6 alkyl), C(O)N(C 1 ~C 6 alkyl) 2 , or C(O)-(4- to 8-membered heterocycle), where C 1 ~C 6 Alkyl and C 1 ~C 6 alkoxy is optionally C 6 ~C 10 substituted once, twice, or three times with aryl, C(O)-(4- to 8-membered heterocycle) is optionally substituted with C 1 ~C 3 Substituted once, twice, or three times with alkyl.

[0099] In some embodiments, L is C 1 ~C 3 Alkyl or absent. In some embodiments, L is C 1 ~C 3 It is an alkyl. In certain embodiments, L is absent.

[0100] In some embodiments, R 1 is NH 2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 It is an alkyl. In some embodiments, R 1 is N(C 1 ~C 6 alkyl) 2 C optionally replaced with 1 ~C 6 It is an alkyl. In some embodiments, R 1 is N(C 1 ~C 3 alkyl) 2 C optionally replaced with 1 ~C 3 It is an alkyl. In some embodiments, R 1 is methyl or ethyl, where ethyl is optionally N(CH 2 CH 3 ) 2 will be replaced with

[0101] In some embodiments, R 2 is NH2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 It is an alkyl. In some embodiments, R 2 is N(C 1 ~C 6 alkyl) 2 C optionally replaced with 1 ~C 6 It is an alkyl. In some embodiments, R 2 is N(C 1 ~C 3 alkyl) 2 C optionally replaced with 1 ~C 3 It is an alkyl. In some embodiments, R 2 is methyl or ethyl, where ethyl is optionally N(CH 2 CH 3 ) 2 will be replaced with

[0102] In some embodiments, R 1 and R 2 are the same.

[0103] In some embodiments, R 3 is C 1 ~C 6 Alkyl, C 1 ~C 6 alkoxy, hydroxy, or C(O)-(4- to 8-membered heterocycle), where C 1 ~C 6 Alkyl and C 1 ~C 6 Alkoxy is optionally C 6 ~C 10 Substituted once with aryl, C(O)-(4- to 8-membered heterocycle) is optionally substituted with C 1 ~C 3 Substituted once with alkyl.

[0104] In some embodiments, R 3 is C 1 ~C 3 Alkyl, C 1 ~C 3 alkoxy, hydroxy, or C(O)-(6-membered heterocycle), where C 1 ~C 3 Alkyl and C 1 ~C 3 Alkoxy is optionally substituted once with phenyl.

[0105] In some embodiments, R 3 is C 1 ~C 3 Alkyl, C 1 ~C 3 alkoxy, hydroxy, or C(O)-(morpholinyl), where C 1 ~C 3 Alkyl and C 1 ~C 3 Alkoxy is optionally substituted once with phenyl.

[0106] In some embodiments, R 3 The group represented by -L has one of the following structures: [ka]

[0107] In some embodiments, L is absent and R 3 is C 1 ~C 6 It is an alkyl.

[0108] Exemplary compounds of formula (III) include the compounds described below, or a pharmaceutically acceptable salt thereof: [ka]

[0109] In another aspect, herein a compound of formula (IV): [ka] or a pharmaceutically acceptable salt thereof, wherein: L is C 3 ~C 7 cycloalkyl, C 1 ~C 6 is alkyl or absent; R 1 is a 5- to 10-membered heteroaryl, NH 2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 is alkyl, R 2 is a 5- to 10-membered heteroaryl, NH 2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 is alkyl, R 3 However, C 6 ~C 10 Aryl, 5- to 10-membered heteroaryl, C 3 ~C 10 Cycloalkyl, C(O)NH-(C 1 ~C 6 alkyl)-PPh 3 , hydroxy, C 1 ~C 6 Alkoxy, or O-(C 1 ~C 6 alkyl)-O-(C 1 ~C 6 alkyl), where C 6 ~C 10 Aryl is a group R 3a 5- to 10-membered heteroaryl substituted once, twice, or three times with R 3b is replaced once, twice, or three times with R 3a , but independently for each occurrence, C 3 ~C 7 cycloalkyl or 4- to 8-membered heterocycle, where the 4- to 8-membered heterocycle is optionally C 1 ~C 3 further substituted once, twice, or three times with alkyl, R 3b , but independently for each occurrence, C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 3 ~C 7 cycloalkyl, or a 4- to 8-membered heterocycle, where the heterocycle is optionally C 1 ~C 3 further substituted once, twice, or three times with alkyl, R 4 is hydrogen, C 1 ~C 3 alkyl, or C 6 ~C 10 Although it is an aryl, However, if L is absent, R 3 is the group R 3a C replaced once, twice, or three times with 6 ~C 10 If aryl or L is absent, then R 3 is the group R 3b is a 6- to 10-membered heteroaryl substituted once, twice, or three times with or when L is absent, R 3 is the group R 3b is a 6- to 10-membered heteroaryl optionally substituted once, twice, or three times with R 4 is H.

[0110] In some embodiments, L is C 3 ~C 7 cycloalkyl or C 1 ~C 6 It is an alkyl. In some embodiments, L is C 3 ~C 7 It is cycloalkyl. In some embodiments, L is C 1 ~C 6 It is an alkyl. In some embodiments, L is C 3 ~C 5 cycloalkyl or C 1 ~C 3 It is an alkyl. In some embodiments, L is C 3 ~C 5 It is cycloalkyl. In some embodiments, L is C 1 ~C 3 It is an alkyl.

[0111] In certain embodiments, L is -CH 2 -is. In certain embodiments, L is -CH 2 CH 2 -is. In certain embodiments, L is -CH 2 CH 2 CH 2 -is. In certain embodiments, L is -CH 2 CH 2 CH 2 CH 2 -is. In certain embodiments, L is -CH(CH 3 )-is. In certain embodiments, L is -CH(CH 2 CH3 )-is. In certain embodiments, L is -C(CH 3 ) 2 -is.

[0112] In some embodiments, L is C 3 ~C 7 cycloalkyl or C 3 ~C 5 cycloalkyl, where the cycloalkyl group is a group R 3 and a quaternary carbon that forms the point of attachment to the rest of the scaffold. Thus, in certain embodiments, L is represented by one of the following groups: [ka]

[0113] In some embodiments, R 1 is C 1-6 It is an alkyl. In some embodiments, R 1 is C 1-3 It is an alkyl. In some embodiments, R 1 is methyl or ethyl. In some embodiments, R 1 is methyl. In some embodiments, R 1 is ethyl.

[0114] In some embodiments, R 1 is C optionally substituted with a 5-membered heteroaryl 1 ~C 6 It is an alkyl. In some embodiments, R 1 is optionally replaced by frill C 1 ~C 6 It is an alkyl. In some embodiments, R 1 is CH 2 -It's frilly.

[0115] In some embodiments, R 2 is C 1-6 It is an alkyl. In some embodiments, R 2 is C 1-3 It is an alkyl. In some embodiments, R 2 is methyl or ethyl. In some embodiments, R 2 is methyl. In some embodiments, R 2 is ethyl.

[0116] In some embodiments, R 2 is C optionally substituted with a 5-membered heteroaryl 1 ~C 6 It is an alkyl. In some embodiments, R 2 is optionally replaced by frill C 1 ~C 6 It is an alkyl. In some embodiments, R 2 is CH 2 -It's frilly.

[0117] In some embodiments, R 1 and R 2 are the same.

[0118] In some embodiments, R 3 is C 6 ~C 10 Aryl, 5- to 10-membered heteroaryl, C 3 ~C 10 cycloalkyl, or C 1 ~C 6 alkoxy, where C 6 ~C 10 Aryl is the group R 3a 5- to 10-membered heteroaryl substituted once, twice, or three times with R 3b is substituted once, twice, or three times.

[0119] In some embodiments, R 3 is a 5- to 10-membered heteroaryl or C 3 ~C 10 cycloalkyl, where the 5- to 10-membered heteroaryl is optionally a group R 3b is substituted once, twice, or three times.

[0120] In some embodiments, R 3 is phenyl, pyrazolyl, pyridinyl, benzofuranyl, benzothiazolyl, benzodioxolyl, C 3 ~C 6 Cycloalkyl, adamantyl, C(O)NH-(C 1 ~C 6 alkyl)-PPh 3 , hydroxy, C 1 ~C 6 Alkoxy, or O-(C 1 ~C 6 alkyl)-O-(C 1 ~C 6 alkyl), where phenyl is a group R 3a pyrazolyl, pyridinyl, benzofuranyl, benzothiazolyl, and benzodioxolyl are optionally substituted once, twice, or three times with 3b is substituted once, twice, or three times.

[0121] In some embodiments, R 3 is phenyl, pyrazolyl, pyridinyl, benzofuranyl, benzothiazolyl, benzodioxolyl, or C 1 ~C 6 alkoxy, where pyrazolyl, pyridinyl, benzofuranyl, benzothiazolyl, and benzodioxolyl optionally represent the group R 3b is replaced once or twice.

[0122] In some embodiments, R 3 is pyridinyl, benzofuranyl, or benzodioxolyl, where pyridinyl, benzofuranyl, and benzodioxolyl optionally represent the group R 3b is replaced once or twice.

[0123] In some embodiments, R 3 is benzofuranyl or benzodioxolyl, where benzofuranyl and benzodioxolyl optionally represent the group R 3b is replaced once or twice.

[0124] In some embodiments, R 3a is independently for each occurrence, C 1 ~C 3 A 4- to 8-membered heterocycle optionally further substituted once, twice, or three times with alkyl. In some embodiments, R 3a is a 4- to 8-membered heterocycle optionally further substituted once with methyl, independently at each occurrence.

[0125] In some embodiments, R 3a is, independently at each occurrence, pyrrolidinyl, pyrrolidinonyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, or piperazinyl, each of which is optionally C 1 ~C 3 Further substituted once, twice, or three times with alkyl. In some embodiments, R 3a is, independently at each occurrence, pyrrolidinyl, pyrrolidinonyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, or piperazinyl, each of which is optionally further substituted once with methyl. In some embodiments, R 3a is, independently at each occurrence, pyrrolidinyl, pyrrolidinonyl, or morpholinyl. In some embodiments, R 3a is represented, at each occurrence independently, by a group selected from: [ka]

[0126] In some embodiments, R 3b is independently for each occurrence, C 1 ~C 3 Alkyl, C 1 ~C 3 alkoxy, or a 4- to 8-membered heterocycle, where the heterocycle is optionally C 1 ~C 3 Further substituted once, twice, or three times with alkyl. In some embodiments, R 3b is independently for each occurrence, C 1 ~C 3 Alkoxy or a 4- to 8-membered heterocycle, where the heterocycle is optionally further substituted once with methyl.

[0127] In some embodiments, R 3b is independently for each occurrence, C 1 ~C 3 Alkyl, C 1 ~C 3 alkoxy or a heterocycle selected from the group consisting of pyrrolidinyl, pyrrolidinonyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, and piperazinyl, wherein the heterocycle 1 ~C 3 Further substituted once, twice, or three times with alkyl. In some embodiments, R 3b is independently for each occurrence, C 1 ~C 3 Alkyl, C 1 ~C 3 alkoxy or a heterocycle selected from the group consisting of pyrrolidinyl, pyrrolidinonyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, and piperazinyl, where the heterocycle is optionally further substituted once with methyl. be done. In some embodiments, R 3bis, independently at each occurrence, methyl, methoxy, or a heterocycle selected from the group consisting of pyrrolidinyl and morpholinyl. In some embodiments, R 3b is independently for each occurrence, [ka] represented by a group selected from

[0128] In some embodiments, R 4 is hydrogen, C 1 ~C 3 Alkyl or phenyl. In some embodiments, R 4 is hydrogen, methyl, or phenyl. In some embodiments, R 4 is hydrogen or C 1 ~C 3 It is an alkyl. In some embodiments, R 4 is hydrogen or methyl. In some embodiments, R 4 is hydrogen. In some embodiments, R 4 is methyl. In some embodiments, R 4 is phenyl.

[0129] In some embodiments, L is C 1 ~C 6 is alkyl and R 3 is C 1 ~C 6 It is alkoxy.

[0130] In some embodiments, R 3 The group represented by -L is represented by one of the following: [ka]

[0131] In some embodiments, R 3 The group represented by -L is represented by one of the following: [ka]

[0132] In some embodiments, R 3 is C 1 ~C 3 is pyridinyl, optionally substituted once, twice, or three times with alkoxy or a 4- to 8-membered heterocycle, where the 4- to 8-membered heterocycle is optionally substituted with C 1 ~C 3 Substituted once with alkyl.

[0133] In some embodiments, if L is absent, then R 3 is the group R 3a C replaced once, twice, or three times with 6 ~C 10 If aryl or L is absent, then R 3 is the group R 3b is a 6- to 10-membered heteroaryl substituted once, twice, or three times. In another embodiment, if L is absent, R 3 is the group R 3a C replaced once, twice, or three times with 6 ~C 10 If aryl or L is absent, then R 3 is the group R 3b is a 6- to 10-membered heteroaryl optionally substituted once, twice, or three times with R 4 is H.

[0134] In some embodiments, if L is absent, then R 3 is C 1 ~C 3 Pyridinyl substituted once, twice, or three times with alkoxy.

[0135] In some embodiments, if L is absent, then R 3 is phenyl substituted with a 4- to 8-membered heterocycle.

[0136] In some embodiments, if L is absent, then R 3 is the group R 3a C replaced once, twice, or three times with 6 ~C 10 If aryl or L is absent, then R 3 is the group R 3b is a 6- to 10-membered heteroaryl substituted once, twice, or three times.

[0137] In some embodiments, L is C 3 ~C 5 cycloalkyl or C 1 ~C 3 is alkyl and R 3 is pyridinyl optionally substituted once, twice, or three times with a 4- to 8-membered heterocycle, and R 4 is methyl.

[0138] Exemplary compounds of formula (IV) include the following compounds, or pharmaceutically acceptable salts thereof: [ka] [ka] [ka] [ka]

[0139] In certain embodiments, the compound of formula (IV) is one of the following compounds, or a pharmaceutically acceptable salt thereof: [ka]

[0140] In certain embodiments, the compound of formula (IV) has the structure of Compound 2: [ka]

[0141] In certain embodiments, the compound of formula (IV) has the structure of compound 59: [ka]

[0142] In certain embodiments, the compound of formula (IV) has the structure of compound 60: [ka]

[0143] In certain embodiments, the compound of formula (IV) has the structure of compound 61: [ka]

[0144] In certain embodiments, the compound of formula (IV) has the structure of compound 74: [ka]

[0145] In certain embodiments, the compound of formula (IV) has the structure of compound 74: [ka]

[0146] In another aspect, herein a compound of formula (V): [ka] or a pharmaceutically acceptable salt thereof, wherein: R 1 is a 5- to 10-membered heteroaryl, NH 2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 is alkyl, R 2 is a 5- to 10-membered heteroaryl, NH 2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 is alkyl, R 3 is a 4- to 8-membered heterocycle or a 5-membered heteroaryl, where the 4- to 8-membered heterocycle is optionally a group R 3a , the 5-membered heteroaryl is optionally substituted once, twice, or three times with R 3b is replaced once, twice, or three times with R 3a , but independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkyl-(C 6 ~C 10 aryl), C 1 ~C 6Alkyl-(5- to 10-membered heteroaryl), S(O) 2 H, S(O) 2 -(C 1 ~C 6 alkyl), S(O) 2 -(C 3 ~C 7 cycloalkyl), or S(O) 2 -(C 6 ~C 10 aryl), where each heteroaryl is optionally C 1 ~C 6 alkyl or C 6 ~C 10 further substituted 1-4 times with aryl, each C 6 ~C 10 aryl is optionally C 1 ~C 6 further substituted with alkyl 1 to 4 times, R 3b , but independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 haloalkyl, C 1 ~C 6 Alkyl-N(R 5 ) 2 ,(C 1 ~C 6 alkyl)-O-(C 1 ~C 6 alkyl), halo, nitro, cyano, C 6 ~C 10 Aryl, C(O)-(4- to 8-membered heterocycle), C 1 ~C 6 Alkyl-(C 6 ~C 10 aryl), C 1 ~C 6 Alkyl-(5- to 10-membered heteroaryl), or C 1 ~C 6 Alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle, C 6 ~C 10 Aryl and 5- to 10-membered heteroaryl optionally C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 further substituted with haloalkyl, or halo 1 to 4 times, R 4 is hydrogen or C 1-3 is alkyl, R 5 However, each occurrence independently indicates that hydrogen, C 1 ~C 6 alkyl, or C 1 ~C 3 Alkyl-(C 6 ~C 10 aryl).

[0147] In some embodiments, R 1 is C 1-6 It is an alkyl. In some embodiments, R 1 is C 1-3 It is an alkyl. In some embodiments, R 1 is methyl or ethyl. In some embodiments, R 1 is methyl. In some embodiments, R 1 is ethyl.

[0148] In some embodiments, R 1 is C optionally substituted with a 5-membered heteroaryl 1 ~C 6 It is an alkyl. In some embodiments, R 1 is optionally replaced by frill C 1 ~C 6 It is an alkyl. In some embodiments, R 1 is CH 2 -It's frilly.

[0149] In some embodiments, R 2 is C 1-6 It is an alkyl. In some embodiments, R 2 is C 1-3 It is an alkyl. In some embodiments, R 2 is methyl or ethyl. In some embodiments, R 2 is methyl. In some embodiments, R 2 is ethyl.

[0150] In some embodiments, R 2 is C optionally substituted with a 5-membered heteroaryl 1 ~C 6 It is an alkyl. In some embodiments, R 2 is optionally replaced by frill C 1 ~C 6 It is an alkyl. In some embodiments, R 2 is CH 2 -It's frilly.

[0151] In some embodiments, R 1 and R 2 are the same.

[0152] In some embodiments, R 3 is a 5- to 6-membered heterocycle or a 5-membered heteroaryl, where the 5- to 6-membered heterocycle is optionally a group R 3a , the 5-membered heteroaryl is optionally substituted once, twice, or three times with R 3b is substituted once, twice, or three times.

[0153] In some embodiments, R 3 is tetrahydrofuranyl, morpholinyl, piperidinyl, furyl, thiophenyl, pyrrolyl, oxazolyl, pyrazolyl, or imidazolyl, where tetrahydrofuranyl, morpholinyl, and piperidinyl optionally represent the group R 3a furyl, thiophenyl, pyrrolyl, oxazolyl, pyrazolyl, and imidazolyl are optionally substituted once, twice, or three times with the group R 3b is substituted once, twice, or three times.

[0154] In some embodiments, R 3 is the group R 3b is furyl, thiophenyl, oxazolyl, pyrazolyl, or imidazolyl, optionally substituted once, twice, or three times with . In another embodiment, R 3 is the group R 3b is furyl, thiophenyl, oxazolyl, pyrazolyl, or imidazolyl, substituted once, twice, or three times with .

[0155] In some embodiments, R 3 is the group R 3b is a frill that is optionally replaced once, twice, or three times with . In another embodiment, R 3 is the group R 3b is a frill that is replaced once, twice, or three times.

[0156] In some embodiments, R 3 is the group R 3b is thiophenyl, optionally substituted once, twice, or three times with . In another embodiment, R 3 is the group R 3b is thiophenyl substituted once, twice, or three times with .

[0157] In some embodiments, R 3 is the group R 3b is oxazolyl, optionally substituted once, twice, or three times with . In another embodiment, R 3 is the group R 3b is oxazolyl substituted once, twice, or three times with .

[0158] In some embodiments, R 3 is the group R 3b pyrazolyl, optionally substituted once, twice, or three times with . In another embodiment, R 3 is the group R 3b pyrazolyl substituted once, twice, or three times with .

[0159] In some embodiments, R 3 is the group R 3b imidazolyl optionally substituted once, twice, or three times with . In another embodiment, R 3 is the group R 3b imidazolyl substituted once, twice, or three times with .

[0160] In some embodiments, R 3 is tetrahydrofuranyl, morpholinyl, or piperidinyl, each of which optionally represents the group R 3a is substituted once, twice, or three times.

[0161] In some embodiments, R 3a is independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkyl-(C 6 ~C 10 aryl), C 1 ~C 6 Alkyl-(5- to 10-membered heteroaryl), S(O) 2 -(C 1 ~C 6 alkyl), or S(O) 2 -(C 6 ~C 10 aryl), where each heteroaryl is optionally C 1 ~C 6 alkyl or C 6~C 10 further substituted 1-4 times with aryl, each C 6 ~C 10 Aryl is optionally C 1 ~C 6 Further substituted with alkyl 1 to 4 times.

[0162] In some embodiments, R 3a is independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkyl-(phenyl), C 1 ~C 6 Alkyl-(5- to 6-membered heteroaryl), S(O) 2 -(C 1 ~C 6 alkyl), or S(O) 2 -(phenyl), where each heteroaryl is optionally C 1 ~C 3 further substituted 1 to 4 times with alkyl or phenyl, each phenyl optionally being C 1 ~C 3 Further substituted with alkyl 1 to 4 times.

[0163] In some embodiments, R 3a is independently for each occurrence, [ka] It is.

[0164] In some embodiments, R 3b is independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkyl-N(R 5 ) 2 ,(C 1 ~C 6 alkyl)-O-(C 1 ~C 6 alkyl), halo, nitro, C 6 ~C 10 Aryl, C(O)-(4- to 8-membered heterocycle), C 1 ~C 6 Alkyl-(C 6 ~C 10 aryl), C 1 ~C 6 Alkyl-(5- to 10-membered heteroaryl), or C 1 ~C 6 Alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle, C 6 ~C 10 Aryl and 5- to 10-membered heteroaryl are optionally C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 Further substituted with haloalkyl or halo 1 to 4 times.

[0165] In some embodiments, R 3b is independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkyl-N(R 5 ) 2 , halo, C 6 ~C 10 Aryl, C 1 ~C 6 Alkyl-(4- to 8-membered heterocycle), or C 1 ~C 6 Alkyl-(C 6 ~C 10 aryl), where each 4- to 8-membered heterocycle and C 6 ~C 10 Aryl is optionally C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 Further substituted with haloalkyl or halo 1 to 4 times.

[0166] In some embodiments, R 3b is independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 3 Alkyl-N(R 5 ) 2 , halo, phenyl, C 1 ~C 3 Alkyl-(5- to 6-membered heterocycle), or C 1 ~C 6 alkyl-phenyl, where each 5- to 6-membered heterocycle and phenyl are optionally C 1 ~C 3 Further substituted with alkyl or halo 1 to 4 times.

[0167] In some embodiments, R 3b is independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkyl-N(R 5 ) 2 ,(C 1 ~C 6 alkyl)-O-(C 1 ~C 6 alkyl), halo, nitro, C 6 ~C 10 Aryl, C(O)-(4- to 8-membered heterocycle), C 1 ~C 6 Alkyl-(C 6 ~C 10 aryl), C 1 ~C 6 Alkyl-(5- to 10-membered heteroaryl), or C 1 ~C 6 Alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle, C 6 ~C 10 Aryl and 5- to 10-membered heteroaryl are optionally -CH 3 ,-CH 2 CH 3 ,-OCH 3 ,-CH 2 F,CHF 2 ,-CF 3 , -F, or -Cl are further substituted 1 to 4 times.

[0168] In some embodiments, R 3b is independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkyl-N(R 5 ) 2 ,(C 1 ~C 6 alkyl)-O-(C 1 ~C 6 alkyl), halo, nitro, phenyl, C(O)-(4- to 8-membered heterocycle), C 1 ~C 6 Alkyl-phenyl, C 1 ~C 6 Alkyl-(5- to 10-membered heteroaryl), or C 1 ~C 6 Alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle is independently from the group consisting of pyrrolidinyl, pyrrolidinonyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, and piperazinyl. each 5- to 10-membered heteroaryl is selected from the group consisting of furyl and tetrahydroisoquinolinyl; each 4- to 8-membered heterocycle, phenyl, and 5- to 10-membered heteroaryl are optionally selected from the group consisting of furyl and tetrahydroisoquinolinyl; So, -CH 3 ,-CH 2 CH 3 ,-OCH 3 ,-CH 2 F,CHF 2 ,-CF 3 , -F, or -Cl are further substituted 1 to 4 times.

[0169] In some embodiments, R 3b is independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkyl-N(R 5 ) 2 ,(C 1 ~C 6 alkyl)-O-(C 1 ~C 6 alkyl), halo, nitro, phenyl, C(O)-(4- to 8-membered heterocycle), C 1 ~C 6 Alkyl-phenyl, C 1 ~C 6 Alkyl-(5- to 10-membered heteroaryl), or C 1 ~C 6 Alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle is independently selected from the group consisting of pyrrolidinyl, morpholinyl, piperidinyl, and piperazinyl, and each 5- to 8-membered heterocycle is 10-membered heteroaryl is selected from the group consisting of furyl and tetrahydroisoquinolinyl, each 4- to 8-membered heterocycle, phenyl, and 5- to 10-membered heteroaryl, optionally -CH 3 ,-OCH 3 ,-CF 3 , or further substituted with -F 1 to 4 times.

[0170] In some embodiments, R 3b is independently for each occurrence, [ka] It is.

[0171] In some embodiments, R 3b is independently for each occurrence, [ka] It is.

[0172] In some embodiments, R 3b is independently for each occurrence, [ka] It is.

[0173] In some embodiments, R 3b is independently for each occurrence, [ka] It is.

[0174] In some embodiments, R 3b is independently for each occurrence, [ka] It is.

[0175] In some embodiments, R 3 is C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 haloalkyl, C 1 ~C 6 Alkyl-N(R 5 ) 2 ,(C 1 ~C 6 alkyl)-O-(C 1 ~C 6 alkyl), halo, nitro, cyano, C 6 ~C 10 Aryl, C(O)-(4- to 8-membered heterocycle), C 1 ~C 6 Alkyl-(C 6 ~C 10 aryl), C 1 ~C 6 Alkyl-(5- to 10-membered heteroaryl), or C 1 ~C 6 Furyl, optionally substituted once, twice, or three times with alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle, C 6 ~C 10 Aryl and 5- to 10-membered heteroaryl are optionally C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 Further substituted with haloalkyl or halo 1 to 4 times.

[0176] In some embodiments, R 3 is C 1 ~C 6 Alkyl, C 1 ~C 6 Alkyl-N(R 5 ) 2 , halo, C(O)-(4- to 8-membered heterocycle), or C 1 ~C 6 is furyl, optionally substituted once, twice, or three times with alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle is optionally substituted with C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 Further substituted with haloalkyl or halo 1 to 4 times.

[0177] In some embodiments, R 3 is C 1 ~C 6 Alkyl-N(R 5 ) 2 or C 1 ~C 6 is furyl, optionally substituted once, twice, or three times with alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle is optionally substituted with C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 Further substituted with haloalkyl or halo 1 to 4 times.

[0178] In some embodiments, R 3 is C 1 ~C 3 Alkyl-N(C 1 ~C 4 alkyl) 2 or C 1 ~C 3 is furyl, optionally substituted once with alkyl-(5- to 6-membered heterocycle), where the 5- to 6-membered heterocycle is optionally substituted with C 1 ~C 3 Further substituted with alkyl 1 to 4 times.

[0179] In some embodiments, R 3 is C 1 ~C 3 Alkyl-N(C 1 ~C 4 alkyl) 2 or C 1 ~C 3 furyl, substituted once with alkyl-(5- to 6-membered heterocycle), where the 5- to 6-membered heterocycle is optionally C 1 ~C 3 Further substituted with alkyl 1 to 4 times.

[0180] In some embodiments, R 3 is C 1 ~C 6 alkyl, halo, C 6 ~C 10 aryl, or C 1 ~C 6 Alkyl-(C 6 ~C 10 thiophenyl, oxazolyl, pyrazolyl, or imidazolyl, optionally substituted once, twice, or three times with 6 ~C 10 Aryl is optionally C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 Further substituted with haloalkyl or halo 1 to 4 times.

[0181] In some embodiments, R 3 is methyl, ethyl, halo, phenyl, or C 1 ~C 3 thiophenyl, oxazolyl, pyrazolyl, or imidazolyl, optionally substituted once, twice, or three times with alkyl-phenyl, where each phenyl is optionally substituted with C 1 ~C 3 Further substituted with alkyl or halo 1 to 4 times.

[0182] In some embodiments, R 3 teeth, [ka] [ka] It is.

[0183] In some embodiments, R 3 teeth, [ka] It is.

[0184] In some embodiments, R 3 teeth, [ka] It is.

[0185] In some embodiments, R 3 teeth, [ka] It is.

[0186] In some embodiments, R 3 teeth, [ka] It is.

[0187] In some embodiments, R 4 is hydrogen or methyl. In some embodiments, R 4 is hydrogen. In some embodiments, R 4 is methyl.

[0188] In some embodiments, R 5 is C 1 ~C 6 alkyl or C 1 ~C 3 Alkyl-(C 6 ~C 10 aryl). In another embodiment, R 5 is C 1 ~C 4 alkyl or C 1 ~C 3 It is alkyl-phenyl. In another embodiment, R 5 is C 1 ~C 4 Alkyl or benzyl.

[0189] In some embodiments, R 1 is not methyl and R 2 is not methyl and R 4 If is not hydrogen, then R 3b is independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 haloalkyl, C 1 ~C 6 Alkyl-N(R 5 ) 2 ,(C 1 ~C 6 alkyl)-O-(C 1 ~C 6 alkyl), halo, nitro, cyano, C 6 ~C 10 Aryl, C(O)-(4- to 8-membered heterocycle), C 1 ~C 6 Alkyl-(C 6 ~C 10 aryl), C 1 ~C 6 Alkyl-(5- to 10-membered heteroaryl), or C 1 ~C 6 Alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle, C 6 ~C 10 Aryl and 5- to 10-membered heteroaryl are optionally C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 Further substituted one or two times with haloalkyl, or halo.

[0190] In some embodiments, R 4 If is not hydrogen, then R 3b is independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 haloalkyl, C 1 ~C 6 Alkyl-N(R 5 ) 2 ,(C 1 ~C 6 alkyl)-O-(C 1 ~C 6 alkyl), halo, nitro, cyano, C 6 ~C 10 Aryl, C(O)-(4- to 8-membered heterocycle), C 1 ~C 6 Alkyl-(C 6 ~C 10 aryl), C 1 ~C 6 Alkyl-(5- to 10-membered heteroaryl), or C 1 ~C 6 Alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle, C 6 ~C 10 Aryl and 5- to 10-membered heteroaryl are optionally C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 Further substituted one or two times with haloalkyl, or halo.

[0191] In some embodiments, R 3 is oxazolyl, then R 3 does not have the following structure: [ka]

[0192] In certain embodiments of the compound of formula (V), or a pharmaceutically acceptable salt thereof, R 1 is C 1 ~C 3 is alkyl, R 2 is C 1 ~C 3 is alkyl, R 3 is the group R 3b is a 5-membered heteroaryl optionally substituted once, twice, or three times with R 3b is independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkyl-N(R 5 ) 2 ,(C 1 ~C 6 alkyl)-O-(C 1 ~C 6 alkyl), halo, C 6 ~C 10 Aryl, C(O)-(4- to 8-membered heterocycle), C 1 ~C 6 Alkyl-(C 6 ~C 10 aryl), C 1 ~C 6 Alkyl-(5- to 10-membered heteroaryl), or C 1 ~C 6 Alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle, C 6 ~C 10 Aryl and 5- to 10-membered heteroaryl are optionally C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 further substituted with haloalkyl, or halo 1 to 4 times, R 4 is hydrogen or methyl, R 5 is independently for each occurrence, C 1 ~C 4 Alkyl or benzyl.

[0193] In another embodiment of the compound of formula (V), or a pharmaceutically acceptable salt thereof, R 1 is C 1 ~C 3 is alkyl, R 2 is C 1 ~C 3 is alkyl, R 3 is the group R 3b is a frill optionally substituted once, twice, or three times with R 3b is independently for each occurrence, C 1 ~C 6 Alkyl-N(R 5 ) 2 or C 1 ~C 6 alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle is optionally C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 further substituted with haloalkyl, or halo 1 to 4 times, R 4 is hydrogen or methyl, R 5 is independently for each occurrence, C 1 ~C 4 Alkyl or benzyl.

[0194] In another embodiment of the compound of formula (V), or a pharmaceutically acceptable salt thereof, R 1 is C 1 ~C 3 is alkyl, R 2 is C 1 ~C 3 is alkyl, R 3 is the group R 3b is a frill optionally substituted once, twice, or three times with R 3b is independently for each occurrence, C 1 ~C 6 Alkyl-N(R 5 ) 2 or C 1 ~C 6 alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle is optionally C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 further substituted with haloalkyl, or halo 1 to 4 times, R 4 is hydrogen or methyl, R 5 is independently for each occurrence, C 1 ~C 4 Alkyl or benzyl, but However, R 1 is C 2 ~C 3 is alkyl and R 2 is C 2 ~C 3 is alkyl and R 4 If is methyl, then R 3b is independently for each occurrence, C 1 ~C 6 Alkyl-N(R 5 ) 2 or C 1 ~C 6 alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle is optionally C 1 ~C 3 Alkyl, C1 ~C 3 Alkoxy, C 1 ~C 3 Further substituted one or two times with haloalkyl, or halo.

[0195] In another embodiment of the compound of formula (V), or a pharmaceutically acceptable salt thereof, R 1 is C 1 ~C 3 is alkyl, R 2 is C 1 ~C 3 is alkyl, R 3 is the group R 3b is a frill optionally substituted once, twice, or three times with R 3b is independently for each occurrence, C 1 ~C 6 Alkyl-N(R 5 ) 2 or C 1 ~C 6 alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle is optionally C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 further substituted with haloalkyl, or halo 1 to 4 times, R 4 is hydrogen or methyl, R 5 is independently for each occurrence, C 1 ~C 4 Alkyl or benzyl, but However, R 4 If is methyl, then R 3b is independently for each occurrence, C 1 ~C 6 Alkyl-N(R 5 ) 2 or C 1 ~C 6 alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle is optionally C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 Further substituted one or two times with haloalkyl, or halo.

[0196] Exemplary compounds of formula (V) include the following compounds, or pharmaceutically acceptable salts thereof: [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka]

[0197] In certain embodiments, the compound of formula (V) is one of the following compounds, or a pharmaceutically acceptable salt thereof: [ka] [ka] [ka]

[0198] In certain embodiments, the compound of formula (V) has the structure of compound 25: [ka]

[0199] In certain embodiments, the compound of formula (V) has the structure of compound 32: [ka]

[0200] In certain embodiments, the compound of formula (V) has the structure of compound 34: [ka]

[0201] In certain embodiments, the compound of formula (V) has the structure of compound 35: [ka]

[0202] In certain embodiments, the compound of formula (V) has the structure of compound 37: [ka]

[0203] In certain embodiments, the compound of formula (V) has the structure of compound 80: [ka]

[0204] In certain embodiments, the compound of formula (V) has the structure of compound 81: [ka]

[0205] In certain embodiments, the compound of formula (V) has the structure of compound 82: [ka]

[0206] In certain embodiments, the compound of formula (V) has the structure of compound 84: [ka]

[0207] In certain embodiments, the compound of formula (V) has the structure of compound 85: [ka]

[0208] In certain embodiments, the compound of formula (V) has the structure of compound 86: [ka]

[0209] In certain embodiments, the compound of formula (V) has the structure of compound 87: [ka]

[0210] In certain embodiments, the compound of formula (V) has the structure of compound 88: [ka]

[0211] In certain embodiments, the compound of formula (V) has the structure of compound 90: [ka]

[0212] In certain embodiments, the compound of formula (V) has the structure of compound 94: [ka]

[0213] In certain embodiments, the compound of formula (V) has the structure of compound 95: [ka]

[0214] In certain embodiments, the compound of formula (V) has the structure of compound 96: [ka]

[0215] In certain embodiments, the compound of formula (V) has the structure of compound 98: [ka]

[0216] In certain embodiments, the compound of formula (V) has the structure of compound 100: [ka]

[0217] In certain embodiments, the compound of formula (V) has the structure of compound 105: [ka]

[0218] In certain embodiments, the compound of formula (V) has the structure of compound 106: [ka]

[0219] In certain embodiments, the compound of formula (V) has the structure of compound 120: [ka]

[0220] In certain embodiments, the compound of formula (V) has the structure of compound 123: [ka]

[0221] Another aspect of the disclosure is a compound selected from the group consisting of the compounds described below, or a pharmaceutically acceptable salt thereof: [ka]

[0222] In certain embodiments, the present disclosure provides a compound having the structure of Compound 54: [ka]

[0223] In another aspect, the disclosure provides a compound having the structure of Compound 20: [ka]

[0224] A further aspect of the disclosure is a compound selected from the group consisting of the compounds described below, or a pharmaceutically acceptable salt thereof: [ka]

[0225] A further aspect of the disclosure is a compound selected from the group consisting of the compounds described below, or a pharmaceutically acceptable salt thereof: [ka]

[0226] synthetic intermediate In another aspect, the present disclosure also relates to synthetic intermediates for the copper complexes described herein. In some embodiments, the synthetic intermediate has the formula (I-A): [ka] It has a structure represented by, where the variable elements L, R 1 ,R 2 ,R 3 , and R 4 corresponds to a variable element with the same name as defined in formula (I).

[0227] Exemplary synthetic intermediates represented by formula (I-A) include: [ka] [ka] [ka]

[0228] In some embodiments, the synthetic intermediate has the formula (II-A): [ka] It has a structure represented by, where the variable element R 1 ,R 2 ,R 3 , and R 4 corresponds to a variable element with the same name as defined in formula (II).

[0229] Exemplary synthetic intermediates represented by formula (II-A) include: [ka] [ka] [ka]

[0230] In some embodiments, the synthetic intermediate has the formula (III-A): [ka] It has a structure represented by, where the variable elements L, R 1 ,R 2 , and R 3 corresponds to a variable element with the same name as defined in formula (III).

[0231] Exemplary synthetic intermediates represented by formula (III-A) include: [ka]

[0232] In another aspect, the present disclosure also relates to synthetic intermediates for the copper complexes described herein. In some embodiments, the synthetic intermediate has the formula (IV-A): [ka] It has a structure represented by, where the variable elements L, R 1 ,R 2 ,R 3 , and R 4 corresponds to a variable element with the same name as defined in formula (IV).

[0233] Exemplary synthetic intermediates represented by formula (IV-A) include: [ka] [ka]

[0234] In some embodiments, the synthetic intermediate has the formula (V-A): [ka] It has a structure represented by, where the variable element R 1 ,R 2 ,R 3 , and R 4 corresponds to a variable element with the same name as defined in equation (V).

[0235] Exemplary synthetic intermediates represented by formula (V-A) include: [ka] [ka] [ka] [ka] [ka]

[0236] Additional exemplary synthetic intermediates of this disclosure include the following compounds: [ka]

[0237] pharmaceutical composition In another aspect, herein is provided a pharmaceutical composition comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, diluent, or carrier. provided.

[0238] The formulation of therapeutic compositions and their subsequent administration (dosing) is within the skill of those skilled in the art. Dosing will depend on the severity and responsiveness of the disease state being treated, with courses of treatment lasting from several days to several months, or until a sufficient reduction in the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the patient's body.

[0239] One of ordinary skill in the art can readily determine optimal dosages, dosing techniques, and repetition rates. Optimal dosages may vary depending on the relative potency of the compounds of the disclosure, and are generally found to be effective in in vitro and in vivo animal models. 50 It can be estimated based on the value. Generally, dosages are from 0.01 μg to 100 g / kg body weight, and may be given more than once daily, weekly, monthly, or yearly, or even once every 2 to 20 years. Those skilled in the art can readily estimate repetition rates of dosing based on measured residence times and concentrations of drug in body fluids or tissues. After successful treatment, it may be desirable to subject the patient to maintenance therapy to prevent recurrence of the disease state, in which case a compound of the present disclosure may be administered at a maintenance dose ranging from 0.01 μg to 100 g / kg body weight. It is administered at least once a day to once every 20 years.

[0240] Different dosing regimens may be used to treat neurodegenerative diseases (eg, ALS). In some embodiments, the daily dosage, such as any of the exemplary dosages listed above, is once a day, twice a day for 3, 4, 5, 6, 7, 8, 9, or 10 days. Administered once, three times, three times, or four times. Depending on the stage and severity of the disease being treated, shorter treatment times (e.g. up to 5 days) may be used with higher doses or longer treatment times (e.g. 10 days or more, or several weeks, or a month, or longer) may be used with lower doses. In some embodiments, once-daily or twice-daily dosages are administered every other day.

[0241] In certain embodiments, compounds of the present disclosure may be administered alone or in combination with at least one pharmaceutically acceptable excipient. The expression "pharmaceutically acceptable" means acceptable for use in the pharmaceutical and veterinary fields, ie, not unacceptably toxic or otherwise unsuitable. Examples of pharmaceutically acceptable adjuvants, diluents, excipients, etc. can be found in “Remington's: The Science and Practice of Pharmacy,” 21st Ed., Lippincott Williams and Wilkins, 2005; Incorporated herein by reference.

[0242] The compounds of the present disclosure can be administered in pure form or in suitable pharmaceutical compositions via any of the accepted modes of administration or agents known in the art. Compounds of the present disclosure can be administered, for example, orally, nasally, parenterally (intravenously, intramuscularly, or subcutaneously), topically, transdermally, intravaginally, intravesically, intracisternally, or rectally. The dosage form can be, for example, a solid, semi-solid, lyophilized powder, or liquid dosage form, such as a tablet, pill, soft elastic capsule or hard, in a unit dosage form suitable for convenient administration of precise dosages. It can be a gelatin capsule, powder, solution, suspension, suppository, aerosol, etc. Some examples of suitable pharmaceutical carriers that include pharmaceutical diluents are gelatin capsules; sugars such as lactose and sucrose; starches such as corn starch and potato starch; Cellulose derivatives; gelatin; talc; stearic acid; magnesium stearate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and theobroma oil; propylene glycol, glycerin; sorbitol; polyethylene glycol; water; agar; alginic acid; etc. saline, and phosphate buffer; and other compatible materials commonly used in pharmaceutical formulations. A particular route of administration is oral, in particular one that allows a convenient daily dosage regimen to be adjusted according to the severity of the disease being treated.

[0243] Auxiliaries and adjuvants may include, for example, preservatives, wetting agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, emulsifying agents, and dispensing agents. Emulsifiers can include polysorbates such as TWEEN, eg, TWEEN-20 and TWEEN-80. Inhibition of the action of microorganisms is generally provided by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. Isotonic agents such as sugars, sodium chloride, and the like may also be included. Long-term absorption of injectable pharmaceutical forms can be brought about by the use of agents that delay absorption, such as aluminum monostearate and gelatin. Auxiliary agents may also include wetting agents, emulsifying agents, pH buffering agents, and antioxidants such as citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene, and the like.

[0244] Solid dosage forms can be prepared with coatings and shells such as enteric coatings and others well known in the art. They may contain pacifying agents and may be of a composition such that they release the compounds of the disclosure in certain parts of the intestinal tract in a delayed manner. Examples of embedding compositions that can be used are polymeric substances and waxes. Compounds of the present disclosure can also be in microencapsulated form, including one or more of the excipients mentioned above, if appropriate.

[0245] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. Such dosage forms include, for example, a compound of the present disclosure, and an optional pharmaceutical adjuvant, in a carrier such as water, saline, aqueous dextrose, glycerol, ethanol, and the like; for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, acetic acid, and the like. solubilizers and emulsifiers such as ethyl, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide; oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor and sesame oil, glycerol; It is prepared by forming a solution or suspension, such as by dissolving or dispersing in tetrahydrofurfuryl alcohol, polyethylene glycol, fatty acid ester of sorbitan; or a mixture of these substances.

[0246] Generally, depending on the intended mode of administration, pharmaceutically acceptable compositions will contain from about 1% to 99% by weight of a compound disclosed herein and 99% by weight of a pharmaceutically acceptable excipient. % to 1% by weight. In one example, the composition is from about 5% to about 75% by weight of a compound of the present disclosure, with the balance being suitable pharmaceutical excipients.

[0247] Actual methods of preparing such dosage forms are known or will be apparent to those skilled in the art. See, eg, Remington's Pharmaceutical Sciences, 18th Ed. (Mack Publishing Company, Easton, Pa., 1990).

[0248] Method of treatment The methods described herein include administering to a subject in need thereof a therapeutically effective amount of a compound disclosed herein. A "therapeutically effective amount" is an amount of a compound of the present disclosure that, when administered alone to a patient, effectively treats a neurodegenerative disease. The amount that is found to be a "therapeutically effective amount" for a particular subject in a given case is the amount that is found to be a "therapeutically effective amount" for the disease under consideration, even if such dosage is considered to be a "therapeutically effective amount" by a medical professional. or may not be effective in 100% of subjects similarly treated for the disease condition. The amount of a compound of the present disclosure that corresponds to a therapeutically effective amount depends largely on the type of disease, the stage of the disease, the age of the patient being treated, and other facts.

[0249] Thus, in certain aspects, the present disclosure provides a method of treating or preventing a neurodegenerative disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure. . In particular, the method comprises administering to the subject a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), or (V). Non-limiting examples of neurodegenerative diseases that may be treated or prevented with compounds disclosed herein include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson's disease, Examples include Huntington's disease and Alzheimer's disease. In a preferred embodiment, the neurodegenerative disease treated or prevented by the compounds of this disclosure is ALS. In certain embodiments, the ALS is familial ALS. In certain embodiments, the ALS is sporadic ALS.

[0250] Although the amount of the compounds disclosed herein should result in effective treatment or prevention of neurodegenerative diseases, the amount is preferably not unduly toxic to the patient (i.e., the amount is preferably , within toxicity limits as established by medical guidelines). In some embodiments, limits on total dosage are established either to prevent undue toxicity of neurodegenerative diseases or to provide more effective treatment, or both. Typically, the amounts contemplated herein are per day, but half-day and two- or three-day cycles are also contemplated herein.

[0251] In certain embodiments, the subject in need is a treatment naive individual. In certain embodiments, the subject in need thereof has received prior treatment for ALS, where the prior treatment is other than administration of a compound of the present disclosure, and the prior treatment comprises: is insufficient (e.g., as rated by the subject and / or physician), is not effective, and / or does not result in a detectable improvement in one or more parameters or symptoms associated with ALS. and / or not causing biological effects that correlate with the underlying pathology that caused the symptoms of ALS.

[0252] In certain embodiments, the subject in need is a human who has a genetic mutation associated with ALS. In further embodiments, the genetic mutation associated with ALS comprises a mutation in the SOD1 gene.

[0253] In certain embodiments, compounds of the present disclosure are administered to a subject in combination with additional ALS treatment therapies. Current treatments for ALS include the administration of riluzole and edaravone, which have been shown to be moderately effective. Other therapies for ALS include medications to treat specific symptoms associated with the disease, such as baclofen or diazepam to treat cramps, spasms, and spasticity. Muscle relaxants may be prescribed. Gabapentin may be prescribed to help control pain. Medications such as amitriptyline, trihexyphenidyl, scopaderm, and glycopyrrolate can be administered to treat hypersalivation in the mouth due to difficulty swallowing. Drug treatment may also be required to treat constipation, fatigue, depression, difficulty sleeping, and emotional dysregulation associated with ALS.

[0254] In certain embodiments, a compound of the present disclosure produces a plasma C of about 50-650 ng / mL in a subject. max administered at a dose that achieves "C max '' is defined as the highest concentration of active compound reached in the plasma or spinal cord after administration of the drug.

[0255] In another aspect, the disclosure provides a method of treating, preventing, or diagnosing cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of the disclosure. include. In particular, isotopes of the compounds disclosed herein (e.g., 64 Cu) may also be used. Accordingly, in another aspect, the present disclosure provides a method of performing positron emission tomography (PET) imaging of a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the present disclosure. , followed by performing a PET scan on the subject.

[0256] In yet another aspect, the disclosure provides a method of treating or preventing an infectious disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of the disclosure. .

[0257] In a further aspect, the disclosure provides a method of treating a disease or disorder associated with a copper metabolism disorder (e.g., Menkes disease or Wilson disease) in a subject in need thereof, the method providing a therapeutically effective comprising administering an amount of a compound of the present disclosure. In some embodiments, the subject has a congenital SOD1 deficiency or mutation. In some embodiments, the subject does not have a congenital SOD1 deficiency or mutation.

[0258] Preparation method Certain embodiments of the present disclosure relate to processes for the preparation of compounds of formula (I), or pharmaceutically acceptable salts thereof, as described herein.

[0259] In certain embodiments, the process comprises a compound of formula (I-A): [ka] at least the step of mixing with a copper(II) salt to form a compound of formula (I), or a pharmaceutically acceptable salt thereof; During the ceremony, L is C 3 ~C 7 cycloalkyl, C 1 ~C 6 is alkyl or absent; R 1 is a 5- to 10-membered heteroaryl, NH 2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 is alkyl, R 2 is a 5- to 10-membered heteroaryl, NH 2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 is alkyl, R 3 However, C 6 ~C 10 Aryl, 5- to 10-membered heteroaryl, C(O)NH-(C 1 ~C 6 alkyl)-PPh 3 , hydroxy, C 1 ~C 6 Alkoxy, or O-(C 1 ~C 6 alkyl)-O-(C 1 ~C 6 alkyl), where C 6 ~C 10 Aryl is a group R 3a 5-10 membered heteroaryl substituted once, twice, or three times with R 3b is replaced once, twice, or three times with R 3a , but independently for each occurrence, C 3 ~C 7 cycloalkyl or 4- to 8-membered heterocycle, where the 4- to 8-membered heterocycle is optionally C 1 ~C 3 further substituted once, twice, or three times with alkyl, R 3b , but independently for each occurrence, C 1 ~C 3 Alkoxy, C 3 ~C 7 cycloalkyl, or a 4- to 8-membered heterocycle, where the heterocycle is optionally C 1 ~C 3 further substituted once, twice, or three times with alkyl, R 4 is hydrogen, C 1 ~C 3 alkyl, or C 6 ~C 10 Although it is an aryl, However, if L is absent, R 3 is the group R 3a C replaced once, twice, or three times with 6 ~C 10 If aryl or L is absent, then R 3 is the group R 3b The condition is that it is a 6- to 10-membered heteroaryl substituted with once, twice, or three times.

[0260] In some embodiments, the copper(II) salt is CuCl 2 Or Cu(OAc) 2 , or its hydrate.

[0261] Another aspect of the present disclosure relates to a process for the preparation of a compound of formula (II), or a pharmaceutically acceptable salt thereof, as described herein.

[0262] In certain embodiments, the process comprises a compound of formula (II-A): [ka] at least the step of mixing with a copper(II) salt to form a compound of formula (II); During the ceremony, R 1 is a 5- to 10-membered heteroaryl, NH 2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 is alkyl, R 2 is a 5- to 10-membered heteroaryl, NH 2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 is alkyl, R 3 is a 4- to 8-membered heterocycle or a 5-membered heteroaryl, where the 4- to 8-membered heterocycle is optionally a group R 3a , the 5-membered heteroaryl is optionally substituted once, twice, or three times with R 3b is replaced once, twice, or three times with R 3a , but independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkyl-(C 6 ~C 10 aryl), S(O) 2 H, S(O) 2 -(C 1 ~C 6 alkyl), S(O) 2 -(C 3 ~C 7 cycloalkyl), or S(O) 2 -(C 6 ~C 10aryl), R 3b , but independently for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkyl, halo, nitro, cyano, C(O)-(4- to 8-membered heterocycle), or C 1 ~C 6 alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle is optionally C 1 ~C 3 further substituted once, twice, or three times with alkyl, R 4 is hydrogen or C 1-3 It is an alkyl.

[0263] In some embodiments, the copper(II) salt is CuCl 2 Or Cu(OAc) 2 , or its hydrate.

[0264] In another embodiment, the process comprises mixing a compound of formula (II-A) with a zinc salt to form a compound of formula (II-B): [ka] and mixing the compound of formula (II-B) with a copper(II) salt to form the compound of formula (II).

[0265] In some embodiments, the zinc salt is Zn(OAc) 2 or its hydrate.

[0266] In some embodiments, the copper(II) salt is CuCl 2 Or Cu(OAc) 2 , or its hydrate.

[0267] Yet another aspect of the present disclosure relates to a process for the preparation of a compound of formula (III), or a pharmaceutically acceptable salt thereof, as described herein.

[0268] In certain embodiments, the process comprises a compound of formula (III-A): [ka] at least the step of mixing with a copper(II) salt to form a compound of formula (III); During the ceremony, L is C 1 ~C 6 is alkyl or absent; R 1 is a 5- to 10-membered heteroaryl, NH 2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 is alkyl, R 2 is a 5- to 10-membered heteroaryl, NH 2 ,NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 alkyl) 2 optionally replaced with C 1 ~C 6 is alkyl, R 3 However, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkyl, halo, hydroxy, C(O)NH 2 ,C(O)NH(C 1 ~C 6 alkyl), C(O)N(C 1 ~C 6 alkyl) 2 , or C(O)-(4- to 8-membered heterocycle), where C 1 ~C 6 Alkyl and C 1 ~C 6 alkoxy is optionally C 6 ~C 10 substituted once, twice, or three times with aryl, C(O)-(4- to 8-membered heterocycle) is optionally substituted with C 1 ~C 3 Substituted once, twice, or three times with alkyl.

[0269] In some embodiments, the copper(II) salt is CuCl 2 Or Cu(OAc) 2 , or its hydrate.

[0270] In another embodiment, the process comprises mixing a compound of formula (III-A) with a zinc salt to form a compound of formula (III-B): [ka] and mixing the compound of formula (III-B) with a copper(II) salt to form the compound of formula (III).

[0271] In some embodiments, the zinc salt is Zn(OAc) 2 or its hydrate.

[0272] In some embodiments, the copper(II) salt is CuCl 2 Or Cu(OAc) 2 , or its hydrate.

[0273] Another aspect of the disclosure relates to a process for the preparation of a compound of formula (IV), or a pharmaceutically acceptable salt thereof, as described herein.

[0274] In certain embodiments, the process comprises a compound of formula (IV-A): [ka] at least the step of mixing with a copper(II) salt to form a compound of formula (IV), or a pharmaceutically acceptable salt thereof; In the formula, variable elements L and R 1 ,R 2 ,R 3 , and R 4 corresponds to a variable element with the same name as defined in formula (IV).

[0275] In some embodiments, the copper(II) salt is CuCl 2 Or Cu(OAc) 2 , or its hydrate.

[0276] Yet another aspect of the present disclosure relates to a process for the preparation of a compound of formula (V), or a pharmaceutically acceptable salt thereof, as described herein.

[0277] In certain embodiments, the process comprises a compound of formula (V-A): [ka] at least the step of mixing with a copper(II) salt to form a compound of formula (V), or a pharmaceutically acceptable salt thereof; In the formula, the variable element R 1 ,R 2 ,R 3 , and R 4 corresponds to a variable element with the same name as defined in equation (V).

[0278] In some embodiments, the copper(II) salt is CuCl 2 Or Cu(OAc) 2 , or its hydrate.

[0279] In another embodiment, the process comprises mixing a compound of formula (V-A) with a zinc salt to form a compound of formula (V-B): [ka] and mixing a compound of formula (V-B) with a copper(II) salt to form a compound of formula (V).

[0280] In some embodiments, the zinc salt is Zn(OAc) 2 or its hydrate.

[0281] In some embodiments, the copper(II) salt is CuCl 2 Or Cu(OAc) 2 , or its hydrate.

Example

[0282] The present disclosure further relates to the following examples. These examples are included merely to illustrate certain aspects and embodiments of the disclosure and are not intended to limit the disclosure. Therefore, this disclosure should in no way be construed as limited to the following examples, but rather to encompass any and all variations that become apparent as a result of the teachings provided herein. Should.

[0283] Example 1: Preparation of compounds 1-22 Scheme 1: Synthesis of compound 1 [ka] Synthesis of N-methoxy-N-methyl-2-(pyridin-4-yl)acetamide: [ka] 4-pyridineacetic acid (4.2 g, 24.2 mmol), N,O-dimethylhydroxylamine (2.8 g, 29.1 mmol), HOBt (3.9 g, 29.1 mmol), and TEA (12 ml) in DCM (100 ml) at 4 °C. EDCI (5.6 g, 29.1 mmol) was added to the stirred mixture of 84.7 mmol). The reaction was stirred at ambient temperature overnight. The mixture was washed with water (100ml) and brine (100ml). The organic layer is treated with anhydrous Na 2 S.O. 4 dried, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, eluent 100% DCM to 5% MeOH). Yield 2.9g (66%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.14 min). MS (ESI) m / z 232.3 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 3.21 (s, 3H), 3.66 (s, 3H), 3.78 (s, 2H), 7.24 (d, 2H), 8.55 (d, 2H).

[0284] Synthesis of 3-ethoxy-1-(pyridin-4-yl)but-3-en-2-one: [ka] A solution of ethyl vinyl ether (3.1g, 42.9mmol) in tetrahydrofuran (100ml) was cooled to -78°C and tert-butyllithium in pentane (1.7M, 23.0ml, 38.8mmol) was added. The mixture was warmed to 0°C over a period of 1 hour, stirred for 45 minutes, and cooled to -30°C. A solution of N-methoxy-N-methyl-2-(pyridin-4-yl)acetamide (0.7 g, 3.8 mmol) in tetrahydrofuran (20 mL) was added and the reaction was stirred at 0° C. for 2 hours. The progress of the reaction was monitored by TLC. NH mixture 4 Pour into Cl aqueous solution (100 ml) and add Et 2 Extracted with O (3 x 50 ml). The combined extracts were 2 S.O. 4 The solution was decanted and the solvent was removed under reduced pressure. The title compound was used in the next step without further purification. Yield 0.2g (27%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.72 min). MS (ESI) m / z 192.4 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.40 (t, 3H), 3.83 (q, 2H), 3.99 (s, 2H), 4.41 (d, 1H), 5.25 (d, 1H), 7.18 (dd, 1H), 8.55 ( dd, 1H), 8.54 (dd, 2H).

[0285] INT-1, ((2Z,2'E)-2,2'-(1-(pyridin-4-yl)butane-2,3-diylidene)bis(N-methylhydrazine-1-carbothioamide)) Synthesis: [ka] 3-Ethoxy-1-(pyridin-4-yl)but-3-en-2-one (0.2 g, 1.04 mmol) was dissolved in EtOH (5 ml), methylthiosemicarbazide (0.22 g, 2.08 mmol) and 3 Drop H 2 S.O. 4 was added and the reaction mixture was stirred at reflux for 4 hours and at ambient temperature overnight. The progress of the reaction was monitored by TLC. Filter the precipitate, add EtOH, Et 2 Washed with O and dried. Yield 0.21g (60%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.98 min). MS (ESI) m / z 338.9 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 2.28 (s, 3H), 2.98 (d, 3H), 3.02 (d, 3H), 4.76 (s, 2H), 7.72 (d, 2H), 8.36 (dd, 1H), 8.50 ( dd, 1H), 8.78 (d, 2H), 10.35 (s, 1H), 10.85 (s, 1H).

[0286] INT-5, ((2Z,2'E)-2,2'-(5-(pyridin-4-yl)pentane-2,3-diylidene)bis(N-methylhydrazine-1-carbothioamide)) Synthesis: [ka] INT-5 was made using a procedure similar to that for preparing INT-1. Yield 1.54g (85%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.94 min). MS (ESI) m / z 352.5 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 2.15 (s, 3H), 2.66 (t, 2H), 3.01 (d, 6H), 3.28 (t, 2H), 7.32 (d, 2H), 8.21 (dd, 1H), 8.33 ( dd, 1H), 8.45 (d, 2H), 10.21 (s, 1H), 10.67 (s, 1H).

[0287] INT-6, ((2Z,2'E)-2,2'-(5-(pyridin-3-yl)pentane-2,3-diylidene)bis(N-methylhydrazine-1-carbothioamide)) Synthesis: [ka] INT-6 was made using a procedure similar to that for preparing INT-1. Yield 0.42g (49%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.94 min). MS (ESI) m / z 352.4 [MH]+.

[0288] INT-9, ((2E,2'E)-2,2'-(1-(pyridin-3-yl)butane-2,3-diylidene)bis(N-methylhydrazine-1-carbothioamide)) Synthesis: [ka] INT-9 was made using a procedure similar to that for preparing INT-1. Yield 8.6g (76%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.91 min). MS (ESI) m / z 338.4 [MH]+.

[0289] INT-10, ((2E,2'E)-2,2'-(1-(6-methoxypyridin-3-yl)propane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide )) composition: [ka] INT-10 was made using a procedure similar to that for preparing INT-1. Yield 1.2g (46.2%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.52 minutes, MS (ESI) m / z 382.0 [MH] +. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 0.94 (t, 3H), 1.15 (t, 3H), 2.35 (s, 3H), 3.34 (q, 2H), 3.60 (q, 2H), 3.91 (s, 3H), 6.44 ( d, 1H), 7.62 (d, 1H), 8.05 (s, 1H), 8.68 (br.s, 1H), 9.54 (s, 1H), 10.71 (s, 1H).

[0290] INT-11, ((2E,2'E)-2,2'-(1-(6-methoxypyridin-3-yl)propane-1,2-diylidene)bis(N-methylhydrazine-1-carbothioamide )) composition: [ka] INT-11 was made using a procedure similar to that for preparing INT-1. Yield 0.7g (56.6%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.41 minutes, MS (ESI) m / z 354.5 [MH] +. 1 H-NMR (400MHz, CDCl 3): δ (ppm) 2.36 (s, 3H), 2.87 (s, 3H), 3.03 (s, 3H), 3.92 (s, 3H), 6.95 (d, 1H), 7.15 (br.s, 1H), 7.61 (d, 1H), 8.04 (s, 1H), 8.62 (br.s, 1H), 9.54 (s, 1H), 10.56 (s, 1H).

[0291] Synthesis of compound 1: [ka] CuCl 2 ·2H 2 O (0.08g, 0.48mmol) was added to INT-1 (0.15g, 0.44mmol) in ethanol (6ml). The mixture was stirred at ambient temperature overnight. The complex was isolated as a reddish-brown powder. The precipitate formed was collected by filtration after cooling, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and copious amounts of diethyl ether (5 x 50 ml) and then dried in vacuo. Yield 0.075g (42%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.29). MS (ESI) m / z 399.1 [MH]+.

[0292] Synthesis of compound 5: [ka] The title compound was prepared from INT-5 following the method for preparing compound 1. The complex was isolated as a reddish-brown powder. The precipitate formed was collected by filtration after cooling, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and copious amounts of diethyl ether (5 x 50 ml) and then dried in vacuo. Yield 0.5g (78%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.26). MS (ESI) m / z 413.4 [MH]+.

[0293] Synthesis of compound 6: [ka] The title compound was prepared from INT-6 following the method for preparing compound 1. The complex was isolated as a reddish-brown powder. The precipitate formed was collected by filtration after cooling, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and copious amounts of diethyl ether (5 x 50 ml) and then dried in vacuo. Yield 0.18g (95%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.25). MS (ESI) m / z 412.9 [MH]+.

[0294] Synthesis of compound 9: [ka] The title compound was prepared from INT-9 following the method for preparing Compound 1. The complex was isolated as a reddish-brown powder. The precipitate formed was collected by filtration after cooling, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and copious amounts of diethyl ether (5 x 50 ml) and then dried in vacuo. Yield 2.3g (97%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.30). MS (ESI) m / z 399.1 [MH]+.

[0295] Synthesis of compound 10: [ka] The title compound was prepared from INT-10 following the method for preparing compound 1. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.13g (37.3%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.31). MS (ESI) m / z 443.5 [MH]+.

[0296] Synthesis of compound 11: [ka] The title compound was prepared from INT-11 following the method for preparing compound 1. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.12g (34.5%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.97). MS (ESI) m / z 415.3 [MH]+.

[0297] Scheme 2: Synthesis of compound 2 [ka] Synthesis of ethyl 2-(pyridin-3-yl)acetate: [ka] A stirred solution of 3-pyridineacetic acid (25.0 g, 145 mmol) in EtOH (250 ml) at 0-5°C was added with SOCl 2 (11.6ml, 160mmol) was added over a period of 15 minutes. The reaction was then heated to reflux for an additional 16 hours. EtOH was evaporated under reduced pressure. 2M Na in the residue 2 C.O. 3 Aqueous solution (30ml) was added and the resulting mixture was extracted with EtOAc (3x400ml). The combined organic layers were washed with brine (100 mL) and anhydrous Na 2 S.O. 4 , filtered and concentrated to give the title compound as a colorless liquid. Yield 22.3g (93%). 1 H-NMR (400MHz, CDCl 3 ): δ (ppm): 1.26 (t, 3 H), 3.62 (s, 2 H), 4.17 (q, 2 H), 7.27-7.28 (m, 1 H), 7.64-7.65 (m, 1 H) , 8.53 (m, 2 H).

[0298] Synthesis of ethyl 1-(pyridin-3-yl)cyclopentane-1-carboxylate: [ka] To a stirred suspension of sodium hydride (7.3 g, 181 mmol, 60% in oil) in dry THF (160 ml) at 0°C was added ethyl 2-(pyridin-3-yl)acetate in dry THF (35 ml). (10.0g, 60.5mmol) was added dropwise. The reaction mixture was stirred at 0° C. for 30 minutes (until gas formation ceased). Dibromobutane (19.6 g, 90.5 mmol) was then added at 0° C. and the reaction mixture was stirred at ambient temperature for 14 hours. The reaction mixture was then quenched with saturated aqueous ammonium chloride solution (60ml). The reaction mixture was extracted with EtOAc (3x40ml). The organic phase was washed with brine (100 ml) and anhydrous Na 2 S.O. 4 dried, filtered and concentrated. The resulting dark solid was purified by flash chromatography (silica gel, eluting with hexane-ethyl acetate, 4:1 to 1:1). Yield 9.8g (74%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.01 min). MS (ESI) m / z 220.6 [MH]+. 1 H-NMR (400MHz, CDCl3): δ (ppm) 1.16 (t, 3H), 1.74-1.78 (m, 4H), 1.88-1.98 (m, 2H), 2.67-2.73 (m, 2H), 4.09 (q , 2H), 7.23-7.27 (m, 1H), 7.67-7.71 (m, 1H), 8.49 (dd, 1H), 8.65 (dd, 1H).

[0299] Synthesis of 1-(pyridin-3-yl)cyclopentane-1-carboxylic acid: [ka] A solution of ethyl 1-(pyridin-3-yl)cyclopentane-1-carboxylate (8.4 g, 38.5 mmol) in MeOH (60 ml) was added to a 20% aqueous solution of LiOH (2.5 g, 96,2 mmol). . The reaction mixture was stirred at 60°C for 8 hours. The solvent was then removed by lyophilization and the corresponding crude product was used in the next step without further purification. Yield 7g (80%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.82 min). MS (ESI) m / z 192.1 [MH]+. 1 H-NMR (400MHz, DMSO-d 6): δ (ppm) 1.66-1.70 (m, 4H), 1.85-1.92 (m, 2H), 2.52-2.58 (m, 2H), 7.56 (dd, 1H), 7.98-8.02 (m, 1H), 8.58 (dd, 1H), 8.66 (d, 1H), 12.66 (br.s, 1H).

[0300] Synthesis of N-methoxy-N-methyl-1-(pyridin-3-yl)cyclopentane-1-carboxamide: [ka] 1-(pyridin-3-yl)cyclopentane-1-carboxylic acid (5.0 g, 22.0 mmol), N,O-dimethylhydroxylamine (2.6 g, 26.4 mmol), HOBt( EDCI (5.1 g, 26.4 mmol) was added to a stirred mixture of 3.6 g, 26.4 mmol) and TEA (10.8 ml, 77 mmol). The reaction was stirred at ambient temperature overnight. The mixture was washed with water (100ml) and brine (100ml). The organic layer is treated with anhydrous Na 2 S.O. 4 dried, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, eluent 100% DCM to 5% MeOH) to give the title compound. Yield 2.5g (49%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.84 min). MS (ESI) m / z 235.3 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.66-1.81 (m, 4H), 2.05-2.11 (m, 2H), 2.42-2.48 (m, 2H), 2.89 (s, 3H), 3.13 (s, 3H), 7.34 (q , 1H), 7.65 (d, 1H), 8.49 (d, 1H), 8.59 (d, 1H).

[0301] Synthesis of 2-ethoxy-1-(1-(pyridin-3-yl)cyclopentyl)prop-2-en-1-one: [ka] A solution of ethyl vinyl ether (1.69g, 23.6mmol) in tetrahydrofuran (40ml) was cooled to -78°C and tert-butyllithium in pentane (1.7M, 13.0ml, 21.5mmol) was added. The mixture was warmed to 0°C over a period of 1 hour, stirred for 45 minutes, and cooled to -30°C. A solution of N-methoxy-N-methyl-1-(pyridin-3-yl)cyclopentane-1-carboxamide (1.0 g, 4.3 mmol) in THF (15 ml) was added and the reaction was heated at 0 °C for 4 h. Stirred. The progress of the reaction was monitored by TLC. NH mixture 4 Pour into Cl aqueous solution (100 ml) and add Et 2 Extracted with O (3 x 50 ml). The combined extracts were 2 S.O. 4 It was dried with. The solution was decanted and the solvent removed under reduced pressure. The title compound was used without further purification. Yield 0.85g (81%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.11 min). MS (ESI) m / z 246.4 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.05 (t, 3H), 1.69-1.73 (m, 4H), 2.06-2.08 (m, 2H), 2.46-2.52 (m, 2H), 3.50 (q, 2H),4.30 (d , 1H), 5.18 (d, 1H), 7.21-7.25 (m, 1H), 7.51-7.54 (m, 1H), 8.45 (dd, 1H), 8.52 (d, 1H).

[0302] INT-2, ((2Z,2'E)-2,2'-(1-(1-(pyridin-3-yl)cyclopentyl)propane-1,2-diylidene)bis(N-methylhydrazine-1- Synthesis of carbothioamide): [ka] 2-Ethoxy-1-(1-(pyridin-3-yl)cyclopentyl)prop-2-en-1-one (0.85 g, 3.5 mmol) was dissolved in EtOH (5 ml) and methylthiosemicarbazide (0.80 g, 7.7 mmol) and 3 drops of H 2 S.O. 4 was added and the reaction mixture was stirred at reflux for 4 hours and at ambient temperature overnight. The progress of the reaction was monitored by TLC. Filter the precipitate, add EtOH, Et 2 Washed with O and dried. Yield 0.21g (15%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.00 min). MS (ESI) m / z 392.3 [MH]+.

[0303] INT-3, ((2Z,2'E)-2,2'-(1-(1-(pyridin-3-yl)cyclobutyl)propane-1,2-diylidene)bis(N-methylhydrazine-1- Synthesis of carbothioamide): [ka] INT-3 was made using a procedure similar to that for preparing INT-2. Yield 0.08g (10%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.01 min). MS (ESI) m / z 378.5 [MH]+.

[0304] INT-4, ((2Z,2'E)-2,2'-(4-(pyridin-3-yl)pentane-2,3-diylidene)bis(N-methylhydrazine-1-carbothioamide)) Synthesis: [ka] INT-4 was made using a procedure similar to that for preparing INT-2. Yield 0.58g (42%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.96 min). MS (ESI) m / z 352.3 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.52 (d, 3H), 2.24 (s, 3H), 2.90 (d, 3H), 3.00 (d, 3H), 5.23 (q, 1H), 7.32-7.34 (m, 1H), 7.39-7.42 (m, 1H), 7.62 (d, 1H), 8.40 (s, 1H), 8.46 (d, 2H), 9.84 (s, 1H), 10.30 (s, 1H).

[0305] Synthesis of compound 2: [ka] CuCl 2 ·2H 2 O (0.08g, 0.5mmol) was added to INT-2 (0.18g, 0.46mmol) in ethanol (6mL). The mixture was stirred at ambient temperature overnight. The complex was isolated as a reddish-brown powder. The precipitate formed was collected by filtration after cooling, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and copious amounts of diethyl ether (5 x 50 ml) and then dried in vacuo. Yield 0.08g (39%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.01). MS (ESI) m / z 453.4 [MH]+.

[0306] Synthesis of compound 3: [ka] The title compound was prepared from INT-3 following the method for preparing compound 2. The complex formed was isolated as a reddish-brown powder. The precipitate formed was collected by filtration after cooling, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and copious amounts of diethyl ether (5 x 50 ml) and then dried in vacuo. Yield 0.05g (61%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.49). MS (ESI) m / z 439.0 [MH]+.

[0307] Synthesis of compound 4: [ka] The title compound was prepared from INT-4 following the method for preparing compound 2. The complex was isolated as a reddish-brown powder. The precipitate formed was collected by filtration after cooling, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and copious amounts of diethyl ether (5 x 50 ml) and then dried in vacuo. Yield 0.61g (89%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.30). MS (ESI) m / z 413.5 [MH]+.

[0308] Scheme 3: Synthesis of compound 7 [ka] Synthesis of 2-(6-morpholinopyridin-3-yl)acetonitrile: [ka] A solution of (6-chloropyridin-3-yl)acetonitrile (1.8 g, 11.8 mmol), triethylamine (3.3 ml, 23.5 mmol), and morpholine (1.13 g, 13.1 mmol) in n-butanol (15 ml) was heated to 150°C. The mixture was heated for 2 hours and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, CCl4-ethyl acetate 8:2). Yield 0.7g (29%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.91 min). MS (ESI) m / z 204.1 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 2.42 (d, 4H), 3.69 (d, 4H), 3.86-3.88 (m, 2H), 6.83-6.87 (m, 1H), 7.52-7.55 (m, 1H), 8.08 (s , 1H).

[0309] Synthesis of 2-(6-morpholinopyridin-3-yl)acetic acid: [ka] A mixture of 2-(6-morpholinopyridin-3-yl)acetonitrile (1.0 g, 5.2 mmol) in concentrated hydrochloric acid (15 mL) was refluxed for 3 hours. The liquid was evaporated in vacuo to give the crude product as a white solid (1.40g, 86.8%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.51 min). MS (ESI) m / z 223.6 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 3.66 (s, 2H), 3.73 (s, 8H), 7.36 (d, 1H), 7.94 (dd, 1H), 7.97 (d, 1H), 13.94 (br.s, 1H).

[0310] Synthesis of N-methoxy-N-methyl-2-(6-morpholinopyridin-3-yl)acetamide: [ka] 2-(6-morpholinopyridin-3-yl)acetic acid (1.4 g, 4.5 mmol), N,O-dimethylhydroxylamine (0.53 g, 5.4 mmol), HOBt (0.73 g, 5.4 mmol) and TEA (2.2 ml, 15.7 mmol) was added EDCI (1.03 g, 5.4 mmol). The reaction was stirred at ambient temperature overnight. The mixture was washed with water (100ml), brine (100ml). The organic layer is treated with anhydrous Na 2 S.O. 4 dried, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, eluent 100% DCM to 5% MeOH) to give the crude title product. Yield 1.0g (84%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.91 min). MS (ESI) m / z 266.5 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 3.20 (s, 3H), 3.48 (t, 4H), 3.65 (s, 2H), 3.68 (s, 3H),3.82 (t, 4H), 6.63 (d, 1H), 7.52 ( dd, 1H), 8.09 (d, 1H).

[0311] Synthesis of 3-ethoxy-1-(6-morpholinopyridin-3-yl)but-3-en-2-one: [ka] A solution of ethyl vinyl ether (3.0g, 41.8mmol) in tetrahydrofuran (50ml) was cooled to -78°C and tert-butyllithium in pentane (1.7M, 20.2ml, 34.6mmol) was added. The mixture was warmed to 0°C over a period of 1 hour, stirred for 45 minutes, cooled to -30°C and magnesium bromide etherate (8.9g, 34.6mmol) was added. The mixture was warmed to 0 °C over a period of 15 minutes and a solution of N-methoxy-N-methyl-2-(6-morpholinopyridin-3-yl)acetamide (1.0 g, 3.8 mmol) in tetrahydrofuran (20 mL) was added. did. The mixture was allowed to reach room temperature and stirred overnight. The progress of the reaction was monitored by TLC. NH mixture 4 Pour into Cl aqueous solution (100 ml) and add Et 2 Extracted with O (3 x 50 ml). The combined extracts were 2 S.O. 4 It was dried with. The solution was decanted and the solvent removed under reduced pressure. The title compound was used in the next step without further purification. Yield 0.26g (25%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.96 min). MS (ESI) m / z 277.5 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.43 (t, 3H), 2.01-2.04 (m, 4H), 3.46-3.51 (m, 4H), 3.82 (q, 2H), 3.84 (s, 2H), 4.41 (d, 1H) ), 5.22 (d, 1H), 6.39 (dd, 1H), 7.38 (dd, 1H), 8.01 (dd, 1H).

[0312] INT-7, ((2E,2'E)-2,2'-(1-(6-morpholinopyridin-3-yl)butane-2,3-diylidene)bis(N-ethylhydrazine-1-carbothioamide )) composition: [ka] 3-Ethoxy-1-(6-morpholinopyridin-3-yl)but-3-en-2-one (0.26 g, 0.94 mmol) was dissolved in EtOH (5 ml) and ethylthiosemicarbazide (0.22 g, 1.88 mmol) and 3 drops of H 2 S.O. 4 was added and the reaction mixture was stirred at reflux for 4 hours and at ambient temperature overnight. The progress of the reaction was monitored by TLC. Filter the precipitate, add EtOH, Et 2 Washed with O and dried. Yield 0.41g (97%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.14 min). MS (ESI) m / z 451.5 [MH]+.

[0313] INT-8, ((2E,2'E)-2,2'-(1-(6-(pyrrolidin-1-yl)pyridin-3-yl)butane-2,3-diylidene)bis(N-ethyl Synthesis of hydrazine-1-carbothioamide): [ka] INT-8 was made using a procedure similar to that for preparing INT-7. Yield 0.25g (99%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.17 min). MS (ESI) m / z 435.5 [MH]+.

[0314] Synthesis of compound 7: [ka] CuCl 2 ·2H 2 O (0.07g, 0.4mmol) was added to INT-7 (0.18g, 0.4mmol) in ethanol (6mL). The mixture was stirred at ambient temperature overnight. The complex was isolated as a reddish-brown powder. The precipitate formed was collected by filtration after cooling, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and copious amounts of diethyl ether (5 x 50 ml) and then dried in vacuo. Yield 0.03g (14%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.55). MS (ESI) m / z 512.7 [MH]+.

[0315] Synthesis of compound 8: [ka] The title compound was prepared from INT-8 following the method for preparing compound 7. The complex was isolated as a reddish-brown powder. The precipitate formed was collected by filtration after cooling, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and copious amounts of diethyl ether (5 x 50 ml) and then dried in vacuo. Yield 0.05g (16%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.57). MS (ESI) m / z 496.5 [MH]+.

[0316] Scheme 4: Synthesis of compound 12 [ka] Synthesis of 1-(4-acetylphenyl)pyrrolidin-2-one: [ka] in a mixture of pyrrolidin-2-one (1.7 g, 20.0 mmol), 1-(4-iodophenyl)ethanone (4.1 g, 16.7 mmol), CuI (0.32 g, 1.67 mmol), and glycine (0.25 g, 3.34 mmol). , potassium phosphate (2.1 g, 40.0 mmol) was added. The glass tube was evacuated, filled with argon at room temperature, and sealed. DMF (0.5 mL) was added via syringe under argon. The mixture was then stirred at 100°C for 24 hours. The cooled mixture was partitioned between water and ethyl acetate. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic extracts were washed with brine and Na 2 S.O. 4 dried, filtered and concentrated in vacuo. The residue was purified by column chromatography (silica gel, eluting with a gradient of 1:8 to 1:2 ethyl acetate-hexanes) to give the title compound. Yield 3.2g (94%). 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 2.22 (m, 2H), 2.60 (s, 3H), 2.66 (t, 2H), 3.92 (t, 2H), 7.77 (dd, 2H), 7.99 (dd, 2H).

[0317] Synthesis of 2-oxo-2-(4-(2-oxopyrrolidin-1-yl)phenyl)acetaldehyde: [ka] SeO in flask 2 (0.16g, 1.5mmol), 1,4-dioxane (3ml), and water (0.5ml) were charged. Heat the mixture to 50 °C and add SeO 2 The mixture was stirred until most of it was dissolved. 1-(4-acetylphenyl)pyrrolidin-2-one (0.3 g, 1.47 mmol) was added and the reaction was heated at mild reflux overnight. The progress of the reaction is determined by TLC (CCl 4 -EtOAc 7:3). Selenium solid precipitated over the course of the reaction. The mixture was cooled in an ice bath and filtered through diatomaceous earth to remove selenium. The filter cake was washed with a portion of 1,4-dioxane. The filtrate was concentrated in vacuo until most of the 1,4-dioxane was removed. The crude product was used in the next step without further purification. Yield 0.25g (83%).

[0318] INT-12, (2Z,2'E)-2,2'-(1-(4-(2-oxopyrrolidin-1-yl)phenyl)ethane-1,2-diylidene)bis(N-ethylhydrazine- Synthesis of 1-carbothioamide): [ka] 2-oxo-2-(4-(2-oxopyrrolidin-1-yl)phenyl)acetaldehyde (0.25 g, 1.2 mmol) was dissolved in EtOH (5 mL) and ethylthiosemicarbazide (0.35 g, 2.4 mmol) and 3 drops of H 2 S.O. 4 was added and the reaction mixture was stirred at reflux for 4 hours and at ambient temperature for 15 hours. The progress of the reaction is determined by TLC (CCl 4 -EtOAc 7:3). Filter the precipitate formed and add EtOH, water, Et 2 Washed with O and dried. Yield 0.45g (73%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.49 min). MS (ESI) m / z 420.5 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.15 (t, 3H), 1.19 (t, 3H), 2.94-2.11 (m, 2H), 2.28 (s, 1H0, 3.36-3.47 (m, 1H), 3.57-3.65 (m, 4H), 3.82 (t, 2H), 7.69-7.82 (m, 4H), 7.94 (d, 1H), 8.23 ​​(s, 1H), 8.91 (t, 1H), 11.77 (s, 1H), 12.31 (s , 1H).

[0319] INT-14, ((2Z,2'E)-2,2'-(1-(4-(pyrrolidin-1-yl)phenyl)ethane-1,2-diylidene)bis(N-ethylhydrazine-1- Synthesis of carbothioamide): [ka] INT-14 was made using a procedure similar to that for preparing INT-12. Yield 0.3g (15.5%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.92 minutes, MS (ESI) m / z 406.3 [MH] +. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.12-1.24 (m, 6H), 1.91-2.06 (m, 4H), 3.19-3.29 (m,4H), 3.53-3.66 (m, 4H), 6.58 (d, 2H), 7.65 (d, 2H), 7.93 (br.s, 1H), 8.22 (s, 1H), 8.74 (br.s, 1H), 11.73 (s, 1H), 12.16 (s, 1H).

[0320] Synthesis of INT-15, ((2Z,2'E)-2,2'-(1-(4-morpholinophenyl)ethane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide)) : [ka] INT-15 was made using a procedure similar to that for preparing INT-12. Yield 1.1g (53.5%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.66 minutes, MS (ESI) m / z 422.4 [MH] +. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.16 (t, 3H), 1.20 (t, 3H), 3.16-3.24 (m, 4H), 3.54-3.66 (m, 4H), 3.71-3.79 (m, 4H), 7.00 (d , 2H), 7.23 (br.s, 1H), 7.70 (d, 2H), 7.95 (br.s, 1H), 8.83 (br.s, 1H), 11.74 (s, 1H), 12.23 (s, 1H) ).

[0321] Synthesis of compound 12: [ka] CuCl 2 ·2H 2 O (0.16 g, 0.9 mmol) was added to INT-12 (0.4 g, 0.9 mmol) in ethanol. The mixture was stirred at ambient temperature for 15 hours. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.016g (4%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.84). MS (ESI) m / z 481.3 [MH]+.

[0322] Synthesis of compound 14: [ka] The title compound was prepared from INT-14 following the method for preparing compound 12. The complex formed precipitated as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.057g (49.6%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.34). MS (ESI) m / z 467.0 [MH]+.

[0323] Synthesis of compound 15: [ka] The title compound was prepared from INT-15 following the method for preparing compound 12. The complex formed precipitated as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, and then dried in vacuo to give the title product. Yield 0.17g (85%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.97). MS (ESI) m / z 483.5 [MH]+.

[0324] Scheme 5: Synthesis of compound 13 [ka] Synthesis of 4-morpholinobenzonitrile: [ka] A stirred solution of 4-fluorobenzonitrile (2.0 g, 16.5 mmol) in anhydrous dimethylformamide (5 ml), morpholine (1.44 g, 16.5 mmol), and K 2 C.O. 3 (2.85g, 20.6mmol) was added and heated at 110°C for 18 hours. Water was added and the precipitate formed was filtered and washed with water and hexane. Yield 2.6g (83%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.24 min). MS (ESI) m / z 189.1 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 3.27 (t, 4H), 3.72 (t, 4H), 7.02 (d, 2H), 7.60 (d, 2H).

[0325] Synthesis of 4-morpholinobenzoic acid: [ka] A stirred solution of 4-morpholin-4-yl-benzonitrile (2.6 g, 14.7 mmol) and sodium hydroxide (2.2 g, 58.8 mmol) in a mixture of water (90 ml) and MeOH (5 ml) was heated on a water bath for 5 hours. The mixture was heated to reflux for an hour. The solution was then cooled to room temperature and acidified with aqueous HCl (10%). The precipitate was filtered, washed with water, dried under vacuum at 60° C. and crystallized from EtOH to give compound 2. Yield 2.0g (70%). 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 3.12 (t, 2H), 3.24 (t, 2H), 3.73 (t, 4H), 6.96 (t, 2H), 7.77 (t, 2H), 12.31 (br.s, 1H).

[0326] Synthesis of N-methoxy-N-methyl-4-morpholinobenzamide: [ka] 4-morpholinobenzoic acid (1.4 g, 6.7 mmol), N,O-dimethylhydroxylamine (1.3 g, 8.7 mmol), HOBT (1.0 g, 7.7 mmol), and TEA (0.9 EDCI (1.4 g, 9 mmol) was added to the mixture. The reaction was stirred at ambient temperature overnight. The mixture was washed with water (15ml), 1N aqueous HCl (20ml), water (50ml) and brine (100ml). The organic layer is treated with anhydrous Na 2 S.O. 4 dried, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, eluent 100% DCM to 5% MeOH) to give the crude title product. Yield 0.97g (58%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.12 min). MS (ESI) m / z 251.6 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 3.26 (t, 4H), 3.36 (s, 3H), 3.59 (s, 3H), 3.89 (t, 4H), 6.89 (d, 2H), 7.74 (d, 2H).

[0327] Synthesis of 2-ethoxy-1-(4-morpholinophenyl)prop-2-en-1-one: [ka] A solution of ethyl vinyl ether (0.9g, 12.2mmol) in dry tetrahydrofuran (25ml) was cooled to -78°C and tert-butyllithium in pentane (1.7M, 6.6ml, 11.1mmol) was added. The mixture was warmed to 0°C over a period of 1 hour, stirred for 45 minutes, and cooled to -30°C. A solution of N-methoxy-N-methyl-4-morpholinobenzamide (0.93g, 3.7mmol) in THF (10ml) was then added and the mixture was stirred at 0°C for 4 hours. The progress of the reaction was monitored by TLC. NH mixture 4 Pour into Cl aqueous solution (100 ml) and add Et 2 Extracted with O (3 x 100ml). The combined extracts were 2 S.O. 4 dried, filtered and evaporated. The product was used in the next step without further purification. Yield 0.6g (62%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.40 min). MS (ESI) m / z 262.0 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.42 (t, 3H), 3.33 (t, 4H), 3.87 (t, 4H), 3.94 (q, 2H), 4.65 (d, 1H), 4.91 (d, 1H), 6.87 ( d, 2H), 7.92 (d, 2H).

[0328] Synthesis of INT-13, ((2Z,2'E)-2,2'-(1-(4-morpholinophenyl)propane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide)) : [ka] 2-Ethoxy-1-(4-morpholinophenyl)prop-2-en-1-one (0.6 g, 2.3 mmol) was dissolved in EtOH (5 ml) and ethylthiosemicarbazide (0.6 g, 5.1 mmol) and 3 Drop H 2 S.O. 4 was added and the reaction mixture was stirred at reflux for 4 hours and at ambient temperature for 15 hours. Filter the precipitate formed and add EtOH, water, Et 2 Washed with O and dried. Yield 0.3g (30%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.49 min). MS (ESI) m / z 436.4 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 0.93 (t, 3H), 1.15 (t, 3H), 2.33 (s, 3H), 3.19 (t, 4H), 3.34-3.38 (m, 2H), 3.56-3.63 (m, 2H) ), 3.75 (t, 4H), 6.97 (t, 1H), 7.12 (q, 4H), 8.70 (s, 1H), 8.74 (t, 1H), 10.75 (s, 1H).

[0329] Synthesis of compound 13: [ka] CuCl 2 2H 2 O (0.07g, 0.4mmol) was added to INT-13 (0.17g, 0.4mmol) in ethanol. The mixture was stirred at ambient temperature for 15 hours. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.2g (99%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.87). MS (ESI) m / z 497.4 [MH]+.

[0330] Scheme 6: Synthesis of compound 16 [ka] Synthesis of 1-(4-morpholinophenyl)-2-phenylethane-1,2-dione: [ka] To a stirred solution of 4-morpholinobenzaldehyde (24.0 g, 125 mmol) and benzaldehyde (13.3 g, 125 mmol) in EtOH (50 mL) was added a solution of potassium cyanide (0.43 g, 66 mmol) in water (35 ml). The mixture was stirred at reflux for 5 hours and cooled to ambient temperature. The solution was placed in a refrigerator at approximately 8°C for fractional crystallization. The precipitate formed, consisting mainly of alpha-hydroxyketones, was removed by filtration and discarded, and the filtrate was evaporated to dryness in vacuo. The residue was purified by column chromatography (silica gel, eluent EtOAc-hexane). Yield 2.2g (6%). 1H-NMR (400MHz, CDCl 3 ): δ (ppm) 3.36-3.40 (m, 4H), 3.84-3.89 (m, 4H), 6.87 (d, 2H), 7.50 (dd, 2H), 7.64 (dd, 1H), 7.88 (d, 2H) ), 7.99 (d, 2H).

[0331] INT-16, ((2E,2'E)-2,2'-(1-(4-morpholinophenyl)-2-phenylethane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide )) composition: [ka] 1-(4-morpholinophenyl)-2-phenylethane-1,2-dione (0.61 g, 2.06 mmol, 1 eq.) was dissolved in EtOH (15 ml) and methylthiosemicarbazide (0.45 g, 2 eq.) and 3 Drop H 2 S.O. 4 was added and the reaction mixture was stirred at reflux for 4 hours and at ambient temperature for 15 hours. Filter the precipitate formed and add EtOH, water, Et 2 Washed with O and dried. Yield 0.45g (44%). 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.13-1.19 (m, 6H), 3.17-3.20 (m, 4H), 3.55 (q, 4H), 3.70-3.75 (m, 4H), 6.94 (d, 2H), 7.42-7.47 (m, 3H), 7.55 (d, 2H), 7.70-7.74 (m, 2H), 8.88 (ddd, 2H), 9.49 (d, 2H).

[0332] INT-17, ((2E,2'E)-2,2'-(1-(4-morpholinophenyl)-2-phenylethane-1,2-diylidene)bis(N-methylhydrazine-1-carbothioamide )) composition: [ka] INT-17 was made using a procedure similar to that for preparing INT-16. Yield 0.31g (36%). 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 2.99-3.06 (m, 6H), 3.17-3.20 (m, 4H), 3.70-3.74 (m, 4H), 6.94 (d, 2H), 7.42-7.47 (m, 3H), 7.55 (d, 2H), 7.70-7.74 (m, 2H), 8.84 (ddd, 2H), 9.49 (d, 2H).

[0333] Synthesis of compound 16: [ka] Cu(OAc) 2 2H 2 O (0.06 g, 1.1 eq.) was added to INT-16 (0.12 g, 0.26 mmol, 1 eq.) in ethanol. The mixture was stirred at ambient temperature for 15 hours. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.03g (22%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.21 min). MS (ESI) m / z 559.0 [MH]+.

[0334] Synthesis of compound 17: [ka] The title compound was prepared from INT-17 following the method for preparing compound 16. The complex formed precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.03g (22%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.24 min). MS (ESI) m / z 531.2 [MH]+.

[0335] Scheme 7: Synthesis of compound 18 [ka] Synthesis of 5-hydroxy-N-methoxy-N-methylpentanamide: [ka] A suspension of lactone (4 g, 40 mmol, 1 eq.) and N,O-dimethylhydroxyamine hydrochloride (6.04 g, 1.55 eq.) in THF (150 ml) at -20°C was charged with 2.9 M in 2-methyltetrahydrofuran. i-PrMgBr solution (50 ml, 3.6 eq.) was added dropwise over a period of 30 minutes. The mixture was stirred at -20 °C for 3 h and then diluted with 50 mL of saturated NH 4 The reaction was quenched with Cl solution. The layers were separated and the aqueous layer was extracted three times with EtOAc. The combined organic layers were washed with brine and anhydrous MgSO. 4 and concentrated in vacuo. The residue was purified by column chromatography (eluent 80 / 20 EtOAc / hexane to 100% EtOAc). Yield 2.0g (31%). NMR (400MHz, CDCl 3 ): 1.57-1.63 (m, 2H), 1.70-1.76 (m, 2H), 2.44-2.50 (m, 2H), 3.18 (s, 3H), 3.62 (t, 2H), 3.68 (s, 2H). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 0.90 minutes), MS (ESI) m / z 162.4 [MH ]+.

[0336] Synthesis of 5-((tert-butyldiphenylsilyl)oxy)-N-methoxy-N-methylpentanamide: [ka] 5-Hydroxy-N-methoxy-N-methylpentanamide (2.1 g, 13 mmol, 1 eq.), tert-butyldiphenylsilyl chloride (5.4 g, 5 ml, 1.5 eq.), imidazole (1.6 g, (1.8 eq.), and DMAP (0.16 g, 0.1 eq.) was stirred at ambient temperature for 15 hours. The reaction mixture was diluted with water (200ml) and extracted with EtOAc (3x60ml). The combined organic layer was diluted with Na 2 S.O. 4 dried, filtered and the solvent was evaporated. The residue was subjected to column chromatography (SiO 2 / hexane, hexane:EtOAc 5:1). Yield 3g (58.6%). NMR (400MHz, CDCl 3 ): 1.20 (s, 9H), 1.60-1.66 (m, 2H), 1.70-1.78 (m, 2H), 2.41-2.47 (m, 2H), 3.19 (s, 3H), 3.65 (s, 3H), 3.70 (t, 2H), 7.38-7.44 (m, 6H), 7.66-7.71 (m, 4H). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, 3 gradient from 5 to 87% in min, retention time 2.20 min), MS (ESI) m / z 400.5 [MH]+.

[0337] Synthesis of 7-((tert-butyldiphenylsilyl)oxy)-2-ethoxyhept-1-en-3-one: [ka] A solution of ethyl vinyl ether (1.8 g, 2.4 ml, 3.3 eq.) in dry tetrahydrofuran (50 mL) was cooled to -78° C. and tert-butyllithium in pentane (1.7 M, 13 ml, 3 eq.) was added. The mixture was warmed to 0°C over a period of 1 hour, stirred for 45 minutes, then cooled to -30°C. 5-((tert-butyldiphenylsilyl)oxy)-N-methoxy-N-methylpentanamide was added in THF (3.0 g, 7.5 mmol, 1 eq.) and the mixture was stirred at 0° C. for 4 hours. The progress of the reaction was monitored by TLC. NH mixture 4 Pour into Cl aqueous solution, Et 2 Extracted with O. The combined extracts were 2 S.O. 4 dried, filtered and the solvent was evaporated. The product was used in the next step without further purification. Yield 2.5g (81%). NMR (400MHz, CDCl 3 ): 1.02 (s, 9H), 1.35 (t, 3H), 1.58-1.62 (m, 2H), 1.70-1.76 (m, 2H), 2.69 (t, 2H), 3.68 (t, 2H), 3.81 ( q, 2H), 4.40 (d, 1H), 5.18 (d, 1H), 7.38-7.43 (m, 6H), 7.64-7.68 (m, 4H).

[0338] Synthesis of (2Z,2’E)-2,2’-(7-((tert-butyldiphenylsilyl)oxy)heptane-2,3-diylidene)bis(N-ethylhydrazine-1-carbothioamide): [ka] 7-((tert-butyldiphenylsilyl)oxy)-2-ethoxyhept-1-en-3-one (2.0 g, 4.9 mmol, 1 eq) was dissolved in EtOH (50 ml) and ethylthiosemicarbazide (1.16 g, 2 equivalents) and 3 drops of H 2 S.O. 4 was added. The reaction mixture was stirred and heated to reflux for 4 hours, then maintained at ambient temperature for 15 hours. Filter the precipitate formed and add EtOH, water, Et 2 Washed with O and dried. Yield 1.71g (60%). NMR (400MHz, DMSO-d 6 ): 0.88 (s, 9H), 6.72 (t, 6H), 1.40-1.60 (m, 4H), 2.18 (s, 3H), 3.38-3.43 (m, 4H), 3.56-3.62 (m, 4H), 7.38-7.44 (m, 6H), 7.56-7.61 (m, 4H), 10.21-10.23 (m, 2H), 10.38-10.42 (m, 2H).

[0339] Synthesis of INT-18, ((2Z,2’E)-2,2’-(7-hydroxyheptane-2,3-diylidene)bis(N-ethylhydrazine-1-carbothioamide)): [ka] (2Z,2'E)-2,2'-(7-((tert-butyldiphenylsilyl)oxy)heptane-2,3-diylidene)bis(N-ethylhydrazine-1-carboxylate) in THF (25 ml). A mixture of (1.3 g, 2.3 mmol) and n-tetrabutylammonium fluoride trihydrate (0.88 g, 1.2 eq.) was stirred at ambient temperature for 15 hours. The reaction mixture was diluted with water (150ml) and extracted with EtOAc (3x60ml). Separate the organic layer and add Na 2 S.O. 4 dried, filtered and the solvent was evaporated. Yield 0.53g (65%). NMR (400MHz, DMSO-d 6 ): 1.10-1.16 (m, 6H), 1.38-1.48 (m, 4H), 2.19 (s, 3H), 2.84-2.87 (m, 2H), 3.41-3.47 (m, 2H), 3.58-3.62 (m , 4H), 4.50 (t, 1H), 8.26-8.38 (m, 2H), 10.20 (s, 1H), 10.41 (s, 1H).

[0340] Synthesis of compound 18: [ka] Cu(OAc) 2 ·2H 2 O (0.12 g, 1.1 eq.) was added to INT-18 (0.18 g, 0.5 mmol, 1 eq.) in ethanol. The mixture was stirred at ambient temperature for 15 hours. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.06g (25%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.74 min). MS (ESI) m / z 408.5 [MH]+.

[0341] Scheme 8: Synthesis of compound 19 [ka] Synthesis of (2-aminoethyl)triphenylphosphonium bromide: [ka] A stirred solution of triphenylphosphine (4.3g, 16.6mmol) and 2-bromoethylamine hydrobromide (3.4g, 16.6mmol) in n-propanol (100ml) was heated to reflux under nitrogen atmosphere for 72 hours. The mixture was then cooled to room temperature and the solids were filtered, washed with a portion of anhydrous ether and dried in vacuo. The product was dissolved in 50ml of water, the insoluble solid was filtered and the filtrate was concentrated to dryness in vacuo to give the title compound (6.40g, 100%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.25 minutes, MS (ESI) m / z 306.5 [MH] +.

[0342] Synthesis of (4Z,5E)-4,5-bis(2-(methylcarbamothioyl)hydrazineylidene)pentanoic acid: [ka] To a stirred solution of imidazole propionic acid (0.5 g, 3.6 mmol) in water (18 mL) was added a solution of NBS (0.63 g, 1 eq.) in acetonitrile (5.5 mL) in one portion. After stirring for 20 minutes, the acetonitrile was removed in vacuo. To the reaction mixture was added a solution of sodium acetate trihydrate (0.7 g) and methylthiosemicarbazide (1.12 g, 3 eq.) in water (7.5 mL). Crystals began to form within 5 minutes. Crystallization was continued for 14 hours at ambient temperature, and the precipitate was filtered and recrystallized from water. Yield 0.34g (31.3%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.10 minutes, MS (ESI) m / z 305.0 [MH] +. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 2.41 (br.s, 2H), 2.91 (br.s, 2H), 2.99 (br.s, 6H), 7.60 (s, 1H), 8.29 (br.s, 1H), 8.54 (br.s, 1H), 10.80 (s, 1H), 11.73 (s, 1H).

[0343] Synthesis of INT-19, ((2-((4Z,5E)-4,5-bis(2-(methylcarbamothioyl)hydrazineylidene)pentanamido)ethyl)triphenylphosphonium): [ka] (4Z,5E)-4,5-bis(2-(methylcarbamothioyl)hydrazineylidene)pentanoic acid (0.44g, 1.4mmol), (2-aminoethyl)triphenylphosphonium bromide in DMF (15ml) A mixture of (0.55 g, 1 eq.), EDCI (0.3 g, 1.1 eq.), and HOBT (0.21 g, 1.1 eq.) was stirred at room temperature overnight. The reaction mixture was diluted with water (50 ml), extracted with dichloromethane (3 x 20 ml), and the extract was diluted with Na 2 S.O. 4 dried, filtered and evaporated. Yield 0.2g (23.3%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.17 minutes, MS (ESI) m / z 592.8 [MH] +.

[0344] Synthesis of INT-20, ((2-((4Z,5E)-4,5-bis(2-carbamothioylhydrazineylidene)pentanamido)ethyl)triphenylphosphonium): [ka] INT-20 was made using a procedure similar to that for preparing INT-19. Yield 0.76g (74.4%). 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 2.30-2.43 (m, 2H), 2.77-2.92 (m, 2H), 7.59 (s, 1H), 7.80 (br.s, 1H), 7.92 (br.s,1H), 8.33 (br.s, 1H), 8.39 (br.s, 1H), 10.76 (s, 1H), 11.65 (s, 1H).

[0345] Synthesis of INT-21, ((2-((4Z,5E)-4,5-bis(2-(ethylcarbamothioyl)hydrazineylidene)pentanamido)ethyl)triphenylphosphonium): [ka] INT-21 was made using a procedure similar to that for preparing INT-19. Yield 0.76g (74.4%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.33 minutes, MS (ESI) m / z 620.5 [MH] +. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.00-1.21 (m, 6H), 2.29 (br.s, 2H), 2.87 (br.s, 2H), 3.34 (br.s, 2H), 3.49-3.55 (m, 4H) , 3.65-3.77 (m, 2H), 7.58 (s, 1H), 7.77-7.96 (m, 15H), 8.41 (br.s, 1H), 8.53 (br.s, 1H), 8.60 (br.s, 1H), 10.74 (s, 1H), 11.74 (s, 1H).

[0346] Synthesis of compound 19: [ka] Cu(OAc) 2 ·2H2 O (0.025 g, 1.1 eq.) was added to INT-19 (0.087 g, 0.1 mmol, 1 eq.) in ethanol. The mixture was stirred at ambient temperature for 15 hours. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.018g (19%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.56 min). MS (ESI) m / z 653.3 [MH]+.

[0347] Synthesis of compound 20: [ka] The title compound was prepared from INT-20 following the method for preparing compound 19. The product precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.09g (45%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.49 min). MS (ESI) m / z 625.3 [MH]+.

[0348] Synthesis of compound 21: [ka] The title compound was prepared from INT-21 following the method for preparing compound 19. The product precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.09g (45%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.79 min). MS (ESI) m / z 681.2 [MH]+.

[0349] Scheme 9: Synthesis of compound 22 [ka] Synthesis of 2-(2-methoxyethoxy)acetyl chloride: [ka] CH 2 Cl 2 A solution of acid (1) (5.0 g, 37 mmol) in (100 mL) was added with a few drops of DMF followed by SOCl 2 (13.3g, 3eq) was added and the mixture was stirred at ambient temperature for 15 hours. Evaporation of the solvent gave compound (2) (4.4 g, 78%), which was used in the next step without further purification. NMR (400MHz, CDCl 3 ): 3.37 (s, 3H), 3.57-3.60 (m, 2H), 3.74-3.78 (m, 2H), 4.50 (s, 2H).

[0350] Synthesis of N-methoxy-2-(2-methoxyethoxy)-N-methylacetamide: [ka] CH 2 Cl 2 A solution of 2-(2-methoxyethoxy)acetyl chloride (4.4 g, 29 mmol) in (100 mL) was added with N,O-dimethylhydroxylamine hydrochloride (3.4 g, 1.2 eq.) followed by Et 3 N (11.7g, 4eq) was added. The mixture was stirred at ambient temperature for 15 hours, quenched with 10% aqueous HCl, and extracted with EtOAc. The combined organic extracts were 2 S.O. 4 dried, filtered and the solvent was evaporated. The residue was purified on silica gel eluting with a gradient of 10% to 75% EtOAc in hexane to give compound (3) (2.7 g, 53%). NMR (400MHz, CDCl 3 ): 3.18 (s, 3H), 3.39 (s, 3H), 3.57-3.64 (m, 2H), 3.68 (s, 3H), 3.73-3.77 (m, 2H), 4.34 (s, 2H).

[0351] Synthesis of 3-ethoxy-1-(2-methoxyethoxy)but-3-en-2-one: [ka] A solution of ethyl vinyl ether (2.0 g, 2.7 ml, 3.3 eq.) in dry tetrahydrofuran (75 mL) was cooled to -78° C. and tert-butyllithium in pentane (1.7 M, 15 ml, 3 eq.) was added. The mixture was warmed to 0°C over a period of 1 hour, stirred for 45 minutes, then cooled to -30°C. N-methoxy-2-(2-methoxyethoxy)-N-methylacetamide (1.53 g, 8.6 mmol, 1 eq.) in THF was added and the mixture was stirred at 0° C. for 4 hours. The progress of the reaction was monitored by TLC. NH mixture 4 Pour into Cl aqueous solution, Et 2 Extracted with O. The combined extracts were 2 S.O. 4 dried, filtered and the solvent was evaporated. The product was used in the next step without further purification. Yield 0.73g (45%), NMR (400MHz, DMSO-d 6 ): 1.28 (t, 3H), 3.22 (s, 3H), 3.32 (s, 2H), 3.42-3.46 (m, 2H), 3.53-3.58 (m, 2H), 4.52 (s, 2H), 4.62 ( d, 1H), 5.10 (d, 1H).

[0352] Synthesis of INT-22, ((2Z,2’E)-2,2’-(1-(2-methoxy)butane-2,3-diylidene)bis(N-methylhydrazine-1-carbothioamide)): [ka] 3-Ethoxy-1-(2-methoxyethoxy)but-3-en-2-one (0.73 g, 3.9 mmol, 1 eq.) was dissolved in EtOH (100 ml) and methylthiosemicarbazide (0.82 g, 2 eq.) and 3 drops of H 2 S.O. 4 was added. The reaction mixture was stirred and heated to reflux for 4 hours, then maintained at ambient temperature for 15 hours. Filter the precipitate formed and add EtOH, water, Et 2 Washed with O and dried. Yield 0.2g (15%). NMR (400MHz, DMSO-d 6 ): 2.20 (s, 3H), 3.02, 3.04 (m, 6H), 3.28 (s, 3H), 3.48-3.60 (m, 4H), 4.84 (s, 2H), 8.38-8.50 (m, 2H), 10.23 (s, 1H), 10.58 (s, 1H). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.34 min), MS (ESI) m / z 335.6 [MH]+.

[0353] Synthesis of compound 22: [ka] Cu(OAc) 2 ·2H 2 O (0.16 g, 1.1 eq.) was added to thiosemacarbazone 5 (0.2 g, 0.66 mmol, 1 eq.) in ethanol. The mixture was stirred at ambient temperature for 15 hours. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.06g (25%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.77 min). MS (ESI) m / z 396.3 [MH]+.

[0354] Example 2: Preparation of compounds 23-46 INT-25, ((2Z,2'E)-2,2'-(1-(furan-2-yl)propane-1,2-diylidene)bis(N-methylhydrazine-1-carbothioamide)) Synthesis: [ka] INT-25 was made using a procedure similar to that for preparing INT-1 in Example 1. Yield 6.78g (78%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.34 min). MS (ESI) m / z 313.4 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 2.25 (s, 3H), 3.20 (s, 3H), 3.28 (s, 3H), 6.62 (d, 1H), 6.84 (d, 1H), 7.31 (s, 1H), 7.33 ( s, 1H), 7.53 (s, 1H), 7.71 (s, 1H), 8.79 (s, 1H), 10.52 (s, 1H).

[0355] INT-33, ((2E,2'E)-2,2'-(1-(2,5-dimethylfuran-3-yl)propane-1,2-diylidene)bis(N-ethylhydrazine-1- Synthesis of carbothioamide): [ka] INT-33 was made using a procedure similar to that for preparing INT-1 in Example 1. Yield 1.8g (48%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.60 min). MS (ESI) m / z 369.5 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.07 (t, 3H), 1.15 (t, 3H), 2.06 (s, 3H), 2.28 (s, 3H), 2.30 (s, 3H), 3.41-3.48 (m, 2H), 3.55-3.63 (m, 2H), 6.09 (s, 1H), 6.84 (d, 1H), 7.37 (t, 1H), 8.69 (t, 1H), 9.52-10.52 (m, 1H).

[0356] INT-41, ((2E,2'E)-2,2'-(1-(1-ethyl-1H-pyrazol-5-yl)propane-1,2-diylidene)bis(N-methylhydrazine-1 -Synthesis of carbothioamide): [ka] INT-41 was made using a procedure similar to that for preparing INT-1 in Example 1. Yield 0.55g (52.9%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 0.83 minutes, MS (ESI) m / z 341.3 [MH] +.

[0357] Synthesis of compound 25: [ka] The title compound was prepared from INT-25 according to the method for preparing Compound 1 of Example 1. Yield 6.2g (76%). ICP / MS Sulfur: 17.36%, Copper: 16.518%. LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.11 min). MS (ESI) m / z 374.1 [MH]+.

[0358] Synthesis of compound 33: [ka] The title compound was prepared from INT-33 according to the method for preparing Compound 1 of Example 1. The product was isolated as a reddish-brown powder. The precipitate formed was collected by filtration after cooling, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and copious amounts of diethyl ether (5 x 50 ml) and then dried in vacuo. Yield 0.7g (75%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.34 min). MS (ESI) m / z 430.5 [MH]+.

[0359] Synthesis of compound 41: [ka] The title compound was prepared from INT-41 according to the method for preparing Compound 1 of Example 1. The product precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.18g (55.7%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.80 min). MS (ESI) m / z 401.8 [MH]+.

[0360] Scheme 10: Synthesis of compound 23 [ka] Synthesis of methyl 5-(3-oxopropyl)furan-2-carboxylate: [ka] Under an inert atmosphere, to a stirred solution of methyl 5-bromofuroate (5.7 g, 28 mmol, 1 eq.) in DMF (550 ml) was added allyl alcohol (2.28 g, 1.4 eq.), Pd(OAc). 2 (0.189g, 0.03eq), TEBAC (6.39g, 1eq), and Na 2 C.O. 3 (6.85g, 2eq) was added. The mixture was then stirred at 80°C for 2 hours. Once the reaction reaches completion, the resulting mixture is filtered through Celite, concentrated in vacuo at ≦40 °C, diluted with ethyl acetate, washed with brine, concentrated to dryness in vacuo, and the residue is subjected to column chromatography. Purified by chromatography (ethyl acetate:hexane 1:3). Yield 2.7g (53%). 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 2.89(dd, 2H), 3.05(dd, 2H), 3.89(s, 3H), 6.19(s, 1H), 7.09(s, 1H), 9.83(s, 1H).

[0361] Synthesis of methyl 5-(3-morpholinopropyl)furan-2-carboxylate: [ka] Methyl 5-(3-oxopropyl)furan-2-carboxylate (1.6g, 9mmol, 1eq) was dissolved in MeOH (90ml) and molecular sieve 3A (2.64g) was added to the solution. After stirring for 15 minutes, the mixture was cooled to 0°C. To the stirred solution of the aldehyde was added a solution of morpholine (1.15g, 1.5eq) and acetic acid (1.05g, 2eq) in methanol (42ml). After stirring for 2 min, NaBH 3 CN (1.66g, 3eq) was added. The resulting mixture was stirred at 0° C. for 14 hours and allowed to reach ambient temperature naturally. The reaction mixture was diluted with DCM, filtered through Celite, and the filtrate was diluted with NaHCO 3 Washed with aqueous solution. The aqueous phase was extracted twice with DCM. organic phase with Na 2 S.O. 4 dried, filtered and the solvent was evaporated. The residue was subjected to column chromatography (SiO 2 , eluted with EtOAc 100% from EtOAc-hexane 1:5 to 1:3 to 1:1, then CH 2 Cl 2 -MeOH, 10:1). Yield 1.5g (68%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 0.28 minutes. MS (ESI) m / z 254.4 [MH] +, retention time 0.8 min. MS (ESI) m / z 254.6 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.86-1.94 (m, 2H), 2.39-2.44 (m, 2H), 2.44-2.53(m, 4H), 2.66-2.86(m, 2H), 3.68-3.77(m, 4H) , 3.88(s, 3H), 6.16(d, 1H), 7.11(d, 1H).

[0362] Synthesis of 5-(3-morpholinopropyl)furan-2-carboxylic acid: [ka] To a solution of methyl 5-(3-morpholinopropyl)furan-2-carboxylate (1.5 g, 6.0 mmol) in methanol (20 ml) was added a solution of NaOH (0.6 g, 2 eq.) in water (5 ml). and the reaction mixture was stirred at room temperature overnight. Methanol was removed in vacuo and the residue was diluted with water and acidified to pH1. The acidified solution was evaporated to dryness in vacuo and treated with isopropanol. The solid salts were filtered off and the filtrate was evaporated to dryness in vacuo. Yield 1.4g (73.5%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 0.28 minutes. MS (ESI) m / z 240.4 [MH] +, retention time 0.67 min. MS (ESI) m / z 240.1 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.98-2,15 (m,2H), 2.68-2.80 (m, 2H), 2.91-3.17(m, 4H), 3.37-3.49(m, 2H), 3.75-3.99(m, 4H), 6.41(s, 1H), 7.14(s, 1H), 11.26(br.s, 1H), 12.91(br.s, 1H).

[0363] Synthesis of N-methoxy-N-methyl-5-(3-morpholinopropyl)furan-2-carboxamide: [ka] CH at 5℃ 2 Cl 25-(3-morpholinopropyl)furan-2-carboxylic acid (1.2 g, 4.0 mmol, 1 eq.), N,O-dimethylhydroxylamine (0.55 g, 1.3 eq.), HOBt (0.65 g, EDCI (0.83 g, 1 eq.) was added to a stirred mixture of DIPEA (3 ml, 4 eq.) and DIPEA (3 ml, 4 eq.). The reaction was stirred at ambient temperature for 15 hours. The mixture was washed with water and brine. The organic layer is treated with anhydrous Na 2 S.O. 4 , filtered, and the solvent was concentrated under reduced pressure. The product was used without further purification. Yield 0.9g (73%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 0.34 minutes. MS (ESI) m / z 283.6 [MH] +, retention time 0.85 min. MS (ESI) m / z 283.5 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.86-1.94 (m,2H), 2.40-2.53 (m, 6H), 2.71-2.81(m, 2H), 3.34(s, 3H), 3.68-3.74(m, 4H), 3.76 (s,3H), 6.15(d, 1H), 7.07(d, 1H).

[0364] Synthesis of 1-(5-(3-morpholinopropyl)furan-2-yl)ethane-1-one: [ka] A solution of N-methoxy-N-methyl-5-(3-morpholinopropyl)furan-2-carboxamide (0.9 g, 3.0 M, 1 eq) in THF (50 ml) was cooled to 5°C and the odor in THF was A solution of methylmagnesium dihydride (3.4M, 2.8ml, 3 eq.) was added. The reaction mixture was stirred at 5 °C for 2 h and then diluted with NH 4 Pour into Cl aqueous solution, Et 2 Extracted with O. The combined extracts were 2 S.O. 4 and evaporated. The title product was used in the next step without purification. Yield 0.6g (79%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 0.3 minutes, MS (ESI) m / z 238.4 [MH] +, retention time 0.8 min, MS (ESI) m / z 238.4 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.88-1.96 (m, 2H), 2.35-2.64 (m, 9H), 2.73-2.79 (m, 2H), 3.66-3.90 (m, 4H), 6.20 (s, 1H), 7.11 (s, 1H).

[0365] INT-23, ((2E,2'E)-2,2'-(1-(5-(3-morpholinopropyl)furan-2-yl)ethane-1,2-diylidene)bis(N-ethylhydrazine Synthesis of -1-carbothioamide): [ka] A mixture of 1-(5-(3-morpholinopropyl)furan-2-yl)ethan-1-one (0.5 g, 2.0 mmol, 1 eq), NaBr (0.11 g, 0.5 eq), and DMSO (1.1 ml) heated to 85°C, then H 2 S.O. 4 Upon addition of (6 drops) (foaming), the reaction temperature started to rise. When the reaction was heated to 110-115 °C, dimethyl sulfide formation eventually stopped and the reaction mixture became viscous. The viscous material formed was dissolved in EtOH and ethylthiosemicarbazide (0.5 g, 2 eq.) was added to this solution. The reaction mixture was refluxed for 2 hours, then cooled to room temperature, the solvent was evaporated in vacuo and the residue was dissolved in water (25ml) and saturated Na 2 C.O. 3 Neutralized with aqueous solution and extracted with EtOAc (3x50ml). Separate the organic layer and add Na 2 S.O. 4 dried, filtered and the solvent was evaporated. The residue was treated with water. The precipitate formed was filtered and washed with EtOH to obtain the pure title compound. Yield 0.2g (21%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.18 minutes, MS (ESI) m / z 454.4 [MH] +.

[0366] INT-27, ((2E,2'E)-2,2'-(1-(5-(3-morpholinopropyl)furan-2-yl)ethane-1,2-diylidene)bis(N-methylhydrazine Synthesis of -1-carbothioamide): [ka] INT-21 was made using a procedure similar to that for preparing INT-19. Yield 0.16g (15%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.02 minutes, MS (ESI) m / z 426.3 [MH] +.

[0367] Synthesis of compound 23: [ka] CuCl 2 ·2H 2 O (0.034 g, 1 eq.) was added to thiosemicarbazone 6 (0.09 g, 0.2 mmol, 1 eq.) in ethanol. The mixture was stirred at ambient temperature for 15 hours. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.05g (48%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.56 min). MS (ESI) m / z 515.4 [MH]+.

[0368] Synthesis of compound 27: [ka] The title compound was prepared from INT-27 following the method for preparing compound 23. The product precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.095g (87%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.46 min). MS (ESI) m / z 487.5 [MH]+.

[0369] Scheme 11: Synthesis of compound 31 [ka] Synthesis of ethyl 5-(1-chloroethyl)furan-2-carboxylate: [ka] Zinc chloride (3.9 g, 28.6 mmol) was added to a solution of paraldehyde (17.3 g, 131.1 mmol) and ethyl 2-furoate (16.9 g, 120.7 mmol) in chloroform (36 mL). Hydrogen chloride was passed through the mixture with vigorous stirring for 5 hours at 25-30°C. Then 250 mL of chloroform was added and the reaction mixture was washed with water (2 x 30 mL) and then dried over calcium chloride. The solvent was removed under reduced pressure to obtain the desired product 1, which was used in the next step without further purification. Yield 35g (31%). 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.18 (d, 3H), 1.33 (t, 3H), 4.32 (q, 2H), 5.09 (q, 1H), 6.41 (d,1H), 7.07 (d, 1H).

[0370] Synthesis of ethyl 5-(1-(piperidin-1-yl)ethyl)furan-2-carboxylate: [ka] CH 3 Suspension of ethyl 5-(1-chloroethyl)furan-2-carboxylate (5.0 g, 24.6 mmol), piperidine (4.2 g, 49.2 mmol), and potassium carbonate (6.8 g, 49.2 mmol) in CN (100 ml). The liquid was stirred at 50°C for 12 hours. The mixture was cooled to room temperature. CH 3 CN was removed by evaporation and the residue was diluted with 20 ml of 2N aqueous sodium carbonate solution and extracted with dichloromethane. Wash the organic phase with brine and remove Na 2 S.O. 4 dried, filtered and evaporated to dryness. The residue was purified by column chromatography (silica gel, eluent 100% DCM to 5% MeOH) to give the title product, which was used in the next step without further purification. Yield 5.1g (82%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.90 min). MS (ESI) m / z 252.1 [MH]+. 1 H-NMR (400MHz, CDCl 3): δ (ppm) 1.36 (d, 2H), 1.38 (d, 3H), 1.44 (d, 3H), 1.58 (q, 4H), 2.35-2.41 (m, 2H), 2.48-2.53 (m, 2H) ), 3.81 (q, 1H), 4.35 (q, 2H), 6.29 (d, 1H), 7.17 (d, 1H).

[0371] Synthesis of 5-(1-(piperidin-1-yl)ethyl)furan-2-carboxylic acid: [ka] A solution of ethyl 5-(1-(piperidin-1-yl)ethyl)furan-2-carboxylate (5.1 g, 20.3 mmol) in MeOH (50 ml) was added to a 20% aqueous solution of LiOH (1.6 g, 60.9 mmol). added to. The reaction mixture was stirred at 60°C for 8 hours. The solvent was then removed by lyophilization and the corresponding crude product was used in the next step without further purification. Yield 4.4g (83%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.65 min). MS (ESI) m / z 224.4 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.33-1.38 (m, 2H), 1.43 (d, 3H), 1.57-1.61 (m, 4H), 2.07 (s, 1H), 2.60-2.63 (m, 2H), 4.07 (q , 2H), 4.32 (s, 1H), 6.52 (d, 1H), 7.04 (d, 1H).

[0372] Synthesis of N-methoxy-N-methyl-5-(1-(piperidin-1-yl)ethyl)furan-2-carboxamide: [ka] 5-(1-(piperidin-1-yl)ethyl)furan-2-carboxylic acid (5.2 g, 20 mmol), N,O-dimethylhydroxylamine (2.3 g, 24 mmol) in DCM (80 ml) at 4 °C; To a stirred mixture of HOBt (3.2 g, 24 mmol) and TEA (12 ml, 90 mol) was added EDCI (4.6 g, 24 mmol) and then the mixture was stirred at room temperature overnight. The mixture was washed with water (15ml), brine (100ml). The organic layer is treated with anhydrous Na 2 S.O. 4 and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, eluent 100% DCM to 5% MeOH) to give the crude product. Yield 2.2g (42%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.77 min). MS (ESI) m / z 267.5 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.38 (t, 2H), 1.46 (d, 3H), 1.54-1.60 (m, 4H), 2.36-2.41 (m, 2H), 2.50-2.55 (m, 2H), 3.33 (s , 3H), 3.78 (s, 3H), 3.81-3.87 (m, 1H), 6.26 (dd, 1H), 7.23 (dd, 1H).

[0373] Synthesis of 2-ethoxy-1-(5-(1-(piperidin-1-yl)ethyl)furan-2-yl)prop-2-en-1-one: [ka] A solution of ethyl vinyl ether (1.8g, 24.4mmol) in tetrahydrofuran (50ml) was cooled to -78°C and tert-butyllithium in pentane (1.7M, 14.0ml, 22.2mmol) was added. The mixture was warmed to 0°C over a period of 1 hour, stirred for 45 minutes, and cooled to -30°C. To the mixture was added a solution of N-methoxy-N-methyl-5-(1-(piperidin-1-yl)ethyl)furan-2-carboxamide (1.0 g, 3.7 mmol) in THF (15 ml) and the mixture was stirred at 0°C for 4 hours. The progress of the reaction was monitored by TLC. NH mixture 4 Pour into Cl aqueous solution (100 ml) and add Et 2 Extracted with O (3 x 50 ml). The combined extracts were 2 S.O. 4 It was dried with. The product solution was then decanted and the solvent removed under reduced pressure to yield the title compound, which was used in the next step without further purification. Yield 1.1g (87%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.97 min). MS (ESI) m / z 278.6 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.38 (t, 2H), 1.46 (d, 3H), 1.47 (d, 3H), 1.55-1.63 (m, 4H), 2.38-2.44 (m, 2H), 2.51-2.56 (m , 2H), 3.81-3.87 (m, 1H), 3.93 (q, 2H), 4.58 (d, 1H), 5.33 (d, 1H), 6.31 (d, 1H), 7.47 (d, 1H).

[0374] INT-31, ((2Z,2'E)-2,2'-(1-(5-(1-(piperidin-1-yl)ethyl)furan-2-yl)propane-1,2-diylidene) Synthesis of bis(N-ethylhydrazine-1-carbothioamide): [ka] 2-ethoxy-1-(5-(1-(piperidin-1-yl)ethyl)furan-2-yl)prop-2-en-1-one (1.1 g, 3.7 mmol) in EtOH (30 ml) Dissolve ethylthiosemicarbazide (0.9 g, 7.4 mmol) and 3 drops of H 2 S.O. 4 was added. The stirred reaction mixture was heated to reflux for 4 hours and then kept at ambient temperature overnight. The progress of the reaction is determined by TLC (CCl 4 / EtOAc 7:3). Filter the precipitate and add EtOH, water, Et 2 Washed with O and dried. Yield 0.5g (33%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.17 min). MS (ESI) m / z 452.0 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.07 (t, 3H), 1.15 (t, 3H), 1.38-1.55 (m, 3H),1.60-1.66 (m, 4H), 1.70-1.79 (m, 4H), 2.33 (s , 3H), 3.41-3.48 (m, 2H), 3.55-3.63 (m, 2H), 4.72 (s, 1H), 6.91 (dd, 1H), 7.14 (dd, 1H), 7.73 (t, 1H), 8.73 (t, 1H), 9.08-9.78 (m, 2H), 10.48 (s, 1H), 10.55 (s, 1H).

[0375] INT-24, ((2E,2'E)-2,2'-(1-(5-(morpholinomethyl)furan-2-yl)propane-1,2-diylidene)bis(N-ethylhydrazine-1 -Synthesis of carbothioamide): [ka] INT-24 was made using a procedure similar to that for preparing INT-31. Yield 4.6g (63%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.01 min). MS (ESI) m / z 440.5 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.10 (t, 3H), 1.16 (t, 3H), 1.39 , 2.32 (s, 3H), 2.35-2.47 (m, 4H), 3.42-3.58 (m, 2H), 3.58-3.76 (m, 8H), 6.61 (s, 1H), 7.01 (s, 1H), 7.78 (br.s, 1H), 8.70 (br.s, 1H), 10.40 (s, 1H), 10.51 (s, 1H) ).

[0376] INT-32, ((2E,2'E)-2,2'-(1-(5-(morpholinomethyl)furan-2-yl)propane-1,2-diylidene)bis(N-methylhydrazine-1 -Synthesis of carbothioamide): [ka] INT-32 was made using a procedure similar to that for preparing INT-31. Yield 0.25g (54%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.06 minutes. MS (ESI) m / z 412.4 [MH] +. 1 H-NMR (400MHz, DMSO-d 6): δ (ppm) 2.33 (s, 3H), 2.92-3.00(m, 4H), 3.03-3.10(m, 4H), 3.12-3.45(m, 4H), 3.70-3.82(m, 4H), 4.5 (s, 3H), 6.9(s, 1H), 7.07(s, 1H), 7.71(s, 1H), 8.67(s, 1H), 10.39(s, 1H), 10.54(s, 1H).

[0377] INT-37, ((2E,2'E)-2,2'-(1-(5-((4-methylpiperazin-1-yl)methyl)furan-2-yl)propane-1,2-diylidene )Bis(N-ethylhydrazine-1-carbothioamide)) Synthesis: [ka] INT-37 was made using a procedure similar to that for preparing INT-31. Yield 0.9g (61.5%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.06 min). MS (ESI) m / z 453.5 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.10 (t, 3H), 1.16 (t, 3H), 1.39 , 2.32 (s, 3H), 2.55-2.74 (m, 2H), 2,79-2.89 (M, 4H), 3.42 -3.59 (m, 6H), 3.62 (q, 2H), 3.97 (s, 3H), 6.71 (s, 1H), 7.08 (s, 1H), 7.76 (s, 1H), 8.74 (s, 1H), 10.44 (s, 1H), 10.54 (s, 1H).

[0378] INT-39, ((2Z,2'E)-2,2'-(1-(5-(1-morpholinoethyl)furan-2-yl)propane-1,2-diylidene)bis(N-ethylhydrazine Synthesis of -1-carbothioamide): [ka] INT-39 was made using a procedure similar to that for preparing INT-31. Yield 0.2g (20%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.11 min). MS (ESI) m / z 454.3 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.10 (t, 3H), 1.16 (t, 3H), 1.39 (dd, 3H), 2.32 (s, 3H), 2.34-2.38 (m, 2H), 2.47-2.49 (m, 2H) ), 3.48-3.53 (m, 2H), 3.56-3.65 (m, 4H),3.60-3.65 (m, 2H), 3.84-3.90 (m, 1H), 6.56 (dd, 1H), 7.06 (dd, 1H) ), 7.87 (t, 1H), 8.70 (t, 1H), 10.47 (d, 1H), 10.59 (d, 1H).

[0379] Synthesis of compound 31: [ka] CuCl 2 ·2H 2 O (0.2g, 2.4mmol) was added to compound 6 (0.5g, 1.2mmol) in 30ml ethanol. The mixture was stirred at ambient temperature for 15 hours. The precipitate formed was collected by filtration after cooling, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and copious amounts of diethyl ether (5 x 50 ml) and then dried in vacuo. Yield 0.4g (75%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.66 min). MS (ESI) m / z 513.3 [MH]+.

[0380] Synthesis of compound 24: [ka] The title compound was prepared from INT-24 following the method for preparing compound 31. The product precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 4.7g (92%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.48 min). MS (ESI) m / z 501.3 [MH]+.

[0381] Synthesis of compound 32: [ka] The title compound was prepared from INT-32 following the method for preparing compound 31. The product precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.14g (97%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.38 min). MS (ESI) m / z 473.0 [MH]+.

[0382] Synthesis of compound 37: [ka] The title compound was prepared from INT-37 following the method for preparing compound 31. The product precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.8g (96%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.52 min). MS (ESI) m / z 514.3 [MH]+.

[0383] Synthesis of compound 39: [ka] The title compound was prepared from INT-39 following the method for preparing compound 31. The product precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water (2 x 50 ml), ethanol (2 x 50 ml), and copious amounts of diethyl ether (5 x 50 ml), then dried in vacuo. Yield 0.15g (86%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.57 min). MS (ESI) m / z 515.2 [MH]+.

[0384] Scheme 12: Synthesis of compound 26 [ka] Synthesis of methyl 5-(3-oxopropyl)furan-2-carboxylate: [ka] Methyl 5-bromo-furoate (5.7 g, 28 mmol, 1 eq.) was dissolved in 550 ml of DMF under an inert atmosphere. Allyl alcohol (2.28g, 1.4eq), Pd(OAc) 2 (0.189g, 0.03eq), TEBAC (6.39g, 1eq), and Na 2 C.O. 3 (6.85g, 2eq) was added. The mixture was then stirred at 80°C for 2 hours. Upon completion, the resulting mixture was filtered through Celite, the filtrate was concentrated in vacuo at ≦40 °C, diluted with ethyl acetate, washed with brine, concentrated to dryness, and the residue was purified by column chromatography (silica gel, acetic acid). Purified by ethyl-hexane 1:3). Yield 2.7g (53%). 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 2.89(dd, 2H), 3.05(dd, 2H), 3.89(s, 3H), 6.19(s, 1H), 7.09(s, 1H), 9.83(s, 1H).

[0385] Synthesis of methyl 5-(3-(piperidin-1-yl)propyl)furan-2-carboxylate: [ka] Methyl 5-(3-oxopropyl)furan-2-carboxylate (2.7g, 15mmol, 1 eq.) was dissolved in MeOH (150ml) and molecular sieves (4.4g) were added to the solution. After stirring for 15 minutes, the mixture was cooled to 0°C. To a stirred solution of aldehyde 1 was added a solution of piperidine (1.9g, 1.5eq) and acetic acid (1.8g, 2eq) in methanol (70ml) at 0°C. After stirring for 2 min, NaBH 3 CN (2.8g, 3eq) was added. The resulting mixture was stirred for 14 hours and allowed to warm up naturally from 0°C to room temperature. The reaction mixture was then diluted with DCM, filtered through Celite, and the filtrate was diluted with NaHCO 3 Washed with aqueous solution. The aqueous phase was extracted twice with DCM. organic phase with Na 2 S.O. 4dried, filtered and concentrated to dryness in vacuo. The residue was subjected to column chromatography (SiO 2 , first eluted with a gradient of EtOAc / hexane 1:5 to 1:3 to 1:1 to 100% EtOAc, then CH 2 Cl 2 / MeOH, 10:1). Yield 1.8g (49%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 0.94 minutes. MS (ESI) m / z 252.4 [MH] +. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.45-1.66 (m,2H), 1.78-1.88 (m, 2H), 1.96-2.17(m, 4H), 2.57-2.88(m, 6H), 3.41-3.56(m, 2H) , 3.88(s, 3H), 6.23(s, 1H), 7.09(s, 1H).

[0386] Synthesis of 5-(3-(piperidin-1-yl)propyl)furan-2-carboxylic acid: [ka] To a stirred solution of methyl 5-(3-(piperidin-1-yl)propyl)furan-2-carboxylate (1.8 g, 7.0 mmol) in methanol (20 ml) was added NaOH (0.73 g) in water (25 ml). , 2.6 eq.) was added. The reaction mixture was stirred at ambient temperature for 15 hours. Methanol was removed in vacuo and the residue was diluted with water and acidified to pH1. The acidified solution was evaporated to dryness and the residue was treated with isopropanol. The solid salts were filtered off and the filtrate was evaporated to dryness. Yield 1.35g (68%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 0.35 minutes. MS (ESI) m / z 238.3 [MH] +, retention time 0.86 min. MS (ESI) m / z 238.3 [MH]+.

[0387] Synthesis of N-methoxy-N-methyl-5-(3-(piperidin-1-yl)propyl)furan-2-carboxamide: [ka] CH at 5℃ 2 Cl 2 Methyl 5-(3-(piperidin-1-yl)propyl)furan-2-carboxylate (1.35 g, 5.0 M, 1 eq.), N,O-dimethylhydroxylamine (0.72 g, 1.3 eq.) in (25 ml) ), HOBt (0.83 g, 1.1 eq.), and DIPEA (3.3 ml, 4 eq.) was added EDCI (1.04 g, 1.1 eq.). The reaction was then stirred at ambient temperature for 15 hours. The mixture was washed with water and brine. The organic layer is treated with anhydrous Na 2 S.O. 4 dried, filtered, and concentrated under reduced pressure. The product was used further without purification. Yield 0.4g (29%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 0.35 minutes. MS (ESI) m / z 281.5 [MH] +, retention time 0.93 min. MS (ESI) m / z 281.3 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.38-1.48 (m,2H), 1.55-1.64(m, 4H), 1.86-1.97(m, 2H), 2.31-2.48(m, 6H), 2.69-2.81(m, 2H) , 3.34(s, 3H), 3.76(s, 3H), 6.14(d, 1H), 7.07(d, 1H).

[0388] Synthesis of 2-ethoxy-1-(5-(3-(piperidin-1-yl)propyl)furan-2-yl)prop-2-en-1-one: [ka] A solution of ethyl vinyl ether (0.72g, 0.96ml, 7eq) in dry tetrahydrofuran (20mL) was cooled to -78°C and tert-butyllithium in pentane (1.7M, 5ml, 6q) was added. The mixture was warmed to 0°C over a period of 1 hour, stirred for 45 minutes, and cooled to -30°C. A solution of N-methoxy-N-methyl-5-(3-(piperidin-1-yl)propyl)furan-2-carboxamide (0.4 g, 1.4 mmol, 1 eq.) in THF was added and the mixture was brought to 0 °C. The mixture was stirred for 4 hours. The progress of the reaction was monitored by TLC. NH mixture 4 Pour into Cl aqueous solution, Et 2 Extracted with O. The combined extracts were 2 S.O. 4 dried, filtered and evaporated in vacuo. The product was used in the next step without further purification. Yield 0.39g (93%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.04 minutes. MS (ESI) m / z 292.3 [MH] +. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.18-1.48(m, 5H), 1.50-1.64 (m,4H), 1.82-2.03(m,2H), 2.27-2.48 (m, 6H), 2.62-2.78(m, 2H) , 3.84-3.98(m, 2H), 3.92(q, 2H), 4.56(s, 1H), 5.31(s, 1H), 6.21(d, 1H), 7.44(d, 1H).

[0389] INT-26, ((2E,2'E)-2,2'-(1-(5-(3-(piperidin-1-yl)propyl)furan-2-yl)propane-1,2-diylidene) Synthesis of bis(N-ethylhydrazine-1-carbothioamide): [ka] 2-Ethoxy-1-(5-(3-(piperidin-1-yl)propyl)furan-2-yl)prop-2-en-1-one (0.41 g, 1.45 mmol, 1 eq.) was dissolved in EtOH (10 ml). ) and ethylthiosemicarbazide (0.33 g, 2 eq.) and 1 drop of H 2 S.O. 4 was added. The reaction mixture was stirred and heated to reflux for 4 hours, then maintained at ambient temperature for 15 hours. Filter the precipitate formed and add EtOH, water, Et 2 Washed with O and crystallized from EtOH. Yield 0.08g (12%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.21 minutes. MS (ESI) m / z 466.5 [MH] +. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.11(t, 3H), 1.16(t, 1H), 1.53-1.91(m, 6H), 2.05-2.15(m, 2H), 2.32(s, 3H), 2.77-2.89(m , 2H), 3.05-3.19(m, 2H), 3.35-3.45(m, 4H), 3.53(q, 2H), 3.62(q, 2H), 6.49(s, 1H), 7.05(s, 1H), 7.78(s, 1H), 8.72(s, 1H), 10.48(s, 1H), 10.52(s, 1H).

[0390] INT-28, ((2Z,2'E)-2,2'-(1-(5-(3-morpholinopropyl)furan-2-yl)butane-2,3-diylidene)bis(N-ethylhydrazine Synthesis of -1-carbothioamide): [ka] INT-28 was made using a procedure similar to that for preparing INT-26. Yield 0.18g (50%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.15 minutes. MS (ESI) m / z 468.5 [MH] +. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.11(t, 3H), 1.16(t, 1H), 2.04-2.14(m, 2H), 2.32(s, 3H), 2.77-2.86(m, 2H), 3.17-3.26(m , 2H), 3.39-3.73(m, 10H), 3.91-4.04(m, 2H), 6.5(s, 1H), 7.06(s, 1H), 7.8(s, 1H), 8.72(s, 1H), 10.47(s, 1H), 10.52(s, 1H).

[0391] Synthesis of compound 26: [ka] CuCl 2 ·2H 2O (0.026 g, 1 eq.) was added to thiosemicarbazone 6 (0.07 g, 0.15 mmol, 1 eq.) in ethanol. The mixture was stirred at ambient temperature for 15 hours. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.054g (68%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.76 min). MS (ESI) m / z 527.5 [MH]+.

[0392] Synthesis of compound 28: [ka] The title compound was prepared from INT-28 following the method for preparing compound 26. The product precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.14g (85%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.65 min). MS (ESI) m / z 529.0 [MH]+.

[0393] Scheme 13: Synthesis of compound 29 [ka] Synthesis of ethyl 5-(morpholinomethyl)furan-2-carboxylate: [ka] CH 2 Cl 2 To a stirred solution of ethyl 2-chloromethyl-5-furoate (9.6 g, 50 mmol) in (200 ml) were added morpholine (4.43 g, 4.4 ml, 1 eq.), triethylamine (10.3 g, 14 ml, 2 eq.), and KI (0.1 g) were added. The reaction mixture was stirred at room temperature for 15 hours and then washed with water (3 x 50ml). Separate the organic layer and add Na 2 S.O. 4 dried, filtered and the solvent was evaporated. Yield 8g (66%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.82 min). MS (ESI) m / z 240.1 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.38 (t, 3H), 2.50-2.55 (m, 4H), 3.62 (s, 3H), 3.70-3.75 (m, 4H), 4.37 (q, 2H), 6.36 (d, 1H) ), 7.13 (d, 1H).

[0394] Synthesis of 5-(morpholinomethyl)furan-2-carboxylic hydrochloride: [ka] To a solution of ethyl 5-(morpholinomethyl)furan-2-carboxylate (4.6 g, 20 mmol) in methanol (100 ml) was added a solution of NaOH (2 g, 2 eq.) in water (10 ml) and the reaction mixture was stirred at ambient temperature for 15 hours. The methanol was evaporated in vacuo and the residue was diluted with water and acidified to pH1. The acidified solution was evaporated to dryness and the residue was treated with isopropanol. The solid salts were filtered off and the filtrate was evaporated to dryness. Yield 4.4g (86%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.29 min). MS (ESI) m / z 212.3 [MH]+.

[0395] Synthesis of N-methoxy-N-methyl-5-(morpholinomethyl)furan-2-carboxamide: [ka] A mixture of 5-(morpholinomethyl)furan-2-carboxylic hydrochloride (7.1 g, 29 mmol) and 1,1'-carbonyldiimidazole (5.57 g, 1.2 eq.) in DMF (47 mL) at 60 °C for 30 min. Stirred. N,O-dimethylhydroxylamine (3.35 g, 1.2 eq.) and triethylamine (3.2 g, 4.4 ml, 1.1 eq.) were then added. The mixture was stirred at 80 °C for 16 h, then the volatiles were evaporated in vacuo and the residue was dissolved in EtOAc and H 2 It was distributed between O. Separate the organic layer and add Na 2 S.O. 4 dried, filtered and the solvent was evaporated. Yield 7g (96%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 0.28 minutes. MS (ESI) m / z 255.6 [MH] +, retention time 0.78 min. MS (ESI) m / z 255.6 [MH]+. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 2.52-2.55 (m, 4H), 3.35 (s, 3H), 3.64 (s, 2H), 3.71-3.74 (m, 4H), 6.36 (d, 1H), 6.71 (d, 1H ).

[0396] Synthesis of 1-(5-(morpholinomethyl)furan-2-yl)ethan-1-one: [ka] A solution of N-methoxy-N-methyl-5-(morpholinomethyl)furan-2-carboxamide (3.4 g, 13 mmol, 1 eq.) in THF (150 ml) was cooled to 5 °C and methylmagnesium bromide in THF was added. solution (1.4M, 26ml, 3 eq.) was added. The reaction mixture was stirred at 5 °C for 2 h and then diluted with NH 4 Pour into Cl aqueous solution, Et 2 Extracted with O. The combined extracts were 2 S.O. 4 dried, filtered and the solvent was evaporated. Compound 3 was used in the next step without further purification. Yield 2.6g (93%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 0.31 minutes, MS (ESI) m / z 210.1 [MH] +, retention time 0.67 min, MS (ESI) m / z 210.3 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 2.34-2.45 (m, 7H), 3.49-3.63 (m, 6H), 6.54 (s, 1H), 7.46 (s, 1H).

[0397] INT-29, ((2E,2'E)-2,2'-(1-(5-(morpholinomethyl)furan-2-yl)ethane-1,2-diylidene)bis(N-methylhydrazine-1 -Synthesis of carbothioamide): [ka] A mixture of 1-(5-(morpholinomethyl)furan-2-yl)ethan-1-one (1.4 g, 7.0 mmol, 1 eq.), NaBr (0.33 g, 0.5 eq.), and DMSO (3.45 ml) at 85 Heat to °C, then H 2 S.O. 4 Upon addition of (6 drops) (foaming), the reaction temperature started to rise. When the reaction was heated to 110-115 °C, dimethyl sulfide formation eventually stopped and the reaction mixture became viscous. The viscous material formed was dissolved in EtOH and methylthiosemicarbazide (1.41 g, 2 eq.) was added to this solution. The reaction mixture was refluxed for 2 hours, then cooled to room temperature, the solvent was evaporated in vacuo and the residue was dissolved in water (25ml) and saturated Na 2 C.O. 3 Neutralized with aqueous solution and extracted with EtOAc (3x50ml). Separate the organic layer and add Na 2 S.O. 4 dried, filtered and the solvent was evaporated. The residue was treated with water. The precipitate formed was filtered and washed with EtOH to obtain the pure title compound. Yield 0.7g (26%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.08 minutes, MS (ESI) m / z 398.3 [MH] +.

[0398] INT-38, ((2E,2'E)-2,2'-(1-(5-(morpholinomethyl)furan-2-yl)ethane-1,2-diylidene)bis(N-ethylhydrazine-1 -Synthesis of carbothioamide): [ka] INT-38 was made using a procedure similar to that for preparing INT-29. Yield 0.5g (37%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.12 minutes, MS (ESI) m / z 426.0 [MH] +.

[0399] Synthesis of compound 29: [ka] CuCl 2 ·2H 2O (0.062 g, 1 eq.) was added to thiosemicarbazone 6 (0.14 g, 0.4 mmol, 1 eq.) in ethanol. The mixture was stirred at ambient temperature for 15 hours. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.055g (32%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.29 min). MS (ESI) m / z 459.5 [MH]+.

[0400] Synthesis of compound 38: [ka] The title compound was prepared from INT-36 following the method for preparing compound 29. The product precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.07g (77%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.47 min). MS (ESI) m / z 487.4 [MH]+.

[0401] Scheme 14: Synthesis of compound 30 [ka] Synthesis of 5-(morpholine-4-carbonyl)furan-2-carboxylic acid: [ka] To a stirred solution of furan 2,5-dicarboxylic acid (5 g, 32 mmol, 1 eq.) in DMF (100 ml) was added DIPEA (14.5 g, 19.5 ml, 3.5 eq.) and the reaction flask was flushed with argon. A solution of TBTU (12.3g, 1.2eq) in DMF (75ml) was added dropwise over 1 hour at ambient temperature. The reaction mixture was stirred for an additional hour. Morpholine was then added in one portion and the mixture was stirred at ambient temperature for 2 hours. The mixture was cooled in an ice bath, HCl (2N, 170ml) was added, the product was extracted with EtOAc, the EtOAc was evaporated and the residue was washed with EtOH and ether. Yield 6.19g (85%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.33 min). MS (ESI) m / z 226.3 [MH]+, retention time 0.84 min). MS (ESI) m / z 226.3 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 3.52-3.88(m, 8H), 7.09 (d, 1H), 7.29(d, 1H).

[0402] Synthesis of N-methoxy-N-methyl-5-(morpholine-4-carbonyl)furan-2-carboxamide: [ka] 5-(morpholine-4-carbonyl)furan-2-carboxylic acid (2.6 g, 11 mmol, 1 eq), N,O-dimethylhydroxylamine (1.46 g, 1.3 eq), HOBT (1.71, EDCI (2.21 g, 1 eq.) was added to a mixture of DIPEA (2 ml) and DIPEA (2 ml) at 4° C. and the mixture was stirred at room temperature overnight. The reaction mixture was treated with water. Solid material not soluble in water and DCM was removed by filtration. Separate the organic layer and add Na 2 S.O. 4 dried, filtered and the solvent was evaporated. The residue was subjected to column chromatography (SiO2, CH 2 Cl 2 100%). Yield 2.1g (68%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.95 min). MS (ESI) m / z 269.5 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 3.26 (s, 3H), 3.54-3.73 (m, 8H), 3.76 (s, 3H), 7.10 (d, 1H), 7.22 (d, 1H).

[0403] Synthesis of 1-(5-(morpholine-4-carbonyl)furan-2-yl)ethane-1-one: [ka] A solution of N-methoxy-N-methyl-5-(morpholine-4-carbonyl)furan-2-carboxamide (1.45 g, 5.4 mmol, 1 eq) in THF (50 ml) was cooled to 5°C and Methylmagnesium bromide solution (1.4M, 11ml, 3eq) was added. The reaction mixture was stirred at 5 °C for 2 h and then diluted with NH 4 Pour into Cl aqueous solution, Et 2 Extracted with O. The combined extracts were 2 S.O. 4 dried, filtered and the solvent was evaporated. The title product was used in the next step without further purification. Yield 0.45g (37%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.92 min). MS (ESI) m / z 224.4 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 2.46 (s, 3H), 3.57-3.79 (m, 8H), 3.76 (s, 3H), 7.14 (d, 1H), 7.50 (d, 1H).

[0404] Synthesis of 2-(5-(morpholine-4-carbonyl)furan-2-yl)-2-oxoacetaldehyde: [ka] SeO in a three-necked flask 2 (0.42 g, 1.4 eq.), 1,4-dioxane (6 mL), and water (0.36 mL). Heat the mixture to 50 °C and add SeO 2 The mixture was stirred until most of it was dissolved. 1-(5-(morpholine-4-carbonyl)furan-2-yl)ethan-1-one (0.6 g, 0.003 M, 1 eq.) was added and the reaction was heated at mild reflux overnight. Selenium solid precipitated during the course of the reaction. The mixture was cooled in an ice bath and filtered through diatomaceous earth to remove selenium. The filter cake was washed with a portion of 1,4-dioxane. The filtrate was concentrated to give 0.5 g of crude title product, which was used in the next step without further purification. Yield 0.5g (78%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 0.92 minutes, MS (ESI) m / z 238.1 [MH] +.

[0405] INT-30, ((2E,2'E)-2,2'-(1-(5-(morpholine-4-carbonyl)furan-2-yl)ethane-1,2-diylidene)bis(N-ethyl Synthesis of hydrazine-1-carbothioamide): [ka] Crude 2-(5-(morpholine-4-carbonyl)furan-2-yl)-2-oxoacetaldehyde (0.5 g, 2.0 mmol, 1 eq.) was dissolved in EtOH (25 ml) and ethylthiosemicarbazide (0.5 g , 2 equivalents) and 2 drops of H 2 S.O. 4 was added. The reaction mixture was stirred and heated to reflux for 4 hours, then maintained at ambient temperature for 15 hours. Filter the precipitate formed and add EtOH, MeCN, water, Et 2 Washed with O and dried. Yield 0.25g (27%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.37 minutes, MS (ESI) m / z 440.5 [MH] +. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.00-1.26 (m, 6H), 3.43-4.09 (m, 13H), 7.19 (s, 1H), 7.24 (s, 1H), 6.06 (br.s, 1H), 8.92 (br. .s, 1H), 11.98 (s, 1H), 12.29 (s, 1H).

[0406] Synthesis of intermediate ZN-30: [ka] Zn(OAc) 2 2H 2 O (0.19 g, 1.5 eq.) was added to INT-30 (0.73 g, 2.0 mmol, 1 eq.) in ethanol. The mixture was refluxed for 4 hours. The complex formed precipitated out of the mixture as a yellow powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.175g (61%). 1 H-NMR (400MHz, DMSO-d 6): δ (ppm) 1.11(t, 3H), 1.19 (t, 3H), 3.36-3.85 (m, 13H), 7.11 (s, 1H), 7.15 (s, 1H), 8.20 (s, 1H), 8.43 (s, 1H).

[0407] Synthesis of compound 30: [ka] ZN-30 (0.175g, 0.3mmol, 1eq.) was dissolved in DMSO (4ml) and CuCl in water (4ml). 2 2H 2 A solution of O (0.076 g, 1.1 eq.) was added. Stir the mixture for 5 min, filter, add water and Et 2 Washed with O. Yield 0.08g (46%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.86 min). MS (ESI) m / z 501.3 [MH]+.

[0408] Scheme 15: Synthesis of compound 34 [ka] Synthesis of 2-(furan-2-yl)-2-oxoacetaldehyde: [ka] SeO in a three-necked flask 2 (3.2g, 28.6mmol), 1,4-dioxane (37ml), and water (2.5ml) were charged. Heat the mixture to 50 °C and add SeO 2 The mixture was stirred until most of it was dissolved. 1-(2-furyl)ethanone (3g, 27.2mmol) was added and the reaction was heated at mild reflux overnight. The progress of the reaction is determined by TLC (CCl 4 / EtOAc 7:3). Selenium solid precipitated during the course of the reaction. The mixture was cooled in an ice bath and filtered through diatomaceous earth to remove selenium. The filter cake was washed with a portion of 1,4-dioxane. The filtrate was concentrated to yield 3.0 g of crude compound 1, which was used in the next step without further purification. Yield 3.0g (88%).

[0409] INT-34, ((2Z,2'E)-2,2'-(1-(furan-2-yl)ethane-1,2-diylidene)bis(N-methylhydrazine-1-carbothioamide)) Synthesis: [ka] 2-(Furan-2-yl)-2-oxoacetaldehyde (0.7 g, 6 mmol) was dissolved in EtOH (20 mL), methylthiosemicarbazide (1.3 g, 12 mmol) and 3 drops of H 2 S.O. 4 was added. The reaction mixture was stirred and heated to reflux for 4 hours, then maintained at ambient temperature for 15 hours. The progress of the reaction is determined by TLC (CCl 4 / EtOAc 7:3). Filter the precipitate formed and add EtOH, water, Et 2 Washed with O and dried. Yield 0.57g (32%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.35 min). MS (ESI) m / z 299.5 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 3.02 (d, 3H), 3.01 (d, 3H), 6.78 (q, 1H), 7.52 (d, 1H), 7.84 (s, 1H), 7.99-8.04 (m, 1H), 8.13 (dd, 1H), 8.88-8.92 (m, 1H), 10.81 (s, 1H), 11.79 (s,1H).

[0410] INT-35, ((2Z,2'E)-2,2'-(1-(furan-2-yl)ethane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide)) Synthesis: [ka] INT-35 was made using a procedure similar to that for preparing INT-34. Yield 0.47g (24%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 2.23 min). MS (ESI) m / z 327.5 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.07 (t, 3H), 1.15 (t, 3H), 3.41-3.48 (m, 2H), 3.55-3.63 (m, 2H), 6.78 (q, 1H), 7.52 (d, 1H) ), 7.84 (s, 1H), 7.99-8.04 (m, 1H), 8.13 (dd, 1H), 8.88-8.92 (m, 1H), 10.81 (s, 1H), 11.79 (s,1H).

[0411] INT-36, ((2Z,2'E)-2,2'-(1-(5-nitrofuran-2-yl)ethane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide )) composition: [ka] INT-36 was made using a procedure similar to that for preparing INT-34. Yield 0.02g (24%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 10 min, retention time 8.11 min). MS (ESI) m / z 372.5 [MH]+.

[0412] INT-40, ((2Z,2'E)-2,2'-(1-(5-bromothiophen-2-yl)ethane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide )) composition: [ka] INT-40 was made using a procedure similar to that for preparing INT-34. Yield 0.24g (39%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.85 min). MS (ESI) m / z 422.4 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.15 (t, 3H), 1.18 (t, 3H), 3.41-3.49 (m, 4H), 7.25 (d, 1H), 7.33 (d, 1H), 8.09 (t, 1H), 8.16 (s, 1H), 8.60 (t, 1H), 11.75 (s, 1H), 11.90 (s,1H).

[0413] Synthesis of compound 34: [ka] CuCl 2 ·2H 2 O (0.33g, 1.9mmol) was added to INT-34 (0.57g, 1.9mmol) in 10ml ethanol. The mixture was stirred overnight. The complex was isolated as a reddish-brown powder. The precipitate formed was collected by filtration after cooling, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and copious amounts of diethyl ether (5 x 50 ml) and then dried in vacuo. Yield 0.3g (47%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.40 min). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.83 min). MS (ESI) m / z 360.3 [MH]+.

[0414] Synthesis of compound 35: [ka] The title compound was prepared from INT-35 following the method for preparing compound 34. After cooling the product was collected by filtration, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and copious amounts of diethyl ether (5 x 50 ml) and then dried in vacuo. Yield 0.3g (57%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.18 min). MS (ESI) m / z 388.5 [MH]+.

[0415] Synthesis of compound 36: [ka] The title compound was prepared from INT-36 following the method for preparing compound 34. The product was isolated as a reddish-brown powder. Yield 0.026g (40%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.70 min). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.69 min). MS (ESI) m / z 433.2 [MH]+.

[0416] Synthesis of compound 40: [ka] The title compound was prepared from INT-40 following the method for preparing compound 34. The product was isolated as a reddish-brown powder. The precipitate formed was collected by filtration after cooling, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and copious amounts of diethyl ether (5 x 50 ml) and then dried in vacuo. Yield 0.01g (6%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.72 min). MS (ESI) m / z 484.1 [MH]+.

[0417] Scheme 16: Synthesis of compound 42 [ka] Synthesis of 1-(4-(phenylsulfonyl)morpholin-2-yl)ethane-1-one: [ka] To a solution of 1-morpholin-2-yl-ethanone (0.3 g, 2.3 mmol) in DCM (50 ml) was added triethylamine (0.59 g, 2.5 eq.) at 5°C, followed by benzenesulfonyl chloride (0.51 g, 1.25 equivalents) was added. The mixture was stirred at ambient temperature for 15 hours, acidified with 10% aqueous HCl and extracted with DCM. The combined organic extracts were 2 S.O. 4 dried, filtered and evaporated. The residue was purified by column chromatography (silica gel, eluent 10% EtOAc in hexanes). Yield 0.30g (48%). NMR (400MHz, CDCl 3 ): 2.20 (s, 3H), 2.22-2.28 (m, 1H), 2.46 (ddd, 1H), 3.58-3.61 (m, 1H), 3.76 (ddd, 1H), 3.90-3.95 (m, 1H), 4.00-4.09 (m, 2H), 7.54-7.60 (m, 2H), 7.63-7.67 (m, 1H), 7.77-7.80 (m, 2H).

[0418] INT-42, ((2Z,2'Z)-2,2'-(1-(4-(phenylsulfonyl)morpholin-2-yl)ethane-1,2-diylidene)bis(N-ethylhydrazine-1 -Synthesis of carbothioamide)) [ka] SeO in flask 2 (0.14 g, 1.1 eq.), 1,4-dioxane (3.5 mL), and water (0.1 mL). Warm the mixture to 50 °C and add SeO 2 The mixture was stirred until most of it was dissolved. 1-(4-(phenylsulfonyl)morpholin-2-yl)ethan-1-one was added and the reaction was heated at mild reflux for 4 hours. Selenium solid precipitated over the course of the reaction. The mixture was cooled in an ice bath and filtered through diatomaceous earth to remove selenium. The filter cake was washed with a portion of 1,4-dioxane. The filtrate was concentrated in vacuo until most of the 1,4-dioxane was removed. The residue was dissolved in EtOH and filtered. Add thiosemicarbazide and 1 drop of H to the filtrate. 2 S.O. 4 was added and the reaction mixture was refluxed for 2 hours. The precipitate was filtered. Yield 0.08g (15%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.62 minutes), MS (ESI) m / z 486.5 [MH ]+.

[0419] Synthesis of compound 42: [ka] INT-42 (0.08g, 0.17mmol) was dissolved in DMSO (0.4ml) and CuCl in water (0.4ml). 2 ·2H 2 A solution of O (28 mg, 1.0 eq.) was added. The mixture was stirred for 5 minutes, filtered, and the precipitate was dissolved in a saturated solution of potassium carbonate, water, and Et 2 Washed with O. Yield 0.015g (17%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.27 min). MS (ESI) m / z 547.5 [MH]+.

[0420] Scheme 17: Synthesis of compound 43 [ka] Synthesis of methyl morpholine-2-carboxylate hydrochloride: [ka] To a suspension of morpholine-2 carboxylic acid (1.94g, 15mmol, 1eq) in methanol (75ml) was added thionyl chloride (8.8g, 5.4ml, 5eq) dropwise at 0-10°C. The reaction mixture was stirred at room temperature for 1 hour, then heated to reflux for 4 hours. The reaction mixture was evaporated. Yield 2.3g (85.6%). NMR (400MHz, DMSO-d 6 ): 2.78-3.15 (m, 3H), 3.25-3.35 (m, 1H), 3.69 (s, 3H), 3.69-3.81 (m, 1H), 3.95-4.05 (m, 1H), 4.60 (dd, 1H) ), 9.80-10.40 (m, 2H).

[0421] Synthesis of methyl 4-(methylsulfonyl)morpholine-2-carboxylate: [ka] Methyl morpholine-2-carboxylate hydrochloride (2.3 g, 12.7 mmol, 1 eq.), methanesulfonyl chloride (1.74 g, 1.1 ml, 1.2 eq.), and triethylamine (3.2 g, 4.4 ml, 2.5 eq.) was stirred at ambient temperature for 15 hours. The reaction mixture was washed with water and Na 2 S.O. 4 dried, filtered and the solvent was evaporated. Yield 1.3g (46%). NMR (400MHz, CDCl 3 ): 2.83 (s, 3H), 2.95-3.04 (m, 2H), 3.50-3.58 (m, 1H), 3.74-3.80 (m, 1H), 3.82 (s, 3H), 3.83-3.88 (m, 1H) ), 4.09 (ddd, 1H), 4.27 (dd, 1H).

[0422] Synthesis of 4-(methylsulfonyl)morpholine-2-carboxylic acid: [ka] Methyl 4-(methylsulfonyl)morpholine-2-carboxylate (1.3 g, 5.8 mmol, 1 eq.) was dissolved in methanol (50 ml) and a solution of NaOH (0.58 g, 2.5 eq.) in water (10 ml) was added. Added. The reaction mixture was stirred at room temperature overnight. Methanol was removed in vacuo and the residue was diluted with water, acidified to pH 1 with concentrated HCl and extracted with EtOAc. Separate the organic layer and add Na 2 S.O. 4 dried, filtered and concentrated in vacuo. Yield 0.95g (78%). NMR (400MHz, DMSO-d 6 ): 2.32 (s, 3H), 2.87-2.95 (m, 1H), 3.20-3.25 (m, 2H), 3.51-3.59 (m, 2H), 3.83-3.99 (m, 2H).

[0423] Synthesis of N-methoxy-N-methyl-4-(methylsulfonyl)morpholine-2-carboxamide: [ka] To a stirred solution of 4-(methylsulfonyl)morpholine-2-carboxylic acid (0.97g, 5mmol, 1eq) in THF (25ml) at 0°C was added carbonyldiimidazole (0.69g, 0.5eq). N,O-dimethylhydroxylamine hydrochloride (0.45 g, 1 eq.) and triethylamine (2.34 g, 3.2 ml, 5 eq.) were then added to the solution and the ice bath was removed. The reaction mixture was stirred at room temperature until disappearance of acid as determined using TLC. After completion, triethylamine hydrochloride was removed by filtration. The filtrate was concentrated to dryness via rotary evaporation. The residue was purified by short-path silica gel column chromatography, eluting with 20% ethyl acetate in hexane. Yield 0.26g (22%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 0.99 minutes), MS (ESI) m / z 253.1 [MH ]+.

[0424] Synthesis of 2-ethoxy-1-(4-(methylsulfonyl)morpholin-2-yl)prop-2-en-1-one: [ka] A solution of ethyl vinyl ether (0.82 g, 1 ml, 11 eq.) in dry tetrahydrofuran (20 mL) was cooled to -78° C. and tert-butyllithium in pentane (1.7 M, 6 ml, 9.9 eq.) was added. The mixture was warmed to 0°C over a period of 1 hour, stirred for 45 minutes, then cooled to -30°C. Magnesium bromide etherate (2.5g, 9.9eq) was added. The mixture was then warmed to 0° C. over a period of 15 minutes and N-methoxy-N-methyl-4-(methylsulfonyl)morpholine-2-carboxamide was added in THF (0.26 g, 1 mmol, 1 eq.). The mixture was stirred at 0°C for 4 hours. The progress of the reaction was monitored by TLC. NH mixture 4 Pour into Cl aqueous solution, Et 2 Extracted with O. The combined extracts were 2 S.O. 4 dried, filtered and the solvent was evaporated. The product was used in the next step without further purification. Yield 0.17g (62%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.36 minutes), MS (ESI) m / z 527.3 [2MH ]+

[0425] INT-43, ((2Z,2'Z)-2,2'-(1-(4-(methylsulfonyl)morpholin-2-yl)propane-1,2-diylidene)bis(N-ethylhydrazine-1 -Synthesis of carbothioamide): [ka] 2-Ethoxy-1-(4-(methylsulfonyl)morpholin-2-yl)prop-2-en-1-one (0.16 g, 0.6 mmol, 1 eq.) was dissolved in EtOH (20 ml) and ethylthio semicarbazide (0.14 g, 2 eq.) and 1 drop of H 2 S.O. 4 was added. The reaction mixture was stirred and heated to reflux for 4 hours, then maintained at ambient temperature for 15 hours. Filter the precipitate formed and add EtOH, water, Et 2 Washed with O and dried. Yield 0.15g (55%). NMR (400MHz, DMSO-d 6 ): 1.10-1.21 (m, 6H), 1.47-1.53 ​​(m, 1H), 2.16-2.21 (m, 1H), 2.47-2.55 (m, 4H), 2.78-2.84 (m, 1H), 2.95 (br .d, 1H), 3.08-3.16 (m, 1H), 3.30 (s, 3H), 3.42-3.50 (m, 4H), 7.78 (br.s, 1H), 8.69 (br.s, 1H), 10.75 (s, 1H), 12.18 (s, 1H). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.47 min), MS (ESI) m / z 438.4 [MH]+.

[0426] Synthesis of compound 43: [ka] CuCl 2 ·2H 2 O (0.058 g, 1 eq.) was added to thiosemacarbazone 6 (0.15 g, 0.3 mmol, 1 eq.) in ethanol. The mixture was stirred at ambient temperature for 15 hours. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.07g (41%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.06 min). MS (ESI) m / z 499.5 [MH]+.

[0427] Scheme 18: Synthesis of compound 44 [ka] Synthesis of 4-(tert-butoxycarbonyl)morpholine-2-carboxylic acid: [ka] Morpholine-2-carboxylic acid (2g, 15.6mmol) was dissolved in a mixture of dioxane-water (8ml / 4ml), then potassium carbonate (4.3g, 2eq) was added and the mixture was stirred for 30 minutes. Di-tert-butyl dicarbonate (3.7 g, 1.1 eq.) was added, the reaction mixture was stirred overnight, the solvent was evaporated, the residue was dissolved in water, and the solution was dissolved in 10% H 2 S.O. 4 and the product was extracted with EtOAc. Separate the organic layer and add Na 2 S.O. 4 dried, filtered and the solvent was evaporated. Yield 1.7g (47%). NMR (400MHz, DMSO-d 6 ): 1.40 (s, 9H), 3.04-3.10 (m, 2H), 3.42-3.56 (m, 2H), 3.78-3.84 (m, 2H), 4.01-4.07 (m, 1H), 12.95 (br.s , 1H).

[0428] Synthesis of tert-butyl 2-(methoxy(methyl)carbamoyl)morpholine-4-carboxylate: [ka] A solution of CDI in THF (7ml) was added to a solution of 4-(tert-butoxycarbonyl)morpholine-2-carboxylic acid (7ml) in THF at 0°C. The mixture was stirred at room temperature for 1 hour. The mixture was then cooled to 0°C and a suspension of triethylamine (0.7ml) and N,O-dimethylhydroxylamine in MeCN (10ml) was added at 0°C and the reaction was stirred at room temperature for 16 hours. The solvent was then evaporated, the residue was dissolved in DCM, and the solution was mixed with water, acetic acid (20% solution), and saturated NaHCO 3 Washed with. The organic layer was separated and dried. The organic layer was washed with water, separated, and Na 2 S.O. 4 dried, filtered and the solvent was evaporated. The residue was subjected to column chromatography (SiO 2 / hexane:EtOAc 2:1). Yield 0.78g (73%). NMR (400MHz, CDCl 3 ): 1.49 (s, 9H), 3.02 (br.s, 1H), 3.24 (s, 3H), 3.60 (dd, 1H), 3.75 (s, 3H), 3.90 (br.s, 1H), 4.00- 4.30 (m, 2H), 4.85 (br.s, 1H).

[0429] Synthesis of tert-butyl 2-(2-ethoxyacryloyl)morpholine-4-carboxylate: [ka] A solution of ethyl vinyl ether (2g, 2.6ml, 11 eq) in dry tetrahydrofuran (75ml) was cooled to -78°C and tert-butyllithium in pentane (1.7M, 13ml, 8.9eq) was added. The mixture was warmed to 0°C over a period of 1 hour, stirred for 45 minutes, then cooled to -30°C. Magnesium bromide etherate (5.2g, 8.9eq) was added. The mixture was then warmed to 0° C. over a period of 15 minutes and tert-butyl 2-(methoxy(methyl)carbamoyl)morpholine-4-carboxylate was added in THF (0.7 g, 2.6 mmol, 1 eq.). The mixture was stirred at 0°C for 4 hours. The progress of the reaction was monitored by TLC. NH mixture 4 Pour into Cl aqueous solution, Et 2 Extracted with O. The combined extracts were 2 S.O. 4 and evaporated. The product was used in the next step without further purification. Yield 0.6g (82%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.33 min), MS (ESI) m / z 286.1 [MH ]+.

[0430] tert-Butyl 2-((6E,8E)-8-methyl-4,11-dithioxo-3,5,6,9,10,12-hexaazatetradec-6,8-dien-7-yl)morpholine Synthesis of -4-carboxylate: [ka] tert-Butyl 2-(2-ethoxyacryloyl)morpholine-4-carboxylate (0.39 g, 1.4 mmol, 1 eq.) was dissolved in EtOH (150 ml) and ethylthiosemicarbazide (0.33 g, 2 eq.) and 3 drops H 2 S.O. 4 was added. The reaction mixture was stirred and heated to reflux for 4 hours, then maintained at ambient temperature for 15 hours. Filter the precipitate formed and add EtOH, water, Et 2 Washed with O and dried. Yield 0.23g (37.2%). NMR (400MHz, DMSO-d 6 ): 1.10-1.18 (m, 6H), 1.40 (br.d, 9H), 2.20 (s, 3H), 2.90-2.06 (m, 1H), 3.18 (br.s, 1H), 3.52-3.80 (m , 6H), 3.82-3.87 (m, 1H), 4.02-4.07 (m, 2H), 5.12 (br.s, 1H), 8.28 (br.s, 1H), 8.51 (t, 1H), 10.24 (s , 1H), 11.20 (br.s, 1H).

[0431] INT-44, (2E,2'E)-2,2'-(1-(morpholin-2-yl)propane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide) hydrochloride Synthesis: [ka] tert-Butyl 2-((6E,8E)-8-methyl-4,11-dithioxo-3,5,6,9,10,12-hexaazatetradeca-6,8-diene-7- in dioxane To a solution of morpholine-4-carboxylate (0.23g, 0.5mmol) was added HCl / dioxane (3M, 6ml). The reaction mixture was stirred at room temperature overnight. The precipitate formed was filtered. Yield 0.15g (76%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.13 minutes), MS (ESI) m / z 360.4 [MH ]+.

[0432] Synthesis of compound 44: [ka] CuCl 2 ·2H 2 O (0.036 g, 1 eq.) was added to INT-44 (0.1 g, 0.2 mmol, 1 eq.) in ethanol. The mixture was stirred at ambient temperature for 15 hours. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.03g (33%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.47 min). MS (ESI) m / z 421.0 [MH]+.

[0433] Scheme 19: Synthesis of compound 45 [ka] Synthesis of 4-benzylmorpholine-2-carbonitrile: [ka] 2-Chloroacetonitrile (6g, 1.03eq) was dissolved in toluene (16ml). A solution of N-benzylethanolamine (10g, 66mmol) in toluene (5ml) was added and the reaction mixture was stirred at ambient temperature for 15 hours. Toluene (30ml) was then added and the solution cooled to -5°C. A suspension of t-BuOK (7.6g, 1.03 eq.) in THF (128ml) was added slowly and the mixture was stirred at -5°C for 50 minutes. The mixture was washed with brine, dried and evaporated. The residue was purified by column chromatography (silica gel, hexane:EtOAc, gradient from 3:1 to 1:1). Yield 8.4g (62.8%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.22 minutes), MS (ESI) m / z 203.4 [MH ]+.

[0434] Synthesis of 4-benzylmorpholine-2-carboxylic acid: [ka] 4-Benzylmorpholine-2-carbonitrile (1.6g, 7.9mmol, 1 eq.) was dissolved in HCl (6M, 65ml) and the reaction mixture was refluxed for 2.5 hours. Toluene (15ml) was then added and reflux continued for a further 3 hours. The reaction mixture was evaporated to dryness. Yield 1.6g (78.5%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 0.65 minutes), MS (ESI) m / z 222.4 [MH ]+.

[0435] Synthesis of 4-benzyl-N-methoxy-N-methylmorpholine-2-carboxamide: [ka] A solution of CDI (1.2 g, 1.2 eq.) in THF (12 ml) was prepared by adding 4-benzylmorpholine-2-carboxylic acid (1.6 g, 6.2 mmol, 1 eq.) and triethylamine (0.8 eq.) in THF (12 ml) at 0 °C. ml) solution. The mixture was stirred at room temperature for 1 hour. The mixture was then cooled to 0°C and a suspension of triethylamine (1.2ml) and N,O-dimethylhydroxylamine (0.73g, 1.2eq) in MeCN (17ml) at 0°C was added to quench the reaction. Stirred at room temperature for 16 hours. The solvent was then evaporated. The residue was dissolved in DCM and the solution was washed with water, then acetic acid (20% aqueous solution) and saturated NaHCO 3 Washed with aqueous solution. Separate the organic layer and add Na 2 S.O. 4 dried, filtered and the solvent was evaporated. Yield 0.9g (54.8%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.00 min), MS (ESI) m / z 265.1 [MH ]+.

[0436] Synthesis of 1-(4-benzylmorpholin-2-yl)-2-ethoxyprop-2-en-1-one: [ka] A solution of ethyl vinyl ether (0.34 g, 0.5 ml, 3.3 eq.) in dry tetrahydrofuran (20 mL) was cooled to -78° C. and tert-butyllithium in pentane (1.7 M, 2.4 ml, 3 eq.) was added. The mixture was warmed to 0°C over a period of 1 hour, stirred for 45 minutes, then cooled to -30°C. 4-Benzyl-N-methoxy-N-methylmorpholine-2-carboxamide in THF was added (3.0 g, 7.5 mmol, 1 eq.) and the mixture was stirred at 0° C. for 4 h. The progress of the reaction was monitored by TLC. NH mixture 4 Pour into Cl aqueous solution, Et 2 Extracted with O. The combined extracts were 2 S.O. 4 dried, filtered and the solvent was evaporated. The product was used in the next step without further purification. Yield 0.3g (82%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.03 minutes), MS (ESI) m / z 276.1 [MH ]+.

[0437] INT-45, ((2E,2'E)-2,2'-(1-(4-benzylmorpholin-2-yl)propane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide ) composition: [ka] 1-(4-Benzylmorpholin-2-yl)-2-ethoxyprop-2-en-1-one (0.3 g, 1 mmol, 1 eq.) was dissolved in EtOH (10 ml) and ethylthiosemicarbazide (0.26 g , 2 equivalents) and 1 drop of H 2 S.O. 4 was added. The reaction mixture was stirred and heated to reflux for 4 hours, then maintained at ambient temperature for 15 hours. Filter the precipitate formed and add EtOH, water, Et 2 Washed with O and dried. Yield 0.08g (16%). NMR (400MHz, DMSO-d 6): 1.05 (t, 6H), 2.37 (s, 3H), 3.50-3.56 (m, 4H), 3.80 (br.s, 1H), 4.25 (br.s, 2H), 5.65 (br.s, 1H) ), 7.30-7.48 (m, 4H), 8.09 (br.s, 1H), 8.59 (br.s, 1H), 10.22 (s, 1H), 10.80 (br.s, 1H). LCMS (C18 column 20 ×2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.20 min), MS (ESI) m / z 450.4 [MH]+.

[0438] Synthesis of compound 45: [ka] CuCl 2 ·2H 2 O (0.017 g, 1 eq.) was added to INT-45 (0.045 g, 0.1 mmol, 1 eq.) in ethanol. The mixture was stirred at ambient temperature for 15 hours. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.035g (68.5%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.70 min). MS (ESI) m / z 511.3 [MH]+.

[0439] Scheme 20: Synthesis of compound 46 [ka] Synthesis of benzyl 4-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate: [ka] 1-((benzyloxy)carbonyl)piperidine-4-carboxylic acid (21.2g, 80.6mmol), N,O-dimethylhydroxylamine (10.2g, 96.7mmol), HOBT (12.1g, 96.7mmol) in DCM (300ml) EDCI (17.1 g, 96.7 mmol) was added to a mixture of TEA (18.5 ml, 241.8 mmol) at 4° C. and the mixture was stirred at ambient temperature for 15 hours. The mixture was washed with water (50ml), 1N HCl (aq) (50ml), water (100ml) and brine (150ml). The organic layer is treated with anhydrous Na 2 S.O. 4 and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, eluent 100% DCM to 5% MeOH) to give crude 1. Yield 22.7g (92%). NMR (400MHz, DMSO-d 6 ): 1.36-1.43 (m, 2H), 1.64-1.70 (m, 2H), 2.84-2.98 (m, 2H), 3.09 (s, 3H), 3.68 (s, 3H), 4.00-4.06 (m, 2H) ), 5.07-s, 2H), 7.30-7.41 (m, 5H).

[0440] Synthesis of benzyl 4-(2-ethoxyacryloyl)piperidine-1-carboxylate: [ka] A solution of ethyl vinyl ether (2.0g, 28.1mmol) in dry tetrahydrofuran (45ml) was cooled to -78°C and tert-butyllithium in pentane (1.7M, 15.6ml, 25.5mmol) was added. The mixture was warmed to 0°C over a period of 1 hour, stirred for 45 minutes, then cooled to -30°C. Benzyl 4-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate (2.6g, 8.5mmol) was added in THF (15ml) with stirring at 0°C for 4 hours. The progress of the reaction was monitored by TLC. Dilute the mixture NH 4 Pour into Cl (100 ml) and add Et 2 Extracted with O (3 x 100ml). The combined extracts were 2 S.O. 4 dried, filtered and the solvent was evaporated. The product was used in the next step without further purification. Yield 0.77g (29%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.58 min), MS (ESI) m / z 318.2 [MH ]+.

[0441] 4-((6Z,8E)-8-methyl-4,11-dithioxo-3,5,6,9,10,12-hexaazatetradec-6,8-dien-7-yl)piperidine-1- Synthesis of benzyl carboxylate: [ka] Benzyl 4-(2-ethoxyacryloyl)piperidine-1-carboxylate (1.5 g, 4.6 mmol) was dissolved in EtOH (80 ml), ethylthiosemicarbazide (1.2 g, 10.1 mmol) and 3 drops of H 2 S.O. 4 was added. The reaction mixture was stirred and heated to reflux for 4 hours, then maintained at ambient temperature for 15 hours. Filter the precipitate formed and add EtOH, water, Et 2 Washed with O and dried. Yield 0.3g (14%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.47 minutes), MS (ESI) m / z 492.2 [MH ]+.

[0442] INT-46, ((2Z,2'E)-2,2'-(1-(piperidin-4-yl)propane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide)) Synthesis: [ka] 4-((6Z,8E)-8-methyl-4,11-dithioxo-3,5,6,9,10,12-hexaazatetradec-6,8-dien-7-yl)piperidine-1- Benzyl carboxylate (0.35g, 0.7mmol) in CF 3 Dissolved in COOH (5ml) and heated the solution to reflux for 2.5 hours. After cooling to ambient temperature, the reaction mixture was dissolved in saturated NaHCO 3 Dilute with aqueous solution, CH 2 Cl 2 (3 x 15 ml). The organic layer was washed with water, separated, and Na 2 S.O. 4 dried, filtered and the solvent was evaporated. The residue was purified by column chromatography (silica gel, eluent 100% DCM to 5% MeOH) to give the crude title product. Yield 0.25g (98%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.11 minutes), MS (ESI) m / z 358.5 [MH ]+.

[0443] Synthesis of compound 46: [ka] Cu(OAc) 2 ·2H 2 O (0.02g, 0.09mmol) was added to INT-46 (0.03g, 0.08mmol) in methanol. The mixture was stirred at ambient temperature for 15 hours. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.04g (90%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.85 min). MS (ESI) m / z 419.5 [MH]+.

[0444] Example 3: Preparation of compounds 47-53 Scheme 21: Synthesis of compound 47 [ka] Synthesis of 2-(cyclopent-2-en-1-yl)ethane-1-ol: [ka] LiAlH in THF (250ml) 4 To a stirred suspension of (3.76 g, 99.0 mmol, 2.5 eq.) was slowly added a solution of cyclopent-2-eneacetic acid (5.0 g, 39.6 mmol, 1.0 eq.) in THF (50 ml) at 0 °C. . The mixture was heated to reflux for 3 hours, then cooled to 0°C. Reactant Na 2 S.O. 4 (10%) and Et 2 Extracted with O (3 x 100ml). The combined extracts were 2 S.O. 4 dried, filtered and evaporated. The product was used in the next step without further purification. Yield 4.06g (91%). 1 H-NMR (400MHz, CDCl 3): δ (ppm) 1.40-1.48 (m, 1H), 1.50-1.51 (m, 1H), 1.56-1.64 (m, 1H), 1.67-1.76 (m, 1H), 2.04-2.13 (m, 1H) , 2.27-2.37 (m, 2H), 2.78 (br.s, 1H), 3.66-3.75 (m, 2H), 5.68-5.71 (m, 1H), 5.74-5.76 (m, 1H).

[0445] Synthesis of tert-butyl(2-(cyclopent-2-en-1-yl)ethoxy)diphenylsilane: [ka] To a solution of 2-(cyclopent-2-en-1-yl)ethane-1-ol (4.05 g, 36.1 mmol) in dichloromethane (200 ml) were added tert-butyldiphenylsilyl chloride (11.9 g, 43.3 mmol), triethylamine. (4.7g, 46.9mmol), and 4-(dimethylamino)pyridine (0.22g, 1.8mmol) were added and the mixture was stirred at room temperature for 3 hours. After quenching the reaction by adding 1N hydrochloric acid, the mixture was extracted with dichloromethane. The organic extracts were washed with water, aqueous sodium bicarbonate, and brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography of the residue (silica gel, hexane-ethyl acetate 50:1) provided compound 2. Yield 11.3g (89%). 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 0.99 (s, 9H), 1.26-1.35 (m, 1H), 1.43-1.51 (m, 1H), 1.61-1.69 (m, 1H), 1.88-1.97 (m, 1H), 2.13 -2.30 (m, 2H), 2.70-2.76 (m, 1H), 3.68 (t, 2H), 5.62-5.65 (m, 1H), 5.66-5.70 (m, 1H), 7.41-7.46 (m, 6H) , 7.60-7.62 (m, 4H).

[0446] Synthesis of 3-(2-((tert-butyldiphenylsilyl)oxy)ethyl)cyclopentane-1,2-diol: [ka] tert-Butyl(2-(cyclopent-2-en-1-yl)ethoxy)diphenylsilane (9.0g, 25.6mmol) with H 2 Dissolved in a mixture of O-tBuOH (1:3), then N-methylmorpholine N-oxide (3.9 g, 33.3 mmol) and OsO 4 (0.004g of 4% aqueous solution, 0.001 eq.) was added. The reaction mixture was purified by TLC (CHCl 3 -CH 3 Stir at 60 °C until complete, while monitoring with OH, 20:1), filter the solid catalyst, rinse with EtOAc, and dilute the filtrate with Na 2 S 2 O 3 The reaction was stopped with an aqueous solution (10%) of The aqueous layer was extracted with EtOAc, the organic extracts were combined and Na 2 S.O. 4 dried, filtered and the solvent was evaporated. The crude product was purified by flash chromatography (CHCl 3 -MeOH, gradient from 1:0 to 95:5) to give diol 3. Yield 6.3g (64%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.99 min). MS (ESI) m / z 385.1 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 0.98 (s, 9H), 1.26-1.55 (m, 2H), 1.66-1.68 (m, 1H), 1.69-1.78 (m, 2H), 1.79-1.88 (m, 2H), 3.59 -3.60 (m, 1H), 3.67 (q, 2H), 3.74-3.88 (m, 1H), 4.09 (dd, 1H), 4.32 (dd, 1H), 7.41-7.48 (m, 6H), 7.60-7.62 (m, 4H).

[0447] Synthesis of 3-(2-((tert-butyldiphenylsilyl)oxy)ethyl)cyclopentane-1,2-dione: [ka] Dimethylsulfoxide (3.6g, 46.8mmol) was added to a stirred solution of oxalyl chloride (2.97g, 23.4mmol) in dichloromethane (100ml) at -78°C. After 15 minutes, a solution of 3-(2-((tert-butyldiphenylsilyl)oxy)ethyl)cyclopentane-1,2-diol (3.0 g, 7.9 mmol) in dichloromethane (20 ml) was slowly added ( (over a period of 15 minutes) and the resulting solution was stirred at -78°C for 1 hour. Triethylamine (7.3g, 70mmol) was then added and the mixture was stirred at -78°C for 15 minutes, then warmed to ambient temperature. The reaction mixture was washed with water and the organic layer was diluted with Na 2 S.O. 4 dried, filtered and evaporated. Yield 1.6g (54%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 2.01 min). MS (ESI) m / z 381.1 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 0.97 (s, 9H), 1.90 (t, 1H), 2.27-2.35 (m, 2H), 2.46-2.51 (m, 2H), 3.52-3.46 (m, 2H), 3.63-3.86 (m, 2H), 7.41-7.48 (m, 6H), 7.60-7.62 (m, 4H).

[0448] (2E,2'E)-2,2'-(3-(2-((tert-butyldiphenylsilyl)oxy)ethyl)cyclopentane-1,2-diylidene)bis(N-ethylhydrazine-1-carbo Synthesis of thioamide): [ka] 3-(2-((tert-butyldiphenylsilyl)oxy)ethyl)cyclopentane-1,2-dione (1.6 g, 4.2 mmol) was dissolved in EtOH (25 ml) and ethylthiosemicarbazide (1.02 g, 4.4 mmol) and 3 drops of H 2 S.O. 4 was added and the reaction mixture was stirred at reflux for 4 hours and at ambient temperature for 15 hours. Filter the precipitate formed and add EtOH, water, Et 2 Washing with O and drying gave product 5. Yield 1.75g ​​(74%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 2.58 min). MS (ESI) m / z 583.3 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 0.99 (s, 9H), 1.11 (t, 3H), 1.20 (t, 3H), 1.41-1.59 (m, 2H), 1.96-2.03 (m, 2H), 2.21-2.29 (m , 1H), 2.71-2.85 (m, 2H),3.53-3.62 (m, 4H), 3.71-3.83 (m, 2H), 7.41-7.48 (m, 6H), 7.61-7.63 (m, 4H). 7.75 (t, 1H), 8.57(t, 1H), 10.73(s, 1H), 12.26(s, 1H).

[0449] INT-47, ((2E,2'E)-2,2'-(3-(2-hydroxyethyl)cyclopentane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide)) Synthesis: [ka] (2E,2'E)-2,2'-(3-(2-((tert-butyldiphenylsilyl)oxy)ethyl)cyclopentane-1,2-diylidene)bis(N- To a solution of ethylhydrazine-1-carbothioamide (0.85 g, 1.46 mmol) was added triethylamine trihydrofluoride at ambient temperature. The resulting mixture was stirred at ambient temperature for 10 hours and treated with saturated aqueous ammonium chloride. The solution was extracted with ether and washed with saturated aqueous ammonium chloride and brine. organic layer with Na 2 S.O. 4 , filter, and concentrate the solvent in vacuo to give the crude title product. Yield 0.18g (36%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.30 min). MS (ESI) m / z 345.0 [MH]+. 1 H-NMR (400MHz, DMSO-d 6): δ (ppm) 1.28 (t, 3H), 1.35 (t, 3H), 1.58-1.81 (m, 2H), 1.86-1.95 (m, 1H), 2.03-2.13 (m, 1H), 2.24-2.33 (m, 1H),2.44-2.57 (m, 1H), 2.65-2.77 (m, 1H),2.85-2.93 (m, 1H), 3.31-3.53 (m, 1H), 3.68-2.82 (m, 5H) , 7.25-7.32 (m, 1H), 7.41-7.48 (m, 1H), 8.75 (s, 1H), 12.27 (s, 1H).

[0450] Synthesis of ZN-47: [ka] Zn(OAc) 2 2H 2 O (0.58g, 2.7mmol) was added to INT-47 (0.61g, 1.8mmol) in ethanol. The mixture was refluxed for 4 hours. The complex formed precipitated out of the mixture as a yellow powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.72g (99%). 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.09 (t, 3H), 1.14 (t, 3H), 1.35-1.48 (m, 2H), 2.01-2.11 (m, 2H), 2.51-2.55 (m, 2H), 2.67-2.73 (m, 1H), 2.76-2.84 (m, 1H), 3.47-3.56 (m, 4H), 4.34 (t, 1H), 4.42 (t, 1H), 7.37 (br.s, 1H), 7.85 (t , 1H).

[0451] Synthesis of compound 47: [ka] ZN-47 (0.72 g, 1.7 mmol) was dissolved in DMSO (3.6 ml) and CuCl in water (3.6 ml) was added. 2 2H 2 A solution of O (0.39g, 1.9mmol) was added. The mixture was stirred for 5 min, the precipitate was filtered, and a saturated solution of potassium carbonate, water, and Et 2 Washed with O. Yield 0.09g (13%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.81 min). MS (ESI) m / z 406.5 [MH]+.

[0452] Scheme 22: Synthesis of compound 48 [ka] Synthesis of 2-(cyclopent-2-en-1-yl)ethane-1-ol: LiAlH in THF (250 ml) cooled to 0 °C 4 To a stirred suspension of (4.14g, 109.0mmol) was slowly added a solution of cyclopent-2-eneacetic acid (5.5g, 43.6mmol, 1.0eq) in THF (50ml). The mixture was heated to reflux for 3 hours, then cooled to 0°C. Reactant Na 2 S.O. 4 (10%) and Et 2 Extracted with O (3 x 100ml). The combined extracts were 2 S.O. 4 dried, filtered and evaporated. The product was used in the next step without further purification. Yield 4.4g (90%). 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.40-1.49 (m, 1H), 1.50-1.51 (m, 1H), 1.58-1.64 (m, 1H), 1.67-1.76 (m, 1H), 2.04-2.13 (m, 1H) , 2.42-2.37 (m, 2H), 2.78 (br.s, 1H), 3.69-3.77 (m, 2H), 5.68-5.71 (m, 1H), 5.74-5.77 (m, 1H).

[0453] Synthesis of ((2-(cyclopent-2-en-1-yl)ethoxy)methyl)benzene: [ka] To a stirred solution of 2-(cyclopent-2-en-1-yl)ethane-1-ol (1.0 g, 8.9 mmol) in DMF (12 ml) at 0°C was added NaH (0.5 g, 13.5 mmol, in mineral oil). 60-65%) was added at once. After stirring for 30 minutes, benzyl chloride (2.03 g, 16.1 mmol) was added to the solution. The reaction was stirred overnight, then quenched with water (15 ml) and Et 2 Extracted with O three times. The combined extracts were washed with water, brine, and Na 2 S.O. 4 dried, filtered and the solvent was evaporated. The crude product was used without purification. Yield 1.8g (99%). 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.33-1.41 (m, 1H), 1.46-1.55 (m, 1H), 1.61-1.69 (m, 1H), 1.93-2.02 (m, 1H), 2.14-2.33 (m, 2H) , 2.70 (t, 1H), 3.47 (t, 2H), 4.45 (s, 2H), 5.70 (t, 2H), 7.25-7.32 (m, 3H), 7.34-7.45 (m, 2H).

[0454] Synthesis of 3-(2-(benzyloxy)ethyl)cyclopentane-1,2-diol: [ka] ((2-(Cyclopent-2-en-1-yl)ethoxy)methyl)benzene (2.2 g, 11.1 mmol) was dissolved in a mixture of H2O-tBuOH (1:3) and then N-methylmorpholine N- Oxide (1.7g, 14.4mmol) and OsO 4 (0.008g of 4% aqueous solution, 0.001 eq.) was added. The reaction mixture was purified by TLC (CHCl 3 -CH 3 Stir at 60 °C until completion, filter the solid catalyst, rinse with EtOAc, and dilute the filtrate with NaOH, 20:1). 2 S 2 O 3 The reaction was stopped with an aqueous solution (10%) of The aqueous layer was extracted with EtOAc, the organic extracts were combined and Na 2 S.O. 4 dried, filtered and the solvent was evaporated. The crude product was purified by flash chromatography (CHCl 3 -MeOH, gradient from 1:0 to 95:5) to give the title product. Yield 1.64g (62%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.20 min). MS (ESI) m / z 237.0 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 0.95-1.03 (m, 1H), 1.29-1.59 (m, 2H), 1.66-1.68 (m, 1H), 1.69-1.78 (m, 2H), 1.79-1.88 (m, 1H) , 3.41-3.48 (m, 2H), 3.45 (qq, 1H), 3.75-3.91 (m, 1H), 4.09 (dd, 1H), 4.32 (dd, 1H), 4.41-4.48 (m, 2H), 7.25 -7.36 (m, 5H).

[0455] Synthesis of 3-(2-(benzyloxy)ethyl)cyclopentane-1,2-dione: [ka] Dimethylsulfoxide (6.1g, 78.0mmol) was added to a stirred solution of oxalyl chloride (4.9g, 39.0mmol) in dichloromethane (150ml) at -78°C. After 15 minutes, a solution of 3-(2-(benzyloxy)ethyl)cyclopentane-1,2-diol (3.1 g, 13.0 mmol) in dichloromethane (20 ml) was added slowly (over a period of 15 minutes). , and the resulting solution was stirred at -78°C for 1 hour. Triethylamine (11.8g, 117.0mmol) was then added and the mixture was stirred at -78°C for 15 minutes and then warmed to ambient temperature. The reaction mixture was washed with water and the organic layer was diluted with Na 2 S.O. 4 dried, filtered and the solvent was evaporated. Yield 2.6g (87%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.26 min). MS (ESI) m / z 233.1 [MH]+.

[0456] INT-48, ((2E,2'E)-2,2'-(3-(2-(benzyloxy)ethyl)cyclopentane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide )) composition: [ka] 3-(2-(benzyloxy)ethyl)cyclopentane-1,2-dione (2.6 g, 11.4 mmol) was dissolved in EtOH (35 ml) and ethylthiosemicarbazide (2.86 g, 23.9 mmol) and 3 drops of H 2 S.O. 4 was added and the reaction mixture was stirred at reflux for 4 hours and at ambient temperature for 15 hours. Filter the precipitate formed and add EtOH, water, Et 2 Washing with O and drying gave the product. Yield 0.40g (9%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.86 min). MS (ESI) m / z 435.4 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.12 (t, 3H), 1.19 (t, 3H), 1.46-1.58 (m, 2H), 2.05-2.15 (m, 1H), 2.22-2.32 (m, 1H), 2.53-2.58 (m, 1H), 2.74-2.82 (m, 2H),3.41-3.63 (m, 6H), 4.47 (d, 2H), 7.26-7.37 (m, 5H), 7.77 (t, 1H), 8.66 (t , 1H), 10.74 (s, 1H), 12.25 (s, 1H).

[0457] INT-49, ((2E,2'E)-2,2'-(3-(2-methoxyethyl)cyclopentane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide)) Synthesis: [ka] INT-49 was made using a procedure similar to that for preparing INT-48. Yield 1.1g (72%). 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.73 (t, 2H), 1.97-2.01 (m, 2H), 2.24-2.27 (m, 1H), 2.36-2.39 (m, 1H), 2.53-2.57 (m, 1H), 2.62 -2.67 (m, 1H), 3.12 (d, 3H), 3.38-3.45 (m, 1H).

[0458] Synthesis of compound 48: [ka] Cu(OAc) 2 2H 2 O (0.26g, 1.12mmol) was added to INT-48 5 (0.4g, 0.92mmol) in ethanol. The mixture was stirred at ambient temperature for 15 hours. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.1g (22%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.98 min). MS (ESI) m / z 496.5 [MH]+.

[0459] Synthesis of compound 49: [ka] The title compound was prepared from INT-49 following the method for preparing compound 48. The product precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.03g (35%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.33 min). MS (ESI) m / z 420.5 [MH]+.

[0460] Scheme 23: Synthesis of compound 50 [ka] Synthesis of 2-(cyclopent-2-en-1-yl)-1-morpholinoethane-1-one: [ka] Oxalyl chloride (2.41 g, 1.2 eq.) was added to a solution of 2-cyclopentene-1-acetic acid (2.0 g, 16 mmol) in dichloromethane (100 ml), 1 drop of DMF was added and the mixture was stirred at ambient temperature for 2 Stir for hours. The solvent was evaporated under reduced pressure, the residue was dissolved in EtOAc, and this solution was diluted with Et 3 N (1.92 g, 1.2 eq.) and morpholine (1.38 g, 1 eq.) were added. The reaction was stirred at ambient temperature overnight. The reaction mixture was washed with water and the organic layer was diluted with Na 2 S.O. 4 dried, filtered and concentrated in vacuo. The residue was subjected to column chromatography (SiO 2 ,C.H. 2 Cl 2 -MeOH, 10:1). Yield 2.1g (67.8%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.16 minutes, MS (ESI) m / z 196.4 [MH] +. 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.41-1.53 ​​(m, 1H), 2.12-2.25 (m, 1H), 2.29-2.46 (m, 4H), 3.09-3.21 (m, 1H), 3.42-3.54 (m, 2H) , 3.58-3.76 (m, 6H), 5.70-5.74 (m, 1H), 5.75-5.83 (m, 1H).

[0461] Synthesis of 2-(2,3-dihydroxycyclopentyl)-1-morpholinoethane-1-one: [ka] 2-(Cyclopent-2-en-1-yl)-1-morpholinoethane-1-one (2.1 g, 10.7 mmol) with H 2 To a stirred solution dissolved in a mixture of O-tBuOH (1:3) was added N-methylmorpholine-N-oxide (1.64 eq.) and OsO 4 (0.035g of 4% aqueous solution, 0.001 eq.) was added. The reaction mixture was stirred at 60° C. for 4 hours and then at ambient temperature for 15 hours. Reactant Na 2 S 2 O 3 (10%), extracted with EtOAc, and the organic layer was 2 S.O. 4 dried, filtered and evaporated. Yield 1.7g (68.9%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 0.83 minutes, MS (ESI) m / z 230.3 [MH] +.

[0462] Synthesis of 3-(2-morpholino-2-oxoethyl)cyclopentane-1,2-dione: [ka] Dimethyl sulfoxide (1.5g, 1.4ml, 4eq) was added to a stirred solution of oxalyl chloride (1.83g, 1.2ml, 3eq) in dichloromethane (40ml) at -78°C. After 5 minutes, a solution of 2-(2,3-dihydroxycyclopentyl)-1-morpholinoethan-1-one (1.1 g, 4.8 mmol, 1 eq.) in dichloromethane (80 ml) was added slowly (15 min. period), the resulting solution was stirred at -78°C for 1 hour. Triethylamine (2.9g, 4ml, 6eq) was then added and the mixture was stirred at -78°C for 15 minutes, then warmed to ambient temperature. The reaction mixture was washed with water and the organic layer was diluted with Na 2 S.O. 4 dried, filtered and evaporated. Yield 0.89g (82.3%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 0.88 minutes, MS (ESI) m / z 225.9 [MH] +.

[0463] INT-50, ((2Z,2'Z)-2,2'-(3-(2-morpholino-2-oxoethyl)cyclopentane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide) )) composition: [ka] 3-(2-morpholino-2-oxoethyl)cyclopentane-1,2-dione (0.89 g, 4 mmol, 1 eq.) was dissolved in EtOH (25 ml) and ethylthiosemicarbazide (0.94 g, 2 eq.) and 3 Drop H 2 S.O. 4 was added and the reaction mixture was stirred at reflux for 4 hours and at ambient temperature for 15 hours. The precipitate formed was filtered, washed with EtOH, water and crystallized from isopropyl alcohol. Yield 0.6g (35.5%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.33 minutes, MS (ESI) m / z 428.5 [MH] +. 1 H-NMR (400MHz, CDCl 3): δ (ppm) 1.14 (t, 3H), 1.20 (t, 3H), 1.46-1.56 (m, 1H), 2.14-2.21 (m, 1H), 2.45-2.55 (m, 2H), 2.74-2.87 (m, 1H), 2.89-2.96 (m, 1H), 3.06-3.13 (m, 1H), 3.46 (br.s, 4H), 3.53-3.65 (m, 8H), 7.78 (br.s, 1H) , 8.69 (br.s, 1H), 10.75 (br.s, 1H), 12.18 (s, 1H).

[0464] Synthesis of ZN-50: [ka] Zn(OAc) 2 2H 2 O (0.15 g, 1.5 eq.) was added to INT-50 (0.2 g, 0.5 mmol, 1 eq.) in ethanol. The mixture was refluxed for 4 hours. The complex formed precipitated out of the mixture as a yellow powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.1g (43.5%). 1 H-NMR (400MHz, CDCl 3 ): δ (ppm) 1.1 (t, 3H), 1.15 (t, 3H), 1.37-1.49 (m, 1H), 2.06-2.17 (m, 1H), 2.33-2.47 (m, 2H), 2.77-2.87 (m, 1H), 2.88-2.96 (m, 1H), 3.00-3.09 (m, 1H), 3.40-3.65 (m, 12H), 7.40 (br.s, 1H), 7.95 (br.s, 1H) .

[0465] Synthesis of compound 50: [ka] ZN-50 (0.075 g, 0.15 mmol, 1 eq.) was dissolved in DMSO (1.8 ml) and CuCl in water (1.8 ml) was added. 2 2H 2 A solution of O (0.034 g, 1.1 eq.) was added. The mixture was stirred for 5 minutes, filtered, and the precipitate was dissolved in a saturated solution of potassium carbonate, water, and Et 2 Washed with O. Yield 0.044g (58.8%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.85 min). MS (ESI) m / z 489.4 [MH]+.

[0466] Scheme 24: Synthesis of compound 51: [ka] Synthesis of INT-51, ((2E,2’E)-2,2’-(3-methylcyclopentane-1,2-diylidene)bis(N-methylhydrazine-1-carbothioamide)): [ka] 3-Methyl-1,2-cyclopentanedione (2 g, 17.8 mmol, 1 eq.) was dissolved in EtOH (100 ml), methylthiosemicarbazide (3.75 g, 2 eq.) and 3 drops of H 2 S.O. 4 was added and the reaction mixture was stirred at reflux for 4 hours and at ambient temperature for 15 hours. Filter the precipitate formed and add EtOH, water, Et 2 Washed with O and dried. Yield 3.87g (80%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.34 minutes, MS (ESI) m / z 287.0 [MH] +. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.05-1.27 (m, 9H), 1.35-1.48 (m, 1H), 2.01-2.15 (m, 1H), 2.47-2.56 (m, 1H), 2.71-2.82 (m, 2H) , 3.49-3.63 (m, 4H), 7.74 (br.s, 1H), 8.65 (br.s, 1H), 10.74 (s, 1H), 12.23 (s, 1H).

[0467] Synthesis of INT-52, ((2E,2’E)-2,2’-(3-methylcyclopentane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide)): [ka] INT-52 was made using a procedure similar to that for preparing INT-51. Yield 5g (90.5%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.59 minutes, MS (ESI) m / z 315.1 [MH] +. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.16 (d, 3H), 1.36-1.47 (m, 1H), 2.09-2.16 (m, 1H), 2.45-2.65 (m, 1H), 2.69-2.82 (m, 2H), 3.02 (br.s, 6H), 7.88 (br.s, 1H), 8.60 (br.s, 1H), 10.82 (s, 1H), 12.33 (s, 1H).

[0468] INT-53, ((2E,2'E)-2,2'-(3-methylcyclopentane-1,2-diylidene)bis(N-(2-(diethylamino)ethyl)hydrazine-1-carbothioamide) ) composition: [ka] INT-53 was made using a procedure similar to that for preparing INT-51. Yield 0.5g (25%). 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 0.92-0.99 (m, 12H), 1.17 (d, 3H), 1.38-1.47 (m, 1H), 2.10-2.18 (m, 1H), 2.58-2.67 (m, 4H), 2.74 -2.82 (m, 2H), 3.54-3.63 (m, 4H), 7.79 (br.s, 1H), 8.50 (br.s, 1H), 10.80 (s, 1H), 12.21 (s, 1H).

[0469] Synthesis of compound 51: [ka] Cu(OAc) 2 2H 2 O (0.61 g, 1.1 eq.) was added to thiosemicarbazone 1 (0.73 g, 2.5 mmol, 1 eq.) in ethanol. The mixture was stirred at ambient temperature for 15 hours. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.46g (51.9%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.51 min). MS (ESI) m / z 348.0 [MH]+.

[0470] Synthesis of compound 52: [ka] The title compound was prepared from INT-52 following the method for preparing compound 51. The complex precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.7g (79%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.62 min). MS (ESI) m / z 376.3 [MH]+.

[0471] Synthesis of compound 53: [ka] The title compound was prepared from INT-53 following the method for preparing compound 51. The product precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.07g (15%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.25 min). MS (ESI) m / z 518.3 [MH]+.

[0472] Example 4: Preparation of compounds 54-65 INT-56, ((2Z,2'E)-2,2'-(1-(pyridin-4-yl)propane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide)) Synthesis: [ka] INT-55 was made using a procedure similar to that for preparing INT-1 in Example 1. Yield 0.030g (5%). LCMS (C18 column 100 × 4.6 mm, 5.0 μm, pore size 100 Å, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 10 min, retention time 5.01 min). MS (ESI) m / z 352.6 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 0.89 (t, 3H), 1.16 (t, 3H), 2.36 (s, 3H), 3.60 (m, 4H), 6.82 (t, 1H), 7.32 (d, 2H), 7.73 ( d, 1H), 8.73 (d, 2H), 9.37 (s, 1H), 10.77 (s, 1H).

[0473] INT-58, ((2Z,2'E)-2,2'-(1-(pyridin-2-yl)propane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide)) Synthesis: [ka] INT-58 was made using a procedure similar to that for preparing INT-1 in Example 1. Yield 0.75g (76.4%). 1 H-NMR (400MHz, DMSO D 6 ): δ (ppm) 0.99 (t, 3H), 1.16 (t, 3H), 2.38 (s, 3H), 3.36-3.46 (m, 2H), 3.56-3.66 (m, 2H), 7.36 (t, 1H) ), 7.55 (dd, 1H), 7.66 (d, 1H), 8.01 (t, 1H), 8.73-8.75 (m, 2H), 10.58 (s, 1H), 11.82 (s, 1H).

[0474] INT-62, ((2Z,2'E)-2,2'-(1-(pyridin-3-yl)propane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide)) Synthesis: [ka] INT-62 was made using a procedure similar to that for preparing INT-1 in Example 1. Yield 0.69g (65%). LCMS (C18 column 100 × 4.6 mm, 5.0 μm, pore size 100 Å, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 10 min, retention time 4.71 min). MS (ESI) m / z 352.1 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 0.90 (t, 3H), 1.15 (t, 3H), 2.37 (s, 3H), 3.60 (m, 4H), 6.81 (t, 1H), 7.53 (m, 1H), 7.71 ( d, 1H), 8.43 (s, 1H), 8.65-8.70 (m, 2H), 9.73 (br.s, 1H), 10.65 (br.s, 1H).

[0475] INT-64, ((2E,2'E)-2,2'-(1-(4-(dimethylamino)phenyl)propane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide) ) composition: [ka] INT-64 was made using a procedure similar to that for preparing INT-1 in Example 1. Yield 0.67g (68.4%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.54 minutes, MS (ESI) m / z 394.5 [MH] +. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 0 / 94 (t, 3H), 1.15 (t, 3H), 2.33 (s, 3H), 2.87 (s, 6H), 6.85 (d, 2H), 7.02 (br.s), 7.11 (d, 2H), 8.71 (br.s, 1H), 10.72 (s, 1H).

[0476] Synthesis of compound 56: [ka] The title compound was prepared from INT-56 according to the method for preparing Compound 1 of Example 1. The complex was isolated as a reddish-brown powder. The product was collected by filtration after cooling, washed with water (2 x 15 ml), ethanol (2 x 15 ml) and then dried in vacuo to give the title product. Yield 0.010g (28%). LCMS (C18 column 20 × 2 mm, 2.5 μm, pore size 100 Å, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 3.41 min). MS (ESI) m / z 413.5 [MH]+.

[0477] Synthesis of compound 58: [ka] The title compound was prepared from INT-58 according to the method for preparing Compound 1 of Example 1. The product precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, diethyl ether, and then dried in vacuo. Yield 0.044g (18.6%). LCMS (C18 column 20 × 2 mm, 2.5 μm, pore size 100 Å, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.36 min). MS (ESI) m / z 413.4 [MH]+.

[0478] Synthesis of compound 62: [ka] The title compound was prepared from INT-62 according to the method for preparing Compound 1 of Example 1. The product was isolated as a reddish-brown powder. The precipitate formed was collected by filtration after cooling, washed with water (2 x 15 ml), ethanol (2 x 15 ml) and then dried in vacuo. Yield 0.094g (27%). LCMS (C18 column 20 × 2 mm, 2.5 μm, pore size 100 Å, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.72 min). MS (ESI) m / z 413.5 [MH]+.

[0479] Synthesis of compound 64 [ka] The title compound was prepared from INT-64 according to the method for preparing Compound 1 of Example 1. The product precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.037g (18%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.31 min). MS (ESI) m / z 455.1 [MH]+.

[0480] INT-63, ((2Z,2'E)-2,2'-(1-(4-(dimethylamino)phenyl)ethane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide) ) composition: [ka] INT-63 was made using a procedure similar to that for preparing INT-34 in Example 2. Yield 0.57g (35%). LCMS (C18 column 20 x 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 minutes, retention time 1.63 minutes, MS (ESI) m / z 380.5 [MH] +. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.12-1.24 (m, 6H), 2.96 (s, 6H), 3.53-3.67 (m, 4H), 6.75 (d, 2H), 7.64 (d, 2H), 7.88 (br.s , 1H), 8.22 (s, 1H), 8.76 (br.s, 1H), 11.73 (s, 1H), 12.18 (s, 1H).

[0481] Synthesis of compound 63: [ka] The title compound was prepared from INT-63 following the method for preparing compound 43 of Example 2. The product precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.075g (47%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.07 min). MS (ESI) m / z 441.1 [MH]+.

[0482] Synthesis of INT-55, ((2E,2’E)-2,2’-(pentane-2,3-diylidene)bis(N-(tert-butyl)hydrazine-1-carbothioamide)): [ka] INT-55 was made using a procedure similar to that for preparing INT-51 in Example 3. Yield 1.97g (34%). NMR (400MHz, DMSO-d 6 ): 0.96 (s, 3H), 1.50 (s, 9H), 1.52 (s, 9H), 2.10 (s, 3H), 2.74 (q, 2H), 7.75 (s, 1H), 7.79 (s, 1H) , 10.30-10.48 (m, 2H).

[0483] Synthesis of INT-65, ((2E,2’E)-2,2’-(pentane-2,3-diylidene)bis(N-ethylhydrazine-1-carbothioamide)): [ka] INT-65 was made using a procedure similar to that for preparing INT-51 in Example 3. Yield 2.37g (49%). 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 0.91 (t, 3H), 1.14 (t, 6H), 2.19 (s, 3H), 2.80 (q, 2H), 3.54 (q, 4H), 8.25-8.40 (m, 2H), 10.15 (s, 1H), 10.27 (s, 1H).

[0484] Synthesis of compound 55: [ka] The title compound was prepared from INT-55 following the method for preparing compound 51 of Example 3. The product precipitated from the reaction mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.4g (82%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 3.41 min). MS (ESI) m / z 420.6 [MH]+.

[0485] Synthesis of compound 65: [ka] The title compound was prepared from INT-65 following the method for preparing compound 51 of Example 3. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.4g (82%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.68 min). MS (ESI) m / z 364.3 [MH]+.

[0486] Scheme 25: Synthesis of compound 54 [ka] Synthesis of N-(furan-2-ylmethyl)hydrazinecarbothioamide: [ka] To a solution of 2-(isothiocyanatomethyl)tetrahydrofuran (10 g, 71.8 mmol) in EtOH (100 ml) was added hydrazine hydrate (4.5 g, 89.75 mmol) at 0 °C and the reaction mixture was stirred for 3 h. . The precipitate formed was collected by filtration, washed with ethanol (2 x 150ml) and dried to give 1. Yield 9.3g (76%). 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.52-1.60 (m, 1H), 1.76-1.90 (m, 3H), 3.39-3.45 (m, 1H), 3.59-3.66 (m, 2H), 3.76 (q, 1H), 3.93 -3.99 (m, 1H), 4.47 (s, 2H), 7.74 (s, 1H), 8.67 (s, 1H).

[0487] Synthesis of INT-54, ((2Z,2’E)-2,2’-(pentane-2,3-diylidene)bis(N-(furan-2-ylmethyl)hydrazine-1-carbothioamide)): [ka] 2,3-pentanedione (0.4 g, 4 mmol) was dissolved in EtOH (60 ml), N-(furan-2-ylmethyl)hydrazinecarbothioamide (1.37 g, 8 mmol), and 3 drops of H 2 S.O. 4 was added and the reaction mixture was stirred at reflux for 4 hours and further overnight at room temperature. The progress of the reaction is determined by TLC (CHCl 3 -MeOH 10:1). Filter the precipitate and add EtOH, water, Et 2 Washed with O and dried. Yield 0.9g (55%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.70 min). MS (ESI) m / z 407.5 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 0.90 (t, 3H), 2.19 (s, 3H), 2.90 (q, 2H), 4.82 (d, 4H), 6.27-6.29 (m, 2H), 6.40 (s, 2H), 7.58 (s, 2H), 8.65 (t, 1H), 8.73 (t, 1H), 10.42 (s, 1H), 10.53 (s, 1H).

[0488] Synthesis of compound 54: [ka] Cu(OAc) 2 ·2H 2 O (0.12 g, 1.1 eq.) was added to INT-54 (0.2 g, 0.5 mmol, 1 eq.) in ethanol. The mixture was stirred at ambient temperature for 15 hours. The complex formed precipitated from the mixture as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, and diethyl ether, then dried in vacuo. Yield 0.022g (9.5%). LCMS (C18 column 20 × 2 mm, particle size 2.5 μm, pore size 100 A, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 2.62 min). MS (ESI) m / z 468.4 [MH]+.

[0489] Scheme 26: Synthesis of compound 57 [ka] Synthesis of 2-oxo-2-(pyridin-2-yl)acetaldehyde: [ka] To a solution of 1-(pyridin-2-yl)ethan-1-one (10.0 g, 82.5 mmol) in DMSO (150 ml) was added 47% HBr (28 ml, 247.5 mmol) and the mixture was heated at 60 °C. Stirred overnight. Reactant NaHCO 3 The reaction was quenched with water and diluted to a total volume of 1000 ml. The product was extracted with EtOAc (3 x 150 ml) and the combined organic layers were washed with anhydrous Na 2 S.O. 4 , filtered and the solvent was removed under reduced pressure to give the crude product as a yellow oil. Yield 2.8g (23%). LCMS (C18 column 20 × 2 mm, 2.5 μm, pore size 100 Å, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 0.32 min). MS (ESI) m / z 136.1 [MH]+.

[0490] INT-57, ((2Z,2'E)-2,2'-(1-(pyridin-2-yl)ethane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide)) Synthesis: [ka] Ethylthiosemicarbazide (1.76g, 14.0mmol) and 1 drop of H 2 S.O. 4 was added to a solution of 2-oxo-2-(pyridin-2-yl)acetaldehyde (1.0g, 7.0mmol) in EtOH (50ml) and the reaction heated to reflux for 4 hours. Filter the precipitate, add EtOH, Et 2 Washed with O and dried. Yield 0.123g (5.9%). LCMS (C18 column 20 × 2 mm, 2.5 μm, pore size 100 Å, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 3 min, retention time 1.41 min). MS (ESI) m / z 338.3 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.21 (dt, 6H), 3.56-3.70 (m, 4H), 7.42 (dd, 1H), 7.86-7.93 (m, 2H), 8.41 (d, 1H), 8.58 (d, 1H) ), 8.89(s, 1H), 8.79 (s, 1H), 9.20 (t, 1H), 12.01 (s, 1H), 12.80 (s, 1H).

[0491] INT-59, ((2Z,2'E)-2,2'-(1-(pyridin-3-yl)ethane-1,2-diylidene)bis(N-methylhydrazine-1-carbothioamide)) Synthesis: [ka] INT-59 was made using a procedure similar to that for preparing INT-57. Yield 0.53g (19%). LCMS (C18 column 20 × 2 mm, 2.5 μm, pore size 100 Å, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 10 min, retention time 4.49 min). MS (ESI) m / z 310.4 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 3.0 (s, 3H), 3.06 (s, 3H), 7.80 (dd, 1H), 8.2(s, 1H), 8.58(d, 1H), 8.78(d, 1H), 8.89( s, 1H), 8.92-8.98(m, 1H), 9.16(s, 1H), 11.78(s, 1H), 12.09(s, 1H).

[0492] INT-60, ((2Z,2'E)-2,2'-(1-(pyridin-3-yl)ethane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide)) Synthesis: [ka] INT-60 was made using a procedure similar to that for preparing INT-57. Yield 0.90g (30%). LCMS (C18 column 20 × 2 mm, 2.5 μm, pore size 100 Å, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 10 min, retention time 5.26 min). MS (ESI) m / z 338.5 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.17 (t, 6H), 3.61 (q, 4H), 7.47 (dd, 1H), 8.0(t, 1H), 8.18(d, 1H), 8.22(s, 1H), 8.62( d, 1H), 8.98-9.07(m, 1H), 11.77(s, 1H), 12.31(s, 1H).

[0493] INT-61, ((2Z,2'E)-2,2'-(1-(pyridin-4-yl)ethane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide)) Synthesis: [ka] INT-61 was made using a procedure similar to that for preparing INT-57. Yield 180 mg (7%). LCMS (C18 column 20 × 2 mm, 2.5 μm, pore size 100 Å, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 10 min, retention time 4.97 min). MS (ESI) m / z 338.5 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ): δ (ppm) 1.18 (t, 3H), 1.20 (t, 3H), 3.58 (q, 2H), 3.64 (q, 2H), 7.80 (d, 1H), 8.04(t, 1H), 8.24( s, 1H), 8.65(d, 1H), 9.12(t, 1H), 11.79(s, 1H), 12.47(s, 1H).

[0494] Synthesis of compound 57: [ka] A solution of INT-57 (0.123 g, 0.365 mmol) in EtOH (10 ml) was added with CuCl in EtOH (2 ml). 2 ·2H 2 A solution of O (0.062g, 0.365mmol) was added. The mixture was stirred at room temperature overnight. The precipitate formed was collected by filtration, washed with water (2 x 10 ml), ethanol (2 x 10 ml), diethyl ether (5 x 5 ml) and dried in vacuo. Yield 0.06g (41.4%). LCMS (C18 column 20 × 2 mm, 2.5 μm, pore size 100 Å, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 min, retention time 1.39). MS (ESI) m / z 399.0 [MH]+.

[0495] Synthesis of compound 59: [ka] The title compound was prepared from INT-59 following the method for preparing compound 57. The title product was collected by filtration, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and diethyl ether (5 x 50 ml) then dried in vacuo. Yield 230 mg (95%). LCMS (C18 column 20 x 2 mm, 2.5 μm, pore size 100 Å, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 minutes, retention time 1.34, 1.47 minutes. MS (ESI) m / z 371.0 [MH] +.

[0496] Synthesis of compound 60: [ka] The title compound was prepared from INT-60 following the method for preparing compound 57. The title product was collected by filtration, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and diethyl ether (5 x 50 ml) then dried in vacuo. Yield 218 mg (92%). LCMS (C18 column 20 x 2 mm, 2.5 μm, pore size 100 Å, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 minutes, retention time 1.58, 1.73 minutes. MS (ESI) m / z 399.0 [MH] +.

[0497] Synthesis of compound 61: [ka] The title compound was prepared from INT-61 following the method for preparing compound 57. The product was collected by filtration, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and diethyl ether (5 x 50 ml) and then dried in vacuo. Yield 140 mg (66%). LCMS (C18 column 20 x 2 mm, 2.5 μm, pore size 100 Å, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% in 4 minutes, retention time 1.48, 1.66 minutes. MS (ESI) m / z 399.0 [MH] +.

[0498] Example 5: Preparation of compounds 66-78 Scheme 27: Synthesis of compound 66 [ka] Synthesis of N-methoxy-N-methyl-2-(pyridin-3-yl)acetamide: [ka] of 3-pyridineacetic acid (25.0 g, 0.144 mol), Weinreb amine (16.8 g, 0.172 mol), HOBt (23.3 g, 0.172 mol), and triethylamine (71 ml, 0.5 mol) in DCM (400 ml) at 5 °C. To the mixture was added EDCI (33.2 g, 172 mol) and the reaction was stirred at ambient temperature for 15 hours. The mixture was washed with water (150ml) and brine (250ml). The organic layer is treated with anhydrous Na 2 S.O. 4 dried, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, eluent EtOAc-hexanes, 2:1) to give compound 1. Yield 20.0g (77%). 1 H-NMR (400 MHz, CDCl 3 ), δ (ppm) : 8.63 - 8.27 (m, 2H), 7.65 (d, J = 7.8 Hz, 1H), 7.28 - 7.03 (m, 1H), 3.76 (s, 2H), 3.67 (s, 3H) , 3.19 (s, 3H).

[0499] Synthesis of 1-(pyridin-3-yl)propan-2-one: [ka] A solution of N-methoxy-N-methyl-2-(pyridin-3-yl)acetamide (9.5 g, 52.7 mmol, 1 eq) in THF (200 ml) was cooled to 5°C and methylmagnesium bromide (in THF) was cooled to 5°C. 1.4M, 46.5ml, 3 eq) was added. The reaction mixture was stirred at 5 °C for 2 h and then diluted with NH 4 Pour into Cl aqueous solution, Et 2 Extracted with O. The combined extracts were diluted with anhydrous Na 2 S.O. 4 and evaporated in vacuo. Compound 2 was used in the next step without further purification. Yield 6.1g (86%). LC-MS 0.27 min, m / z 136.6 [MH]+. 1 H-NMR (400 MHz, CDCl 3 ), δ (ppm) : 8.48 (d, J = 4.7 Hz, 1H), 8.41 (s, 1H), 7.50 (d, J = 7.8 Hz, 1H), 7.31 - 7.12 (m, 1H), 3.67 (d , J = 19.5 Hz, 2H), 2.18 (s, 3H).

[0500] INT-66, ((2Z,2'E)-2,2'-(3-(pyridin-3-yl)propane-1,2-diylidene)bis(N-methylhydrazine-1-carbothioamide)) Synthesis: [ka] A mixture of 1-(pyridin-3-yl)propan-2-one (1.3 g, 6.9 mmol, 1 eq.), NaBr (0.7 g, 1 eq.), and DMSO (2 ml) was heated to 85 °C and diluted with H 2 S.O. 4 (6 drops) was added (foaming, exotherm). When the reaction was heated to 110-115 °C, dimethyl sulfide formation eventually stopped and the reaction mixture became viscous. The viscous oil formed was dissolved in EtOH and methylthiosemicarbazide (2.023g, 2eq) was added. The reaction mixture was heated to reflux for 4 hours, then stirred at room temperature overnight. The precipitate was collected by filtration and diluted with EtOH, MeCN, water, and EtOH. 2 Washed with O and dried to give the title product. Yield 0.95g (30%). LC-MS 0.97 min, m / z 324.6 [MH]+.

[0501] Synthesis of compound 66: [ka] Copper acetate (II) dihydrate (0.72 g, 1.1 eq.) was added to a stirred solution of INT-66 (0.12 g, 0.38 mmol, 1 eq.) in ethanol. The mixture was stirred at room temperature for 15 hours. The complex formed precipitated as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, diethyl ether, and dried in vacuo. Yield 0.14g (99%).

[0502] Scheme 28: Synthesis of compound 67 [ka] Synthesis of N-methoxy-N-methyl-2-(pyridin-4-yl)acetamide: [ka] 4-pyridineacetic acid (4.2 g, 24.2 mmol), Weinreb amine (2.8 g, 29.0 mmol), HOBt (3.9 g, 29.0 mmol), and triethylamine (11.9 ml, 84.7 mmol) in DCM (100 ml) at 5 °C. To the mixture was added EDCI (5.6 g, 29.0 mmol) and the reaction was stirred at room temperature for 15 hours. The mixture was washed with water (150ml) and brine (250ml). The organic layer is treated with anhydrous Na 2 S.O. 4 dried, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, eluent EtOAc-hexane 2:1) to give the title compound. Yield 2.9g (66%). LC-MS 0.97 min, m / z 324.6 [MH]+. 1 H-NMR (400 MHz, CDCl 3 ), δ (ppm) : 8.55 (d, J = 5.3 Hz, 2H), 7.36 - 7.08 (m, 2H), 3.78 (s, 2H), 3.66 (s, 3H), 3.21 (s, 3H).

[0503] Synthesis of 3-ethoxy-1-(pyridin-4-yl)but-3-en-2-one: [ka] A solution of ethyl vinyl ether (4.1 ml, 41.8 mmol) in dry THF (30 ml) was cooled to -78°C and tert-butyllithium (1.7M in pentane, 23 ml, 38.8 mmol) was added. The mixture was warmed to 0°C over a period of 1 hour, stirred for 45 minutes, and cooled to -30°C. A solution of N-methoxy-N-methyl-2-(pyridin-4-yl)acetamide (0.7g, 3.8mmol) in THF (15ml) was added and the reaction was stirred at 0°C for 4 hours. The progress of the reaction was monitored by TLC. NH mixture 4 Pour into Cl aqueous solution (30 ml) and add Et 2 Extracted with O (3 x 50 ml). The combined extracts were diluted with anhydrous Na 2 S.O. 4 dried, filtered and evaporated in vacuo. The product was used in the next step without further purification. Yield 0.2g (27%). LC-MS 0.66 min, m / z 192.4 [MH]+. 1 H-NMR (400 MHz, CDCl 3 ), δ (ppm) : 8.54 (dd, J = 4.4, 1.6 Hz, 2H), 7.23 - 7.06 (m, 2H), 5.23 (t, J = 11.8 Hz, 1H), 4.42 (t, J = 14.5 Hz , 1H), 3.99 (s, 2H), 3.83 (q, J = 7.0 Hz, 2H), 1.40 (t, J = 7.0 Hz, 3H).

[0504] INT-67, ((2Z,2'E)-2,2'-(1-(pyridin-4-yl)butane-2,3-diylidene)bis(N-methylhydrazine-1-carbothioamide)) Synthesis: [ka] 3-Ethoxy-1-(pyridin-4-yl)but-3-en-2-one (0.2 g, 1.05 mmol, 1 eq.) was dissolved in EtOH (20 ml) and methylthiosemicarbazide (0.22 g, 2.1 mmol) was dissolved in EtOH (20 ml). , 2 equivalents) and 3 drops of H 2 S.O. 4 was added and the reaction mixture was heated to reflux for 4 hours, then stirred at room temperature for 15 hours. Filter the precipitate formed and add EtOH, water, Et 2 Washed with O and dried. Yield 0.21g (60.2%). LC-MS 0.91 min, m / z 338.9 [MH]+. 1 H-NMR (400 MHz, DMSO), δ (ppm) : 10.85 (s, 1H), 10.35 (s, 1H), 8.78 (d, J = 6.6 Hz, 2H), 8.51 (d, J = 4.6 Hz, 1H), 8.34 (d, J = 4.5 Hz, 1H), 7.72 (d, J = 6.5 Hz, 2H), 4.76 (s, 2H), 3.00 (dd, J = 14.4, 4.6 Hz, 6H), 2.28 ( s, 3H).

[0505] Synthesis of compound 67: [ka] Copper acetate (II) dihydrate (0.09 g, 0.46 mmol) was added to a stirred solution of thiosemicarbazone 3 (0.15 g, 0.44 mmol) in ethanol. The mixture was stirred at room temperature for 15 hours. The complex formed precipitated as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, diethyl ether, and dried in vacuo. Yield 0.075g (42.3%).

[0506] Scheme 29: Synthesis of compound 68 [ka] Synthesis of ethyl 2-(pyridin-3-yl)acetate: [ka] A stirred solution of 3-pyridineacetic acid (25.0 g, 145 mmol) in EtOH (250 ml) at 0-5°C was added with SOCl 2 (11.6 ml, 160 mmol) was added in small portions over 15 minute intervals. After the addition was complete, the reaction was heated to reflux for an additional 16 hours and the EtOH was evaporated under reduced pressure. 2M Na in the residue 2 C.O. 3 Aqueous solution (30ml) was added and the resulting mixture was extracted with EtOAc (3x400ml). The combined organic layers were washed with brine (100 mL) and anhydrous Na 2 S.O. 4 , filtered and concentrated in vacuo to give compound 1 as a colorless liquid. Yield 22.3g (93%). 1 H-NMR (400MHz, CDCl 3 ), δ (ppm) : 1.26 (t, 3 H), 3.62 (s, 2 H), 4.17 (q, 2 H), 7.27-7.28 (m, 1 H), 7.64-7.65 (m, 1 H) , 8.53 (m, 2 H).

[0507] Synthesis of ethyl 1-(pyridin-3-yl)cyclopentane-1-carboxylate: [ka] To a stirred suspension of sodium hydride (7.3 g, 181 mmol, 60% in mineral oil) in dry THF (160 ml) at 0°C was added ethyl 2-(pyridin-3-yl)acetate in dry THF (35 ml). (10.0g, 60.5mmol) was added dropwise. The reaction mixture was stirred at 0° C. until no more effervescence occurred. 1,4-dibromobutane (19.6 g, 90.5 mmol) was then added at 0° C. and the reaction mixture was stirred at room temperature for 14 hours. The reaction mixture was then quenched with saturated aqueous ammonium chloride solution (60ml). The reaction mixture was extracted with EtOAc (3x40ml). The organic phase was washed with brine (100 ml) and anhydrous Na 2 S.O. 4 dried, filtered and concentrated to dryness in vacuo. Crude material (19 g) was obtained as a dark solid, which was then purified by flash chromatography (silica gel, eluent hexane / ethyl acetate 4:1 to 1:1). Yield 9.8g (74%). LC-MS 1.01 min, m / z 220.6 [MH]+. 1H-NMR (400MHz, CDCl3), δ (ppm) : 1.16 (t, 3H), 1.74-1.78 (m, 4H), 1.88-1.98 (m, 2H), 2.67-2.73 (m, 2H), 4.09 ( q, 2H), 7.23-7.27 (m, 1H), 7.67-7.71 (m, 1H), 8.49 (dd, 1H), 8.65 (dd, 1H).

[0508] Synthesis of 1-(pyridin-3-yl)cyclopentane-1-carboxylic acid: [ka] A solution of ethyl 1-(pyridin-3-yl)cyclopentane-1-carboxylate (8.4 g, 38.5 mmol) in MeOH (60 ml) was added to a solution of LiOH (2.5 g, 96.2 mmol) in water (10 ml). added to. The reaction mixture was stirred at 60°C for 8 hours. The solvent was then removed by lyophilization and the corresponding crude product was used in the next step without further purification. Yield 7g (80%). LC-MS 0.82 min, m / z 192.1 [MH]+. 1 H-NMR (400MHz, DMSO-d 6 ), δ (ppm) : 1.66-1.70 (m, 4H), 1.85-1.92 (m, 2H), 2.52-2.58 (m, 2H), 7.56 (dd, 1H), 7.98-8.02 (m, 1H), 8.58 (dd, 1H), 8.66 (d, 1H), 12.66 (br.s, 1H).

[0509] Synthesis of N-methoxy-N-methyl-1-(pyridin-3-yl)cyclopentane-1-carboxamide: [ka] 1-(Pyridin-3-yl)cyclopentane-1-carboxylic acid (5.0 g, 22.0 mmol), Weinreb amine (2.6 g, 26.4 mmol), HOBt (3.6 g, 26.4 mmol) in DCM (150 ml) at 4 °C. EDCI (5.1 g, 26.4 mmol) was added to a mixture of triethylamine (10.8 ml, 77 mmol) and the reaction was stirred at room temperature overnight. The mixture was then washed with water (100ml) and brine (100ml). The organic layer is treated with anhydrous Na 2 S.O. 4 and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, eluent DCM 100% to DCM / MeOH 95:5 (v / v)) to give the crude product. Yield 2.5g (49%). LC-MS 0.84 min, m / z 235.3 [MH]+. 1 H-NMR (400 MHz, CDCl 3 ), δ (ppm) : 1.66-1.81 (m, 4H), 2.05-2.11 (m, 2H), 2.42-2.48 (m, 2H), 2.89 (s, 3H), 3.13 (s, 3H), 7.34 ( q, 1H), 7.65 (d, 1H), 8.49 (d, 1H), 8.59 (d, 1H).

[0510] Synthesis of 1-(1-(pyridin-3-yl)cyclopentyl)ethane-1-one: [ka] A solution of N-methoxy-N-methyl-1-(pyridin-3-yl)cyclopentane-1-carboxamide (1.27 g, 5.42 mmol, 1 eq) in THF (100 ml) was cooled to 5 °C and bromised. Methylmagnesium (1.4M in THF, 39.1 ml, 10 eq.) was added. The reaction mixture was stirred at 5 °C for 2 h and then diluted with NH 4 Pour into Cl aqueous solution, Et 2 Extracted with O. The combined extracts were diluted with anhydrous Na 2 S.O. 4 and evaporated in vacuo. The title product was used in the next step without further purification. Yield 1g (97%). LC-MS 1.14 min, m / z 190.6 [MH]+.

[0511] INT-68, ((2Z,2'E)-2,2'-(1-(1-(pyridin-3-yl)cyclopentyl)ethane-1,2-diylidene)bis(N-methylhydrazine-1- Synthesis of carbothioamide)) [ka] A mixture of compound 6.1-(1-(pyridin-3-yl)cyclopentyl)ethane-1-one (1.3 g, 6.9 mmol, 1 eq.), NaBr (0.7 g, 1 eq.), and DMSO (2 ml) was heated at 85°C. and H2SO4 (6 drops) was added (foaming, exotherm). When the reaction was heated to 110-115 °C, dimethyl sulfide formation eventually stopped and the reaction mixture became viscous. The viscous oil formed was dissolved in EtOH and methylthiosemicarbazide (1.44g, 2eq) was added. The reaction mixture was heated to reflux for 4 hours, then stirred at room temperature overnight. The precipitate was collected by filtration and diluted with EtOH, MeCN, water, and EtOH. 2 Washed with O and dried to give the title product. Yield 0.5g (19%). LC-MS 1.10 min, m / z 378.8 [MH]+. 1 H-NMR (400 MHz, DMSO), δ (ppm): 12.05 (s, 1H), 11.51 (s, 1H), 8.57 (s, 2H), 8.44 (d, J = 3.9 Hz, 1H), 7.76 ( dd, J = 24.5, 5.8 Hz, 2H), 7.59 (s, 1H), 7.36 (dd, J = 7.7, 4.8 Hz, 1H), 3.02 (dd, J = 46.9, 4.3 Hz, 6H), 2.50 (s , 1H), 2.46 (s, 2H), 2.00 (d, J = 12.5 Hz, 2H), 1.64 (s, 4H).

[0512] Synthesis of compound 68 [ka] Copper (II) chloride dihydrate (0.078g, 0.46mmol) was added to a stirred solution of INT-68 (0.16g, 0.42mmol) in ethanol (30ml). The mixture was stirred at room temperature for 15 hours. The complex was isolated as a reddish-brown powder. The precipitate formed was filtered, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and copious amounts of diethyl ether (5 x 50 ml) and then dried in vacuo. Yield 0.04g (22%).

[0513] Scheme 30: Synthesis of compound 69 [ka] Synthesis of ethyl 2-(pyridin-3-yl)acetate: [ka] A stirred solution of 3-pyridineacetic acid (25.0 g, 145 mmol) in EtOH (250 ml) at 0-5°C was added with SOCl 2 (11.6ml, 160mmol) was added over 15 minute intervals. After the addition was complete, the reaction was heated to reflux for an additional 16 hours, then the EtOH was evaporated under reduced pressure. 2M Na in the residue 2 C.O. 3 Aqueous solution (30ml) was added and the resulting mixture was extracted with EtOAc (3x400ml). The combined organic layers were washed with brine (100 mL) and anhydrous Na 2 S.O. 4 , filtered and concentrated in vacuo to give the title product as a colorless liquid. Yield 22.3g (93%). 1 H-NMR (400MHz, CDCl 3 ), δ (ppm) : 1.26 (t, 3 H), 3.62 (s, 2 H), 4.17 (q, 2 H), 7.27-7.28 (m, 1 H), 7.64-7.65 (m, 1 H) , 8.53 (m, 2 H).

[0514] Synthesis of ethyl 2-(pyridin-3-yl)butanoate: [ka] To a solution of ethyl 2-(pyridin-3-yl)acetate (10.08 g, 61 mmol) in THF (100 mL) was added sodium hydride (2.54 g, 66 mmol, 60% dispersion in oil) in small portions. . After stirring at room temperature for 10 minutes, iodoethane (5.1 ml, 66 mmol) was added and the resulting mixture was stirred at room temperature overnight. The reaction mixture was then converted into NH 4 The reaction was quenched with aqueous Cl, extracted with EtOAc, dried over anhydrous Na2SO4, filtered, and concentrated in vacuo to give compound 2 as a colorless liquid. Yield 10.6g (86%). LC-MS 0.77 min, m / z 194.1 [MH]+. 1 H-NMR (400MHz, CDCl 3 ), δ (ppm) : 0.91 (t, J=8Hz, 3H), 1.22 (t, J=8Hz, 3H), 1.74-1.85 (m, 1H), 2.07-2.18 (m, 1H), 3.46 (t , J=7.6Hz, 1H), 4.07-4.21 (m, 2H), 7.25-7.28 (m, 1H), 7.67-7.70 (m, 1H), 8.51-8.54 (m, 2H).

[0515] Synthesis of 2-(pyridin-3-yl)butanoic acid: [ka] A solution of ethyl 2-(pyridin-3-yl)butanoate (10.6g, 54.8mmol) in MeOH (60ml) was added to a solution of NaOH (5.5g, 137.2mmol) in water (22ml). The reaction mixture was stirred at room temperature for 8 hours. The solvent was then removed by lyophilization and the corresponding crude product was used in the next step without further purification. Yield 10.3g (93%). LC-MS 0.51 min, m / z 166.1 [MH]+. 1 H-NMR (400MHz, CDCl 3 ), δ (ppm) : 0.81 (t, J=6.8Hz, 3H), 1.67-1.78 (m, 1H), 1.96-2.05 (m, 1H), 2.08 (s, 1H), 3.60 (t, J= 7.6Hz, 1H), 7.53-7.56 (m, 1H), 7.92-7.95 (m, 1H), 8.56-8.61 (m, 2H).

[0516] Synthesis of N-methoxy-N-methyl-2-(pyridin-3-yl)butanamide: [ka] 2-(pyridin-3-yl)butanoic acid (10.3 g, 51.0 mmol), Weinreb amine (5.9 g, 61.2 mmol), HOBt (8.3 g, 61.2 mmol), and triethylamine in DCM (150 ml) at 4 °C. (25ml, 176mmol) was added EDCI (11.7g, 61.2mmol) and the reaction was stirred at room temperature overnight. The mixture was washed with water (100ml) and brine (100ml). The organic layer is treated with anhydrous Na 2 S.O. 4 and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, eluent DCM 100% to DCM / MeOH 95:5 (v / v)) to give the crude product. Yield 7.3g (68%). LC-MS 0.76 min, m / z 208.9 [MH]+. 1 H-NMR (400MHz, CDCl 3 ), δ (ppm) : 0.90 (t, J=7.6Hz, 3H), 1.73-1.80 (m, 1H), 2.08-2.15 (m, 1H), 3.17 (s, 3H), 3.57 (s, 3H) , 3.91-3.96 (m, 1H), 7.26-7.28 (m, 1H), 7.74-7.77 (m, 1H), 8.48-8.50 (m, 1H), 8.53 (d, J=2Hz, 1H).

[0517] Synthesis of 2-ethoxy-4-(pyridin-3-yl)hex-1-en-3-one: [ka] A solution of ethyl vinyl ether (4.3ml, 45.1mmol) in dry tetrahydrofuran (30ml) was cooled to -78°C and tert-butyllithium (1.7M in pentane, 24ml, 41mmol) was added. The mixture was warmed to 0°C over a period of 1 hour, stirred for 45 minutes, and cooled to -30°C. A solution of N-methoxy-N-methyl-2-(pyridin-3-yl)butanamide (1.7g, 8.2mmol) in THF (35ml) was added and the reaction was stirred at 0°C for 4 hours. The progress of the reaction was monitored by TLC. NH mixture 4 Pour into Cl aqueous solution (30 ml) and add Et 2 Extracted with O (3 x 50 ml). The combined extracts were diluted with anhydrous Na 2 S.O. 4 dried, filtered and evaporated in vacuo. The product was used in the next step without further purification. Yield 1.15g (64%). LC-MS 1.15 min, m / z 219.9 [MH]+. 1 H-NMR (400 MHz, CDCl 3 ), δ (ppm) : 0.86 (t, J=7.2Hz, 3H), 1.34 (t, J=6.8Hz, 3H), 1.68-1.79 (m, 1H), 2.04-2.15 (m, 1H), 3.62 -3.70 (m, 1H), 3.74-3.82 (m, 1H), 4.27 (t, J=8Hz, 1H), 4.35 (d, J=2Hz, 1H), 5.20(d, J=2.8Hz, 1H) , 7.23-7.27 (m, 1H), 7.55-7.58 (m, 1H), 8.47-8.49 (m, 1H), 8.52 (d, J=2Hz, 1H).

[0518] INT-69, ((2Z,2'E)-2,2'-(3-(pyridin-3-yl)pentane-1,2-diylidene)bis(N-methylhydrazine-1-carbothioamide)) Synthesis: [ka] Compound 6. Methylthiosemicarbazide ( 0.85g, 8.1mmol, 2eq) and 3 drops of H 2 S.O. 4 was added and the reaction mixture was heated to reflux for 4 hours, then stirred at room temperature for 15 hours. Filter the precipitate formed and add EtOH, water, Et 2 Washed with O and dried. Yield 0.67g (45%). LC-MS 1.01 min, m / z 366.3 [MH]+.

[0519] Synthesis of compound 69 [ka] Copper(II) chloride dihydrate (0.12g, 0.73mmol) was added to a stirred solution of INT-69 (0.24g, 0.67mmol) in ethanol (30ml). The mixture was stirred at room temperature overnight. The complex was isolated as a reddish-brown powder. The precipitate formed was filtered, washed with water (2 x 50 ml), ethanol (2 x 50 ml) and copious amounts of diethyl ether (5 x 50 ml) and then dried in vacuo. Yield 0.13g (45%).

[0520] Scheme 31: Synthesis of compound 70 [ka] Synthesis of 2-oxo-2-(pyridin-4-yl)acetaldehyde: [ka] To a solution of 1-pyridin-4-ylethanone (10.0g, 82.5mmol) in DMSO (100ml) was added concentrated HBr (28ml, 247.5mmol) and the mixture was stirred at 50°C overnight. Reaction mixture with NaHCO 3 The reaction was quenched with water and then diluted with water to a total volume of 1000ml. The resulting solution was extracted with EtOAc (3 x 150 ml) and the combined organic layers were diluted with anhydrous Na 2 S.O. 4 After drying and evaporation in vacuo, the product 1 was obtained as a yellow oil. Yield 2.0g (18%). LC-MS 0.35 min, m / z 136.1 [MH]+.

[0521] INT-70, ((2Z,2'E)-2,2'-(1-(pyridin-4-yl)ethane-1,2-diylidene)bis(N-methylhydrazine-1-carbothioamide)) Synthesis: [ka] To a solution of 2-oxo-2-(pyridin-4-yl)acetaldehyde (1.2 g, 8.9 mmol) in EtOH (100 ml) was added methylthiosemicarbazide (1.87 g, 19.8 mmol) followed by 2 drops of H 2 S.O. 4 was added and the reaction mixture was then heated to reflux for 4 hours and stirred at room temperature overnight. Filter the precipitate, add EtOH, Et 2 Washed with O and dried to obtain compound 2. Yield 70 mg (4%). LC-MS (reversed phase C18 column 20 × 2 mm, 2.5 μm, pore size 100 Å, water-acetonitrile + 0.1% TFA, gradient from 5 to 87% over 10 min), 4.27 min, (ESI) m / z 310.1 [MH] +.

[0522] Synthesis of compound 70 [ka] To a solution of INT-70 (70 mg, 0.2 mmol) in EtOH (10 ml) was added a solution of copper(II) chloride dihydrate (42 mg, 0.22 mmol) in EtOH (2 ml). The mixture was stirred at room temperature overnight. The formed precipitate was collected by filtration and washed with water (2 x 5 ml), ethanol (2 x 5 ml), diethyl ether (5 x 5 ml) and then dried in vacuo to give the product as a dehydrated powder. . Yield 42 mg (50%).

[0523] Scheme 32: Synthesis of compound 71 [ka] Synthesis of 1-(pyridin-3-yl)propan-2-one: [ka] A solution of N-methoxy-N-methyl-2-(pyridin-3-yl)acetamide (9.5 g, 52.7 mmol, 1 eq) in THF (200 ml) was cooled to 5°C and methylmagnesium bromide (in THF) was cooled to 5°C. 1.4M, 46.5ml, 3 eq) was added. The reaction mixture was stirred at 5 °C for 2 h and then diluted with NH 4 Pour into Cl aqueous solution, Et 2 Extracted with O. The combined extracts were diluted with anhydrous Na 2 S.O. 4 and evaporated in vacuo. The title product was used in the next step without further purification. Yield 6.1g (86%). LC-MS 0.27 min, m / z 136.6 [MH]+. 1 H-NMR (400 MHz, CDCl 3 ), δ (ppm) : 8.48 (d, J = 4.7 Hz, 1H), 8.41 (s, 1H), 7.50 (d, J = 7.8 Hz, 1H), 7.31 - 7.12 (m, 1H), 3.67 (d , J = 19.5 Hz, 2H), 2.18 (s, 3H).

[0524] INT-71, ((2Z,2'E)-2,2'-(3-(pyridin-3-yl)propane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide)) Synthesis: [ka] A mixture of 1-(pyridin-3-yl)propan-2-one (1.5 g, 11.1 mmol, 1 eq.), NaBr (1.14 g, 1 eq.), and DMSO (2 ml) was heated to 85 °C and diluted with H 2 S.O. 4 (6 drops) was added (foaming, exotherm). When the reaction was heated to 110-115 °C, dimethyl sulfide formation eventually stopped and the reaction mixture became viscous. The viscous oil formed was dissolved in EtOH and ethylthiosemicarbazide (2.64g, 2eq) was added. The reaction mixture was heated to reflux for 4 hours, then stirred at room temperature overnight. The precipitate was collected by filtration and diluted with EtOH, MeCN, water, and EtOH. 2 Washed with O and dried to give the title product. Yield 0.175g (4.5%). LC-MS 1.19 min, m / z 352.8 [MH]+.

[0525] Synthesis of compound 71: [ka] Copper acetate (II) dihydrate (0.055 g, 1 eq.) was added to a stirred solution of INT-71 (0.175 g, 0.5 mmol, 1 eq.) in ethanol. The mixture was stirred at room temperature for 15 hours. The complex formed precipitated as a reddish-brown powder. The precipitate was collected by filtration, washed with water, methanol, diethyl ether, and dried in vacuo. Yield 0.14g (69%).

[0526] Scheme 33: Synthesis of compound 72 [ka] Synthesis of 3-((3r,5r,7r)-adamantan-1-yl)-N-methoxy-N-methylpropanamide: [ka] 3-((3r,5r,7r)-adamantan-1-yl)propanoic acid (5 g, 24 mmol), N,O-dimethylhydroxylamine (2.81 g, 1.2 eq), HOBt in DCM (50 ml) at 5 °C. To a stirred mixture of (3.89 g, 1.2 eq.) and triethylamine (8.5 ml, 6.11 g, 2.5 eq.) was added EDCI (5.52 g, 1.2 eq.) and the reaction was stirred at room temperature for 15 hours. The mixture was washed with water and brine. The organic layer is treated with anhydrous Na 2 S.O. 4 and then concentrated under reduced pressure. The product was purified by column chromatography (silica gel, eluent CCl 4 100% then CCl 4 / EtOAc 8:2). Yield 3.5g (58%). LC-MS 1.88 min, m / z 252.4 [MH]+. 1 H-NMR (400 MHz, CDCl 3 ), δ (ppm) : 3.71 (d, J = 1.6 Hz, 3H), 3.19 (s, 3H), 2.42 - 2.31 (m, 2H), 1.97 (s, 3H), 1.72 (d, J = 11.9 Hz , 3H), 1.68 - 1.58 (m, 4H), 1.50 (s, 6H), 1.43 (dd, J = 9.8, 7.1 Hz, 2H).

[0527] Synthesis of 5-((3r,5r,7r)-adamantan-1-yl)-2-ethoxypent-1-en-3-one: [ka] A solution of ethyl vinyl ether (2.01g, 2.7ml, 3.3 eq) in dry THF (150ml) was cooled to -78°C and tert-butyllithium (1.7M in pentane, 16ml, 3eq) was added. The mixture was warmed to 0°C over a period of 1 hour, stirred for 45 minutes, then cooled to -30°C. A solution of 3-((3r,5r,7r)-adamantan-1-yl)-N-methoxy-N-methylpropanamide (2.12g, 8.4mmol) in THF (15ml) was added and stirring was continued at 0 °C. It lasted for 4 hours. NH mixture 4 Pour into Cl aqueous solution (100 ml) and add Et 2 Extracted with O (3 x 100ml). The combined extracts were diluted with anhydrous Na 2 S.O. 4 dried, filtered and the solvent was evaporated in vacuo. The product was used in the next step without further purification. Yield 2.2g (99.9%). 1 H-NMR (400 MHz, CDCl 3 ), δ (ppm) : 5.18 (s, 1H), 4.36 (d, J = 33.6 Hz, 1H), 3.82 (q, J = 6.9 Hz, 2H), 2.64 (dd, J = 20.9, 13.1 Hz, 2H ), 1.97 (s, 4H), 1.79 - 1.53 (m, 8H), 1.56 - 1.15 (m, 13H).

[0528] INT-72, ((2E,2'E)-2,2'-(5-((3r,5r,7r)-adamantan-1-yl)pentane-2,3-diylidene)bis(N-ethylhydrazine Synthesis of -1-carbothioamide): [ka] 5-((3r,5r,7r)-adamantan-1-yl)-2-ethoxypent-1-en-3-one (2.21 g, 8.4 mmol) was dissolved in EtOH (60 ml) and treated with ethylthiosemicarbazide. (2.01 g, 2 eq.) and 3 drops of H 2 S.O. 4 was added. The stirred reaction mixture was heated to reflux for 4 hours and then kept at room temperature for 15 hours. Filter the precipitate formed and add EtOH, saturated Na 2 C.O. 3 Aqueous solution, water, Et 2 Washed with O and dried. Yield 2.2g (59.6%). LC-MS 2.17 min, m / z 437.5 [MH]+.

[0529] Synthesis of compound 72 [ka] Copper (II) chloride dihydrate (0.23 g, 1 eq.) was added to a stirred solution of INT-72 (0.59 g) in ethanol. The mixture was stirred at room temperature for 15 hours. The complex formed precipitated as a reddish-brown powder. The precipitate was collected by filtration, washed with water, diethyl ether and dried. Yield 0.61g (90.8%).

[0530] Scheme 34: Synthesis of compound 73 [ka] Synthesis of 3-cyclopentyl-N-methoxy-N-methylpropanamide: [ka] 3-Cyclopentylpropanoic acid (3.12 g, 21.9 mmol), N,O-dimethylhydroxylamine (2.57 g, 1.2 eq.), HOBt (4.03 g, 1.2 eq.), and triethylamine (6.1 eq.) in DCM (100 ml) at 5 °C. EDCI (5.05 g, 1.2 eq.) was added to the stirred mixture of 4.43 g (ml, 4.43 g, 2 eq.) and the reaction was stirred at room temperature for 15 h. The mixture was washed with water and brine. The organic layer is treated with anhydrous Na 2 S.O. 4 and then concentrated under reduced pressure. The product was purified by column chromatography (silica gel, eluent DCM 100% to DCM / MeOH 99:1). Yield 3.11g (76.5%). LC-MS 1.63 min, m / z 186.4 [MH]+. 1 H-NMR (400 MHz, CDCl 3 ), δ (ppm) : 3.69 (s, 3H), 3.19 (s, 3H), 2.42 (dd, J = 18.1, 10.2 Hz, 2H), 2.53 - 2.33 (m, 2H), 1.87 - 1.73 (m, 4H), 1.70 - 1.57 (m, 5H), 1.58 - 1.44 (m, 2H), 1.19 - 1.01 (m, 2H).

[0531] Synthesis of 5-cyclopentyl-2-ethoxypent-1-en-3-one: [ka] A solution of ethyl vinyl ether (3.85g, 5.1ml, 6.6eq) in dry THF (100ml) was cooled to -78°C and tert-butyllithium (1.7M in pentane, 28ml, 6eq) was added. The mixture was warmed to 0°C over a period of 1 hour, stirred for 45 minutes, then cooled to -30°C. A solution of 3-cyclopentyl-N-methoxy-N-methylpropanamide (1.5g, 8mmol) in THF (15ml) was added and stirring continued at 0°C for 4 hours. NH mixture 4 Pour into Cl aqueous solution (100 ml) and add Et 2 Extracted with O (3 x 100ml). The combined extracts were diluted with anhydrous Na 2 S.O. 4 dried, filtered and the solvent was evaporated in vacuo. The product was used in the next step without further purification. Yield 1.05g (99.0%). LC-MS 0.91 min, m / z 180.9 [MH]+.

[0532] Synthesis of INT-73, ((2E,2’E)-2,2’-(5-cyclopentylpentane-2,3-diylidene)bis(N-ethylhydrazine-1-carbothioamide)): [ka] 5-Cyclopentyl-2-ethoxypent-1-en-3-one (1.05 g, 8 mmol) was dissolved in EtOH (25 ml), ethylthiosemicarbazide (1.93 g, 2 eq.) and 3 drops of H 2 S.O. 4 was added. The stirred reaction mixture was heated to reflux for 4 hours and then kept at room temperature for 15 hours. Filter the precipitate formed and add EtOH, saturated Na 2 C.O. 3 Aqueous solution, water, Et 2 Washed with O and dried. Yield 2g (68%). LC-MS 1.83 min, m / z 371.5 [MH]+.

[0533] Synthesis of compound 73: [ka] Copper (II) chloride dihydrate (0.23 g, 1 eq.) was added to a stirred solution of INT-73 (0.5 g, 1.3 mmol) in ethanol. The mixture was stirred at room temperature for 15 hours. The complex formed precipitated as a reddish-brown powder. The precipitate was collected by filtration, washed with water, diethyl ether and dried. Yield 0.5g (88.7%).

[0534] Scheme 35: Synthesis of compound 74 [ka] Synthesis of INT-74, ((2Z,2’Z)-2,2’-(3-methoxypropane-1,2-diylidene)bis(N-ethylhydrazine-1-carbothioamide)): [ka] SeO in a three-necked flask 2 (3.6 g, 1.05 eq.), 1,4-dioxane (70 mL), and water (14 mL). Heat the mixture to 50 °C and add SeO 2 The mixture was stirred until most of it was dissolved. 1-Methoxypropan-2-one (2.72g, 30.9mmol) was added and the reaction was heated at mild reflux overnight. Selenium solid precipitated during the course of the reaction. The mixture was cooled in an ice bath and filtered through diatomaceous earth to remove selenium. The filter cake was washed with a portion of 1,4-dioxane. The filtrate was evaporated to dryness and dissolved in EtOH (100ml). Ethylthiosemicarbazide (7.35g, 2eq) and 3 drops of H 2 S.O. 4 was added. The stirred reaction mixture was heated to reflux for 4 hours. Filter the precipitate formed and add EtOH, saturated Na 2 C.O. 3 Aqueous solution, water, Et 2 Washed with O and dried. Yield 2.4g (25.5%). LC-MS 1.37 min, m / z 305.5 [MH]+.

[0535] Synthesis of compound 74: [ka] Copper (II) chloride dihydrate (0.1 g, 1 eq.) was added to a stirred solution of INT-74 (0.184 g, 0.6 mmol) in ethanol. The mixture was stirred at room temperature for 15 hours. The complex formed precipitated as a reddish-brown powder. The precipitate was collected by filtration, washed with water, diethyl ether and dried. Yield 0.1g (45.2%).

[0536] Scheme 36: Synthesis of compound 75 [ka] INT-75, ((2Z,2'E)-2,2'-(1-(benzo[d][1,3]dioxol-5-yl)ethane-1,2-diylidene)bis(N-methyl Synthesis of hydrazine-1-carbothioamide): [ka] SeO in a three-necked flask 2 (2.12 g, 1.05 eq), 1,4-dioxane (41 mL), and water (9 mL) were charged. Heat the mixture to 50 °C and add SeO 2 The mixture was stirred until most of it was dissolved. 1-(Benzo[d][1,3]dioxol-5-yl)ethan-1-one (2.72 g, 30.9 mmol) was added and the reaction was heated at mild reflux overnight. Selenium solid precipitated during the course of the reaction. The mixture was cooled in an ice bath and filtered through diatomaceous earth to remove selenium. The filter cake was washed with a portion of 1,4-dioxane. The filtrate was evaporated to dryness and dissolved in EtOH (100ml). Methylthiosemicarbazide (3.84 g, 2 eq.) and 3 drops of H 2 S.O. 4 was added. The stirred reaction mixture was heated to reflux for 4 hours. Filter the precipitate formed and add EtOH, saturated Na 2 C.O. 3 Aqueous solution, water, Et 2 Washed with O and dried. Yield 2.16g (33.5%). LC-MS 1.53 min, m / z 353.3 [MH]+. 1 H-NMR (400 MHz, DMSO-d6), δ (ppm) : 12.13 (s, 1H), 11.71 (s, 1H), 8.82 (d, J = 4.3 Hz, 1H), 8.21 - 8.04 (m, 2H) ), 7.60 (d, J = 1.5 Hz, 1H), 7.18 (d, J = 8.2 Hz, 1H), 6.98 (d, J = 8.2 Hz, 1H), 6.08 (s, 2H), 3.04 (dd, J = 15.0, 4.5 Hz, 6H).

[0537] Synthesis of ZN-75: [ka] Zinc acetate (0.28 g, 1.5 eq.) was added to INT-75 (0.36 g, 1 mmol) in ethanol. The mixture was heated to reflux for 4 hours. The complex formed precipitated as a yellow powder. The precipitate was collected by filtration, washed with water, methanol, diethy...

Claims

1. Compound of formula (V): 【Chemistry 1】 or a pharma- ceutical acceptable salt thereof, wherein: R 1 is a 5- to 10-membered heteroaryl, NH 2 , NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 Alkyl) 2 Optionally substituted with 1 ~C 6 is alkyl, R 2 is a 5- to 10-membered heteroaryl, NH 2 , NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 Alkyl) 2 Optionally substituted with 1 ~C 6 is alkyl, R 3 is a 4- to 8-membered heterocycle or a 5-membered heteroaryl, wherein the 4- to 8-membered heterocycle optionally contains a group R 3a and the 5-membered heteroaryl is optionally substituted with a group R 3b is substituted once, twice, or three times with R 3a But for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkyl-(C 6 ~C 10 Aryl), C 1 ~C 6 Alkyl-(5- to 10-membered heteroaryl), S(O) 2 H, S (O) 2 - (C 1 ~C 6 Alkyl), S(O) 2 - (C 3 ~C 7 cycloalkyl), or S(O) 2 - (C 6 ~C 10 aryl), where each heteroaryl is optionally selected from C 1 ~C 6 Alkyl or C 6 ~C 10 Further substituted 1 to 4 times with aryl, each C 6 ~C 10 Aryl is optionally C 1 ~C 6 further substituted 1 to 4 times with alkyl; R 3b But for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Alkyl-N(R 5 ) 2 , (C 1 ~C 6 alkyl)-O-(C 1 ~C 6 Alkyl), halo, nitro, cyano, C 6 ~C 10 Aryl, C(O)-(4- to 8-membered heterocycle), C 1 ~C 6 Alkyl-(C 6 ~C 10 Aryl), C 1 ~C 6 alkyl-(5- to 10-membered heteroaryl), or C 1 ~C 6 alkyl-(4- to 8-membered heterocycle), where each 4- to 8-membered heterocycle, C 6 ~C 10 Aryl and 5- to 10-membered heteroaryl are optionally 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 further substituted 1 to 4 times with haloalkyl or halo; R 4 is hydrogen or C 1-3 is alkyl, R 5 independently for each occurrence: hydrogen, C 1 ~C 6 Alkyl, or C 1 ~C 3 Alkyl-(C 6 ~C 10 aryl), The compound or a pharma- ceutical acceptable salt thereof.

2. R 1 is methyl or ethyl, R 2 is methyl or ethyl; The compound of claim 1.

3. R 3 is tetrahydrofuranyl, morpholinyl, piperidinyl, furyl, thiophenyl, pyrrolyl, oxazolyl, pyrazolyl, or imidazolyl, wherein said tetrahydrofuranyl, morpholinyl, and piperidinyl are optionally represented by the group R 3a and said furyl, thiophenyl, pyrrolyl, oxazolyl, pyrazolyl and imidazolyl are optionally substituted with a group R 3b 3. The compound of claim 1 or claim 2, which is substituted once, twice or three times with

4. R 3 is a group R 3b The compound according to any one of claims 1 to 3, which is furyl, thiophenyl, oxazolyl, pyrazolyl or imidazolyl, optionally substituted once, twice or three times with

5. R 3b But for each occurrence, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkyl-N(R 5 ) 2 , Haro, C 6 ~C 10 Aryl, C 1 ~C 6 Alkyl-(4- to 8-membered heterocycle), or C 1 ~C 6 Alkyl-(C 6 ~C 10 aryl), where each 4- to 8-membered heterocycle and C 6 ~C 10 Aryl is optionally C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 1 ~C 3 The compound of any one of claims 1 to 4, further substituted 1 to 4 times with haloalkyl or halo.

6. R 3b but, 【Chemistry 2】 The compound according to any one of claims 1 to 4, selected from the group consisting of:

7. R 3 But, C 1 ~C 3 Alkyl-N(C 1 ~C 4 Alkyl) 2 Or C 1 ~C 3 furyl optionally substituted once with alkyl-(5- to 6-membered heterocycle), wherein said 5- to 6-membered heterocycle is optionally 1 ~C 3 The compound of any one of claims 1 to 4, further substituted 1 to 4 times with alkyl.

8. R 3 but, 【Chemistry 3】 The compound according to any one of claims 1 to 3, selected from the group consisting of:

9. R 4 The compound according to any one of claims 1 to 8, wherein is hydrogen or methyl. 【Request 10】 【Chemical 4-1】 【Chemistry 4-2】 【Chemistry 4-3】 【Chemistry 4-4】 【Chemistry 4-5】 【Chemistry 4-6】 【Chemistry 4-7】 【Chemistry 4-8】 【Chemistry 4-9】 2. The compound of claim 1, selected from the group consisting of:

11. Compound of formula (IV): 【Chemistry 5】 or a pharma- ceutical acceptable salt thereof, wherein: L is C 3 ~C 7 Cycloalkyl, C 1 ~C 6 is alkyl or absent; R 1 is a 5- to 10-membered heteroaryl, NH 2 , NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 Alkyl) 2 Optionally substituted with 1 ~C 6 is alkyl, R 2 is a 5- to 10-membered heteroaryl, NH 2 , NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 Alkyl) 2 Optionally substituted with 1 ~C 6 is alkyl, R 3 But, C 6 ~C 10 Aryl, 5- to 10-membered heteroaryl, C 3 ~C 10 Cycloalkyl, C(O)NH-(C 1 ~C 6 (alkyl)-PPh 3 , Hydroxy, C 1 ~C 6 Alkoxy, or O-(C 1 ~C 6 alkyl)-O-(C 1 ~C 6 alkyl), wherein the C 6 ~C 10 The aryl is a group R 3a and the 5- to 10-membered heteroaryl is optionally substituted with a group R 3b is substituted once, twice, or three times with R 3a But for each occurrence, C 3 ~C 7 cycloalkyl or a 4- to 8-membered heterocycle, wherein the 4- to 8-membered heterocycle is optionally selected from the group consisting of C 1 ~C 3 further substituted once, twice or three times with alkyl; R 3b But for each occurrence, C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, C 3 ~C 7 cycloalkyl, or a 4- to 8-membered heterocycle, wherein the heterocycle is optionally 1 ~C 3 further substituted once, twice or three times with alkyl; R 4 is hydrogen, C 1 ~C 3 Alkyl, or C 6 ~C 10 Although it is aryl, However, if L is absent, then R 3 is a group R 3a C substituted once, twice, or three times with 6 ~C 10 aryl, or when L is absent, R 3 is a group R 3b or, when L is absent, R 3 is a group R 3b is a 6- to 10-membered heteroaryl optionally substituted 1, 2, or 3 times with 4 is H, The compound or a pharma- ceutical acceptable salt thereof. 【Request 12】 【Chemical 6-1】 【Chemistry 6-2】 【Chemistry 6-3】 【Chemistry 6-4】 12. The compound of claim 11, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

13. Compound of formula (III): 【Chemistry 7】 or a pharma- ceutical acceptable salt thereof, wherein: L is C 1 ~C 6 is alkyl or absent; R 1 is a 5- to 10-membered heteroaryl, NH 2 , NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 Alkyl) 2 Optionally substituted with 1 ~C 6 is alkyl, R 2 is a 5- to 10-membered heteroaryl, NH 2 , NH(C 1 ~C 6 alkyl), or N(C 1 ~C 6 Alkyl) 2 Optionally substituted with 1 ~C 6 is alkyl, R 3 But, C 1 ~C 6 Alkyl, C 1 ~C 6 Alkoxy, C 1 ~C 6 Haloalkyl, halo, hydroxy, C(O)NH 2 , C(O)NH(C 1 ~C 6 alkyl), C(O)N(C 1 ~C 6 Alkyl) 2 or C(O)-(4- to 8-membered heterocycle), 1 ~C 6 Alkyl and the C 1 ~C 6 Alkoxy is optionally selected from the group consisting of C 6 ~C 10 aryl, and the C(O)-(4- to 8-membered heterocycle) is optionally substituted with C 1 ~C 3 substituted once, twice or three times with alkyl; The compound or a pharma- ceutical acceptable salt thereof.

14. 【Chemical 8】 14. The compound of claim 13, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

15. 【Chemical 9】 2. A compound selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

16. A pharmaceutical composition comprising a compound according to any one of claims 1 to 15, or a pharma- ceutically acceptable salt thereof, and at least one pharma- ceutically acceptable excipient, diluent, or carrier.

17. The pharmaceutical composition of claim 16 for use in the treatment of a neurodegenerative disease.

18. 18. The pharmaceutical composition of claim 17, wherein the neurodegenerative disease is amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson's disease, Huntington's disease, and Alzheimer's disease.

19. 19. The pharmaceutical composition of claim 17 or 18, wherein the neurodegenerative disease is ALS.

20. 20. The pharmaceutical composition of claim 19, wherein the ALS is familial or sporadic.

21. A pharmaceutical composition described in any one of claims 17 to 20, wherein a subject in need thereof is treatment-naive.

22. The pharmaceutical composition of claim 19 or claim 20, wherein a subject in need thereof has undergone previous treatment for ALS.

23. The pharmaceutical composition of any one of claims 19 to 22, wherein a subject in need thereof is a human, said human having a genetic mutation associated with ALS.

24. 24. The pharmaceutical composition of claim 23, wherein the genetic mutation associated with ALS comprises a mutation in the SOD1 gene.

25. The pharmaceutical composition of any one of claims 19 to 24, wherein the compound is administered to a subject in combination with an additional ALS treatment therapy.